{"anonymous_execution":false,"authentication_required_for_execution":true,"links":{"agent_skill":"/SKILL.md","openapi":"/api/openapi.json","tools":"/tools.json"},"model_count":44,"models":[{"availability":{"catalog_qualified":true,"released":true},"description":"An exposure-response model connecting nivolumab steady-state exposure to competing tumor shrinkage and progression processes and their resulting tumor-size trajectory.","diseases":[{"key":"melanoma_non_small_cell_lung_cancer_and_renal_cell_carcinoma","label":"Melanoma, non-small cell lung cancer, and renal cell carcinoma"}],"links":{"page":"/modeling/models/agrawal-2016-nivolumab-dose-selection-er-tgd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["Exposure-response"],"model_id":"agrawal_2016_nivolumab_dose_selection_er_tgd","name":"Nivolumab exposure and tumor-size dynamics","outputs":[{"description":"Steady-state trough concentration over the selected simulation window.","key":"exploratory_cminss_ug_mL","label":"Steady-state trough concentration","unit":null},{"description":"Tumor size over the selected simulation window.","key":"exploratory_tumor_size_mm","label":"Tumor size","unit":"mm"},{"description":"Tumor size relative to baseline over the selected simulation window.","key":"tumor_size_percent_baseline","label":"Tumor size relative to baseline","unit":"percent"},{"description":"Elapsed time over the selected simulation window.","key":"elapsed_time_weeks","label":"Elapsed time","unit":"week"},{"description":"Elapsed over the selected simulation window.","key":"exploratory_elapsed_weeks","label":"Elapsed","unit":"week"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Steady-state trough concentration coefficient used by the released system of model equations.","description":"Steady-state trough concentration coefficient used by the released system of model equations.","key":"exploratory_cminss_ug_mL","label":"Steady-state trough concentration","max":127.5,"min":42.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ug/mL","value":85},{"category":"model parameter","definition":"Maximum tumor shrinkage rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Maximum tumor shrinkage rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"exploratory_tgd_srmax","label":"Maximum tumor shrinkage rate","max":0.0218312451,"min":0.0072770817,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/week","value":0.0145541634},{"category":"model parameter","definition":"Tumor-shrinkage half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-shrinkage half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"exploratory_tgd_sr_ec50","label":"Tumor-shrinkage half-maximal concentration","max":85.337856045,"min":28.445952015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ug/mL","value":56.89190403},{"category":"model parameter","definition":"Minimum tumor progression rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Minimum tumor progression rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"exploratory_tgd_prmin","label":"Minimum tumor progression rate","max":0.26641509705,"min":0.08880503235,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mm/week","value":0.1776100647},{"category":"model parameter","definition":"Tumor-progression half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-progression half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"exploratory_tgd_pr_ec50","label":"Tumor-progression half-maximal concentration","max":15.492637155,"min":5.164212385,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ug/mL","value":10.32842477}],"description":"How does nivolumab exposure shift the balance between tumor shrinkage and progression? Explore this biological starting configuration through Steady-state trough concentration, Tumor size, Tumor size relative to baseline.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"joint MEL 3 mg/kg, Cminss 85 ug/mL","outputs":[{"classification":"provisional","description":"Steady-state trough concentration over the selected simulation window.","key":"exploratory_cminss_ug_mL","label":"Steady-state trough concentration","unit":null},{"classification":"provisional","description":"Tumor size over the selected simulation window.","key":"exploratory_tumor_size_mm","label":"Tumor size","unit":"mm"},{"classification":"provisional","description":"Tumor size relative to baseline over the selected simulation window.","key":"tumor_size_percent_baseline","label":"Tumor size relative to baseline","unit":"percent"}],"scenario_id":"exploratory_joint_mel_3mgkg_cmin85","scientific_questions":["How does nivolumab exposure shift the balance between tumor shrinkage and progression?"],"time_span":{"end":52,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Steady-state trough concentration coefficient used by the released system of model equations.","description":"Steady-state trough concentration coefficient used by the released system of model equations.","key":"exploratory_cminss_ug_mL","label":"Steady-state trough concentration","max":97.5,"min":32.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ug/mL","value":65},{"category":"model parameter","definition":"Maximum tumor shrinkage rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Maximum tumor shrinkage rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"exploratory_tgd_srmax","label":"Maximum tumor shrinkage rate","max":0.02009667615,"min":0.00669889205,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/week","value":0.0133977841},{"category":"model parameter","definition":"Tumor-shrinkage half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-shrinkage half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"exploratory_tgd_sr_ec50","label":"Tumor-shrinkage half-maximal concentration","max":140.20067211,"min":46.73355737,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ug/mL","value":93.46711474},{"category":"model parameter","definition":"Minimum tumor progression rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Minimum tumor progression rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"exploratory_tgd_prmin","label":"Minimum tumor progression rate","max":0.68920259625,"min":0.22973419875,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mm/week","value":0.4594683975},{"category":"model parameter","definition":"Tumor-progression half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-progression half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"exploratory_tgd_pr_ec50","label":"Tumor-progression half-maximal concentration","max":18.063577785,"min":6.021192595,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ug/mL","value":12.04238519}],"description":"How does nivolumab exposure shift the balance between tumor shrinkage and progression? Explore this biological starting configuration through Steady-state trough concentration, Tumor size, Tumor size relative to baseline.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"joint NSCLC 3 mg/kg, Cminss 65 ug/mL","outputs":[{"classification":"provisional","description":"Steady-state trough concentration over the selected simulation window.","key":"exploratory_cminss_ug_mL","label":"Steady-state trough concentration","unit":null},{"classification":"provisional","description":"Tumor size over the selected simulation window.","key":"exploratory_tumor_size_mm","label":"Tumor size","unit":"mm"},{"classification":"provisional","description":"Tumor size relative to baseline over the selected simulation window.","key":"tumor_size_percent_baseline","label":"Tumor size relative to baseline","unit":"percent"}],"scenario_id":"exploratory_joint_nsclc_3mgkg_cmin65","scientific_questions":["How does nivolumab exposure shift the balance between tumor shrinkage and progression?"],"time_span":{"end":52,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Steady-state trough concentration coefficient used by the released system of model equations.","description":"Steady-state trough concentration coefficient used by the released system of model equations.","key":"exploratory_cminss_ug_mL","label":"Steady-state trough concentration","max":322.5,"min":107.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"ug/mL","value":215},{"category":"model parameter","definition":"Maximum tumor shrinkage rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Maximum tumor shrinkage rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"exploratory_tgd_srmax","label":"Maximum tumor shrinkage rate","max":0.0327475377,"min":0.0109158459,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/week","value":0.0218316918},{"category":"model parameter","definition":"Tumor-shrinkage half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-shrinkage half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"exploratory_tgd_sr_ec50","label":"Tumor-shrinkage half-maximal concentration","max":1130.3786797500002,"min":376.79289325,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"ug/mL","value":753.5857865},{"category":"model parameter","definition":"Minimum tumor progression rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Minimum tumor progression rate defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"exploratory_tgd_prmin","label":"Minimum tumor progression rate","max":0.63417437295,"min":0.21139145765,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mm/week","value":0.4227829153},{"category":"model parameter","definition":"Tumor-progression half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-progression half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"exploratory_tgd_pr_ec50","label":"Tumor-progression half-maximal concentration","max":20.886250935,"min":6.962083645,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ug/mL","value":13.92416729}],"description":"How does nivolumab exposure shift the balance between tumor shrinkage and progression? Explore this biological starting configuration through Steady-state trough concentration, Tumor size, Tumor size relative to baseline.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"joint RCC 10 mg/kg, Cminss 215 ug/mL","outputs":[{"classification":"provisional","description":"Steady-state trough concentration over the selected simulation window.","key":"exploratory_cminss_ug_mL","label":"Steady-state trough concentration","unit":null},{"classification":"provisional","description":"Tumor size over the selected simulation window.","key":"exploratory_tumor_size_mm","label":"Tumor size","unit":"mm"},{"classification":"provisional","description":"Tumor size relative to baseline over the selected simulation window.","key":"tumor_size_percent_baseline","label":"Tumor size relative to baseline","unit":"percent"}],"scenario_id":"exploratory_joint_rcc_10mgkg_cmin215","scientific_questions":["How does nivolumab exposure shift the balance between tumor shrinkage and progression?"],"time_span":{"end":52,"start":0,"step":0.25}}],"targets":[{"key":"pd1","label":"PD-1 / PDCD1"}],"therapeutics":[{"key":"nivolumab","label":"Nivolumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model for HER2-directed antibody–drug conjugates, representing central and peripheral disposition, concentration, and cumulative exposure across dose levels.","diseases":[{"key":"her2_positive_cancers","label":"HER2-positive cancers"}],"links":{"page":"/modeling/models/asiimwe-2025-adc-mbma-cui-poppk","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"antibody-drug conjugate","model_classes":["Meta-model/MBMA","PopPK","ADC"],"model_id":"asiimwe_2025_adc_mbma_cui_poppk","name":"HER2 ADC population PK","outputs":[{"description":"Central HER2 ADC concentration over the selected simulation window.","key":"central_conc_ng_ml","label":"Central HER2 ADC concentration","unit":null},{"description":"Peripheral HER2 ADC concentration over the selected simulation window.","key":"peripheral_conc_mg_l","label":"Peripheral HER2 ADC concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_ng_day_ml","label":"Exposure (AUC)","unit":"ng*day/mL"},{"description":"Central conc over the selected simulation window.","key":"central_conc_mg_l","label":"Central conc","unit":null},{"description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":1.2135,"min":0.4045,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.809},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.9245,"min":1.6415,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.283},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":1.6800000000000002,"min":0.56,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/day","value":1.12},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":1.1219999999999999,"min":0.374,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L","value":0.748}],"description":"How does dose change HER2 ADC concentration and cumulative exposure? Explore this intervention regimen through Central HER2 ADC concentration, Peripheral HER2 ADC concentration, Cumulative ADC exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"T-DM1 0.3 mg/kg cycle-1 fixed-effect","outputs":[{"classification":"provisional","description":"Central HER2 ADC concentration over the selected simulation window.","key":"central_conc_ng_ml","label":"Central HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Peripheral HER2 ADC concentration over the selected simulation window.","key":"peripheral_conc_mg_l","label":"Peripheral HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ng_day_ml","label":"Exposure (AUC)","unit":"ng*day/mL"}],"scenario_id":"tdm1_0p3mgkg_cycle1_fixed_effect_ode","scientific_questions":["How does dose change HER2 ADC concentration and cumulative exposure?"],"time_span":{"end":21,"start":0,"step":0.025}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":1.2135,"min":0.4045,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.809},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.9245,"min":1.6415,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.283},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":1.6800000000000002,"min":0.56,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/day","value":1.12},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":1.1219999999999999,"min":0.374,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L","value":0.748}],"description":"How does dose change HER2 ADC concentration and cumulative exposure? Explore this intervention regimen through Central HER2 ADC concentration, Peripheral HER2 ADC concentration, Cumulative ADC exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"T-DM1 1.8 mg/kg cycle-1 fixed-effect","outputs":[{"classification":"provisional","description":"Central HER2 ADC concentration over the selected simulation window.","key":"central_conc_ng_ml","label":"Central HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Peripheral HER2 ADC concentration over the selected simulation window.","key":"peripheral_conc_mg_l","label":"Peripheral HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ng_day_ml","label":"Exposure (AUC)","unit":"ng*day/mL"}],"scenario_id":"tdm1_1p8mgkg_cycle1_fixed_effect_ode","scientific_questions":["How does dose change HER2 ADC concentration and cumulative exposure?"],"time_span":{"end":21,"start":0,"step":0.025}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":1.2135,"min":0.4045,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.809},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.9245,"min":1.6415,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.283},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":1.6800000000000002,"min":0.56,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/day","value":1.12},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":1.1219999999999999,"min":0.374,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L","value":0.748}],"description":"How does dose change HER2 ADC concentration and cumulative exposure? Explore this intervention regimen through Central HER2 ADC concentration, Peripheral HER2 ADC concentration, Cumulative ADC exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"T-DM1 4.8 mg/kg cycle-1 fixed-effect","outputs":[{"classification":"provisional","description":"Central HER2 ADC concentration over the selected simulation window.","key":"central_conc_ng_ml","label":"Central HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Peripheral HER2 ADC concentration over the selected simulation window.","key":"peripheral_conc_mg_l","label":"Peripheral HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ng_day_ml","label":"Exposure (AUC)","unit":"ng*day/mL"}],"scenario_id":"tdm1_4p8mgkg_cycle1_fixed_effect_ode","scientific_questions":["How does dose change HER2 ADC concentration and cumulative exposure?"],"time_span":{"end":21,"start":0,"step":0.025}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":0.8775,"min":0.2925,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.585},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.1775,"min":1.3925,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.785},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":0.978,"min":0.326,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.652},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":1.8645,"min":0.6215,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.243}],"description":"How does dose change HER2 ADC concentration and cumulative exposure? Explore this intervention regimen through Central HER2 ADC concentration, Peripheral HER2 ADC concentration, Cumulative ADC exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"T-DXd 5.4 mg/kg cycle-1 fixed-effect","outputs":[{"classification":"provisional","description":"Central HER2 ADC concentration over the selected simulation window.","key":"central_conc_ng_ml","label":"Central HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Peripheral HER2 ADC concentration over the selected simulation window.","key":"peripheral_conc_mg_l","label":"Peripheral HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ng_day_ml","label":"Exposure (AUC)","unit":"ng*day/mL"}],"scenario_id":"tdxd_5p4mgkg_cycle1_fixed_effect_ode","scientific_questions":["How does dose change HER2 ADC concentration and cumulative exposure?"],"time_span":{"end":21,"start":0,"step":0.025}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":0.8775,"min":0.2925,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.585},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.1775,"min":1.3925,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.785},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":0.978,"min":0.326,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.652},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":1.8645,"min":0.6215,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.243}],"description":"How does dose change HER2 ADC concentration and cumulative exposure? Explore this intervention regimen through Central HER2 ADC concentration, Peripheral HER2 ADC concentration, Cumulative ADC exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"T-DXd 8 mg/kg cycle-1 fixed-effect","outputs":[{"classification":"provisional","description":"Central HER2 ADC concentration over the selected simulation window.","key":"central_conc_ng_ml","label":"Central HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Peripheral HER2 ADC concentration over the selected simulation window.","key":"peripheral_conc_mg_l","label":"Peripheral HER2 ADC concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ng_day_ml","label":"Exposure (AUC)","unit":"ng*day/mL"}],"scenario_id":"tdxd_8p0mgkg_cycle1_fixed_effect_ode","scientific_questions":["How does dose change HER2 ADC concentration and cumulative exposure?"],"time_span":{"end":21,"start":0,"step":0.025}}],"targets":[{"key":"her2","label":"HER2 / ERBB2"}],"therapeutics":[{"key":"trastuzumab_emtansine_or_trastuzumab_deruxtecan","label":"Trastuzumab emtansine or trastuzumab deruxtecan"},{"key":"trastuzumab_emtansine","label":"trastuzumab emtansine"},{"key":"t_dm1","label":"T-DM1"},{"key":"trastuzumab_deruxtecan","label":"trastuzumab deruxtecan"},{"key":"t_dxd","label":"T-DXd"},{"key":"trastuzumab","label":"trastuzumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A cytokine-network QSP model coupling drug exposure to resting, activated, cytotoxic, and exhausted T cells and to IL-6, IL-10, IL-1beta, IFN-gamma, and TNF-alpha dynamics.","diseases":[{"key":"cytokine_release_syndrome","label":"Cytokine-release syndrome"}],"links":{"page":"/modeling/models/besbassi-2026-crs-qsp-locked-cytokine-network","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":null,"model_classes":["QSP","TCE/BsAb"],"model_id":"besbassi_2026_crs_qsp_locked_cytokine_network","name":"T-cell-engager cytokine-release network","outputs":[{"description":"Drug concentration over the selected simulation window.","key":"Cdrug_nM","label":"Drug concentration","unit":"nM"},{"description":"Activated t over the selected simulation window.","key":"Tact_cells_ul","label":"Activated t","unit":"cell/uL"},{"description":"Il 6 over the selected simulation window.","key":"IL6_pg_ml","label":"Il 6","unit":"pg/mL"},{"description":"Ifn gamma over the selected simulation window.","key":"IFNg_pg_ml","label":"Ifn gamma","unit":"pg/mL"},{"description":"Tnf alpha over the selected simulation window.","key":"TNFa_pg_ml","label":"Tnf alpha","unit":"pg/mL"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":3.1500000000000004,"min":1.05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/hour","value":2.1},{"category":"model parameter","definition":"T-cell activation EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"T-cell activation EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_act_nM","label":"T-cell activation EC50","max":1.5,"min":0.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM","value":1},{"category":"model parameter","definition":"Maximum activated T-cell concentration coefficient used by the released system of model equations.","description":"Maximum activated T-cell concentration coefficient used by the released system of model equations.","key":"Tact_max_cells_ul","label":"Maximum activated T-cell concentration","max":7500,"min":2500,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":10,"unit":"cell/uL","value":5000},{"category":"model parameter","definition":"Macrophage activation EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Macrophage activation EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_mac_pg_ml","label":"Macrophage activation EC50","max":72.9,"min":24.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pg/mL","value":48.6},{"category":"model parameter","definition":"IC50 IL-10 at which the corresponding modeled process is inhibited by half.","description":"IC50 IL-10 at which the corresponding modeled process is inhibited by half.","key":"IC50_IL10_pg_ml","label":"IC50 IL-10","max":75,"min":25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pg/mL","value":50}],"description":"How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release? Explore this biological starting configuration through T-cell agonist concentration, Activated T cells, IL-6, IFN-gamma, TNF-alpha.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"blinatumomab 28 ug/day continuous infusion through day 28","outputs":[{"classification":"provisional","description":"Drug concentration over the selected simulation window.","key":"Cdrug_nM","label":"Drug concentration","unit":"nM"},{"classification":"provisional","description":"Activated t over the selected simulation window.","key":"Tact_cells_ul","label":"Activated t","unit":"cell/uL"},{"classification":"provisional","description":"Il 6 over the selected simulation window.","key":"IL6_pg_ml","label":"Il 6","unit":"pg/mL"},{"classification":"provisional","description":"Ifn gamma over the selected simulation window.","key":"IFNg_pg_ml","label":"Ifn gamma","unit":"pg/mL"},{"classification":"provisional","description":"Tnf alpha over the selected simulation window.","key":"TNFa_pg_ml","label":"Tnf alpha","unit":"pg/mL"}],"scenario_id":"blinatumomab_28ug_day_28day_full_ode_overlay","scientific_questions":["How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release?"],"time_span":{"end":672,"start":0,"step":2}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":0.0075,"min":0.0025,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/hour","value":0.005},{"category":"model parameter","definition":"T-cell activation EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"T-cell activation EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_act_nM","label":"T-cell activation EC50","max":1.5,"min":0.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM","value":1},{"category":"model parameter","definition":"Maximum activated T-cell concentration coefficient used by the released system of model equations.","description":"Maximum activated T-cell concentration coefficient used by the released system of model equations.","key":"Tact_max_cells_ul","label":"Maximum activated T-cell concentration","max":30000,"min":10000,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":100,"unit":"cell/uL","value":20000},{"category":"model parameter","definition":"Macrophage activation EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Macrophage activation EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_mac_pg_ml","label":"Macrophage activation EC50","max":72.9,"min":24.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pg/mL","value":48.6},{"category":"model parameter","definition":"IC50 IL-10 at which the corresponding modeled process is inhibited by half.","description":"IC50 IL-10 at which the corresponding modeled process is inhibited by half.","key":"IC50_IL10_pg_ml","label":"IC50 IL-10","max":75,"min":25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pg/mL","value":50}],"description":"How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release? Explore this biological starting configuration through T-cell agonist concentration, Activated T cells, IL-6, IFN-gamma, TNF-alpha.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"TGN1412 0.1 mg/kg IV bolus in 70 kg subject","outputs":[{"classification":"provisional","description":"Drug concentration over the selected simulation window.","key":"Cdrug_nM","label":"Drug concentration","unit":"nM"},{"classification":"provisional","description":"Activated t over the selected simulation window.","key":"Tact_cells_ul","label":"Activated t","unit":"cell/uL"},{"classification":"provisional","description":"Il 6 over the selected simulation window.","key":"IL6_pg_ml","label":"Il 6","unit":"pg/mL"},{"classification":"provisional","description":"Ifn gamma over the selected simulation window.","key":"IFNg_pg_ml","label":"Ifn gamma","unit":"pg/mL"},{"classification":"provisional","description":"Tnf alpha over the selected simulation window.","key":"TNFa_pg_ml","label":"Tnf alpha","unit":"pg/mL"}],"scenario_id":"tgn1412_0p1mgkg_full_ode_overlay","scientific_questions":["How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release?"],"time_span":{"end":72,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":0.03,"min":0.01,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/hour","value":0.02},{"category":"model parameter","definition":"T-cell activation EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"T-cell activation EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_act_nM","label":"T-cell activation EC50","max":3,"min":1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM","value":2},{"category":"model parameter","definition":"Maximum activated T-cell concentration coefficient used by the released system of model equations.","description":"Maximum activated T-cell concentration coefficient used by the released system of model equations.","key":"Tact_max_cells_ul","label":"Maximum activated T-cell concentration","max":7500,"min":2500,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":10,"unit":"cell/uL","value":5000},{"category":"model parameter","definition":"Macrophage activation EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Macrophage activation EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_mac_pg_ml","label":"Macrophage activation EC50","max":72.9,"min":24.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pg/mL","value":48.6},{"category":"model parameter","definition":"IC50 IL-10 at which the corresponding modeled process is inhibited by half.","description":"IC50 IL-10 at which the corresponding modeled process is inhibited by half.","key":"IC50_IL10_pg_ml","label":"IC50 IL-10","max":75,"min":25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pg/mL","value":50}],"description":"How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release? Explore this biological starting configuration through T-cell agonist concentration, Activated T cells, IL-6, IFN-gamma, TNF-alpha.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"OKT3 5 mg IV bolus","outputs":[{"classification":"provisional","description":"Drug concentration over the selected simulation window.","key":"Cdrug_nM","label":"Drug concentration","unit":"nM"},{"classification":"provisional","description":"Activated t over the selected simulation window.","key":"Tact_cells_ul","label":"Activated t","unit":"cell/uL"},{"classification":"provisional","description":"Il 6 over the selected simulation window.","key":"IL6_pg_ml","label":"Il 6","unit":"pg/mL"},{"classification":"provisional","description":"Ifn gamma over the selected simulation window.","key":"IFNg_pg_ml","label":"Ifn gamma","unit":"pg/mL"},{"classification":"provisional","description":"Tnf alpha over the selected simulation window.","key":"TNFa_pg_ml","label":"Tnf alpha","unit":"pg/mL"}],"scenario_id":"okt3_5mg_full_ode_overlay","scientific_questions":["How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release?"],"time_span":{"end":72,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":0.0075,"min":0.0025,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/hour","value":0.005},{"category":"model parameter","definition":"T-cell activation EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"T-cell activation EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_act_nM","label":"T-cell activation EC50","max":1.5,"min":0.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM","value":1},{"category":"model parameter","definition":"Maximum activated T-cell concentration coefficient used by the released system of model equations.","description":"Maximum activated T-cell concentration coefficient used by the released system of model equations.","key":"Tact_max_cells_ul","label":"Maximum activated T-cell concentration","max":30000,"min":10000,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":100,"unit":"cell/uL","value":20000},{"category":"model parameter","definition":"Macrophage activation EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Macrophage activation EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_mac_pg_ml","label":"Macrophage activation EC50","max":72.9,"min":24.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pg/mL","value":48.6},{"category":"model parameter","definition":"IC50 IL-10 at which the corresponding modeled process is inhibited by half.","description":"IC50 IL-10 at which the corresponding modeled process is inhibited by half.","key":"IC50_IL10_pg_ml","label":"IC50 IL-10","max":75,"min":25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pg/mL","value":50}],"description":"How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release? Explore this biological starting configuration through T-cell agonist concentration, Activated T cells, IL-6, IFN-gamma, TNF-alpha.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"TGN1412 with tocilizumab rescue at 6 h","outputs":[{"classification":"provisional","description":"Drug concentration over the selected simulation window.","key":"Cdrug_nM","label":"Drug concentration","unit":"nM"},{"classification":"provisional","description":"Activated t over the selected simulation window.","key":"Tact_cells_ul","label":"Activated t","unit":"cell/uL"},{"classification":"provisional","description":"Il 6 over the selected simulation window.","key":"IL6_pg_ml","label":"Il 6","unit":"pg/mL"},{"classification":"provisional","description":"Ifn gamma over the selected simulation window.","key":"IFNg_pg_ml","label":"Ifn gamma","unit":"pg/mL"},{"classification":"provisional","description":"Tnf alpha over the selected simulation window.","key":"TNFa_pg_ml","label":"Tnf alpha","unit":"pg/mL"}],"scenario_id":"tgn1412_tocilizumab_6h_rescue_overlay","scientific_questions":["How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release?"],"time_span":{"end":72,"start":0,"step":0.25}}],"targets":[{"key":"cd19","label":"CD19"},{"key":"cd3","label":"CD3"},{"key":"cd28","label":"CD28"},{"key":"il6r","label":"IL-6R / CD126"}],"therapeutics":[{"key":"blinatumomab_and_comparator_t_cell_agonists","label":"Blinatumomab and comparator T-cell agonists"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A coupled subcutaneous PK and indirect-response model linking dupilumab exposure to EASI and IGA response dynamics while accounting for patient and disease covariates.","diseases":[{"key":"moderate_to_severe_atopic_dermatitis","label":"Moderate-to-severe atopic dermatitis"}],"links":{"page":"/modeling/models/briggs-2023-dupilumab-ad-er-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"whole monoclonal antibody","model_classes":["PopPK","PKPD","Exposure-response"],"model_id":"briggs_2023_dupilumab_ad_er_pkpd","name":"Dupilumab exposure and atopic-dermatitis response","outputs":[{"description":"Central dupilumab concentration over the selected simulation window.","key":"central_conc_mg_l","label":"Central dupilumab concentration","unit":null},{"description":"EASI response over the selected simulation window.","key":"easi_response_tukey","label":"EASI response","unit":"dimensionless"},{"description":"IGA response over the selected simulation window.","key":"iga_response","label":"IGA response","unit":"dimensionless"},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"},{"description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":114.14999999999999,"min":38.05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":76.1},{"category":"model parameter","definition":"EASI IC50 at which the corresponding modeled process is inhibited by half.","description":"EASI IC50 at which the corresponding modeled process is inhibited by half.","key":"easi_ic50_mg_l","label":"EASI IC50","max":30.450000000000003,"min":10.15,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mg/L","value":20.3},{"category":"model parameter","definition":"EASI Imax defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"EASI Imax defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"easi_imax","label":"EASI Imax","max":0.399,"min":0.133,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.266},{"category":"model parameter","definition":"EASI effect half-life controlling the time required for the corresponding quantity to decrease by half.","description":"EASI effect half-life controlling the time required for the corresponding quantity to decrease by half.","key":"easi_effect_half_life_day","label":"EASI effect half-life","max":20.549999999999997,"min":6.85,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":13.7},{"category":"model parameter","definition":"IGA IC50 at which the corresponding modeled process is inhibited by half.","description":"IGA IC50 at which the corresponding modeled process is inhibited by half.","key":"iga_ic50_mg_l","label":"IGA IC50","max":40.650000000000006,"min":13.55,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mg/L","value":27.1}],"description":"How do dupilumab exposure and patient covariates shape the onset and depth of EASI and IGA response? Explore this intervention regimen through Central dupilumab concentration, EASI response, IGA response, Cumulative dupilumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Adult severe AD 600 mg load, 300 mg every 2 weeks","outputs":[{"classification":"provisional","description":"Central dupilumab concentration over the selected simulation window.","key":"central_conc_mg_l","label":"Central dupilumab concentration","unit":null},{"classification":"provisional","description":"EASI response over the selected simulation window.","key":"easi_response_tukey","label":"EASI response","unit":"dimensionless"},{"classification":"provisional","description":"IGA response over the selected simulation window.","key":"iga_response","label":"IGA response","unit":"dimensionless"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"}],"scenario_id":"adult_severe_300mg_q2w_16weeks","scientific_questions":["How do dupilumab exposure and patient covariates shape the onset and depth of EASI and IGA response?"],"time_span":{"end":112,"start":0,"step":7}},{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":47.25,"min":15.75,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":31.5},{"category":"model parameter","definition":"EASI IC50 at which the corresponding modeled process is inhibited by half.","description":"EASI IC50 at which the corresponding modeled process is inhibited by half.","key":"easi_ic50_mg_l","label":"EASI IC50","max":30.450000000000003,"min":10.15,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mg/L","value":20.3},{"category":"model parameter","definition":"EASI Imax defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"EASI Imax defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"easi_imax","label":"EASI Imax","max":0.399,"min":0.133,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.266},{"category":"model parameter","definition":"EASI effect half-life controlling the time required for the corresponding quantity to decrease by half.","description":"EASI effect half-life controlling the time required for the corresponding quantity to decrease by half.","key":"easi_effect_half_life_day","label":"EASI effect half-life","max":20.549999999999997,"min":6.85,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":13.7},{"category":"model parameter","definition":"IGA IC50 at which the corresponding modeled process is inhibited by half.","description":"IGA IC50 at which the corresponding modeled process is inhibited by half.","key":"iga_ic50_mg_l","label":"IGA IC50","max":40.650000000000006,"min":13.55,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mg/L","value":27.1}],"description":"How do dupilumab exposure and patient covariates shape the onset and depth of EASI and IGA response? Explore this intervention regimen through Central dupilumab concentration, EASI response, IGA response, Cumulative dupilumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Child severe AD 400 mg load, 200 mg every 2 weeks","outputs":[{"classification":"provisional","description":"Central dupilumab concentration over the selected simulation window.","key":"central_conc_mg_l","label":"Central dupilumab concentration","unit":null},{"classification":"provisional","description":"EASI response over the selected simulation window.","key":"easi_response_tukey","label":"EASI response","unit":"dimensionless"},{"classification":"provisional","description":"IGA response over the selected simulation window.","key":"iga_response","label":"IGA response","unit":"dimensionless"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"}],"scenario_id":"child_severe_200mg_q2w_16weeks","scientific_questions":["How do dupilumab exposure and patient covariates shape the onset and depth of EASI and IGA response?"],"time_span":{"end":112,"start":0,"step":7}}],"targets":[{"key":"il4r","label":"IL4R"},{"key":"cd124","label":"CD124"}],"therapeutics":[{"key":"dupilumab","label":"Dupilumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced plasma PK model representing first-order elimination, concentration, half-life, and cumulative exposure of a positively charged trastuzumab-vc-MMAE ADC.","diseases":[{"key":"her2_positive_preclinical_tumor_models","label":"HER2-positive preclinical tumor models"}],"links":{"page":"/modeling/models/chang-2025-charged-trastuzumab-adc-mice-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Antibody-drug conjugate","model_classes":["PKPD","ADC"],"model_id":"chang_2025_charged_trastuzumab_adc_mice_pkpd","name":"Charged trastuzumab ADC plasma disposition","outputs":[{"description":"Drug concentration over the selected simulation window.","key":"C_nM","label":"Drug concentration","unit":"nM"},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_h_nM","label":"Exposure (AUC)","unit":"h*nM"},{"description":"ADC half-life over the selected simulation window.","key":"ode_half_life_h","label":"ADC half-life","unit":null},{"description":"Elapsed over the selected simulation window.","key":"elapsed_h","label":"Elapsed","unit":"h"},{"description":"Ode AUC endpoint over the selected simulation window.","key":"ode_auc_endpoint_h_nM","label":"Ode AUC endpoint","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Elimination rate constant governing first-order loss from the modeled system.","description":"Elimination rate constant governing first-order loss from the modeled system.","key":"kel_1_h","label":"Elimination rate constant","max":0.024134831460674154,"min":0.008044943820224719,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/h","value":0.016089887640449437}],"description":"Explore how the starting plasma concentration and first-order elimination rate determine charged trastuzumab ADC concentration, half-life, and cumulative plasma exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Charged trastuzumab ADC plasma disposition","outputs":[{"classification":"provisional","description":"Drug concentration over the selected simulation window.","key":"C_nM","label":"Drug concentration","unit":"nM"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_h_nM","label":"Exposure (AUC)","unit":"h*nM"},{"classification":"provisional","description":"ADC half-life over the selected simulation window.","key":"ode_half_life_h","label":"ADC half-life","unit":null}],"scenario_id":"ode_charged_plasma_total_mab_aucinf_h_nm","scientific_questions":["How does the elimination rate determine plasma ADC concentration, half-life, and exposure?"],"time_span":{"end":168,"start":0,"step":1}}],"targets":[{"key":"her2","label":"HER2 / ERBB2"}],"therapeutics":[{"key":"positively_charged_trastuzumab_vc_mmae_adc","label":"Positively charged trastuzumab-vc-MMAE ADC"},{"key":"trastuzumab","label":"trastuzumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced tumor-growth model representing the balance between untreated tumor expansion and SKB264-associated tumor-cell killing.","diseases":[{"key":"trop2_positive_preclinical_tumor_models","label":"TROP2-positive preclinical tumor models"}],"links":{"page":"/modeling/models/cheng-2022-skb264-trop2-adc-preclinical-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb ADC","model_classes":["PKPD","ADC"],"model_id":"cheng_2022_skb264_trop2_adc_preclinical_pkpd","name":"SKB264 tumor-growth inhibition","outputs":[{"description":"Tumor volume over the selected simulation window.","key":"tumor_volume_mm3","label":"Tumor volume","unit":"millimeter**3"},{"description":"Net tumor growth rate over the selected simulation window.","key":"net_tumor_growth_rate_day","label":"Net tumor growth rate","unit":null},{"description":"Tumor growth rate over the selected simulation window.","key":"tumor_growth_rate_day","label":"Tumor growth rate","unit":null},{"description":"Tumor kill rate over the selected simulation window.","key":"tumor_kill_rate_day","label":"Tumor kill rate","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Tumor growth rate governing growth in the modeled biological process.","description":"Tumor growth rate governing growth in the modeled biological process.","key":"tumor_growth_rate_day","label":"Tumor growth rate","max":0.06,"min":0.02,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.04},{"category":"model parameter","definition":"Tumor kill rate governing loss, degradation, or removal in the modeled biological process.","description":"Tumor kill rate governing loss, degradation, or removal in the modeled biological process.","key":"tumor_kill_rate_day","label":"Tumor kill rate","max":1,"min":0,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"1/day","value":0}],"description":"How does the modeled ADC killing rate change tumor-volume dynamics relative to intrinsic growth? Explore this biological starting configuration through Tumor volume, Net tumor growth rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Default model behavior","outputs":[{"classification":"provisional","description":"Tumor volume over the selected simulation window.","key":"tumor_volume_mm3","label":"Tumor volume","unit":"millimeter**3"},{"classification":"provisional","description":"Net tumor growth rate over the selected simulation window.","key":"net_tumor_growth_rate_day","label":"Net tumor growth rate","unit":null}],"scenario_id":"default_model_behavior","scientific_questions":["How does the modeled ADC killing rate change tumor-volume dynamics relative to intrinsic growth?"],"time_span":{"end":30,"start":0,"step":0.25}}],"targets":[{"key":"tacstd2","label":"TACSTD2"},{"key":"trop2","label":"TROP2"},{"key":"egp1","label":"EGP1"}],"therapeutics":[{"key":"skb264_sacituzumab_tirumotecan","label":"SKB264 (sacituzumab tirumotecan)"},{"key":"anti_trop2_humanized_mab_shared_with_immu_132","label":"anti-TROP2 humanized mAb shared with IMMU-132"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced pharmacodynamic turnover model representing the time course of PASI response toward an efalizumab-associated steady state.","diseases":[{"key":"plaque_psoriasis","label":"Plaque psoriasis"}],"links":{"page":"/modeling/models/chetty-2014-efalizumab-fcrn-pbpk-pd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["Other/Unclassified"],"model_id":"chetty_2014_efalizumab_fcrn_pbpk_pd","name":"Efalizumab PASI response dynamics","outputs":[{"description":"PASI score over the selected simulation window.","key":"PASI_score","label":"PASI score","unit":"dimensionless"},{"description":"Current PASI response over the selected simulation window.","key":"PASI_current","label":"Current PASI response","unit":null},{"description":"PASI change rate over the selected simulation window.","key":"pasi_progression_rate_h","label":"PASI change rate","unit":null},{"description":"Effect equilibration time over the selected simulation window.","key":"Tp_h","label":"Effect equilibration time","unit":null},{"description":"Steady-state PASI score over the selected simulation window.","key":"Yss_current_PASI","label":"Steady-state PASI score","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Effect equilibration time coefficient used by the released system of model equations.","description":"Effect equilibration time coefficient used by the released system of model equations.","key":"Tp_h","label":"Effect equilibration time","max":595.5,"min":198.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"hour","value":397},{"category":"model parameter","definition":"Steady-state PASI score coefficient used by the released system of model equations.","description":"Steady-state PASI score coefficient used by the released system of model equations.","key":"Yss_current_PASI","label":"Steady-state PASI score","max":22.200000000000003,"min":7.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"dimensionless","value":14.8}],"description":"How do the response time scale and treatment-associated steady state determine PASI dynamics? Explore this biological starting configuration through PASI score, Current PASI response, PASI change rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Gottlieb escalating-dose PASI progression","outputs":[{"classification":"provisional","description":"PASI score over the selected simulation window.","key":"PASI_score","label":"PASI score","unit":"dimensionless"},{"classification":"provisional","description":"Current PASI response over the selected simulation window.","key":"PASI_current","label":"Current PASI response","unit":null},{"classification":"provisional","description":"PASI change rate over the selected simulation window.","key":"pasi_progression_rate_h","label":"PASI change rate","unit":null}],"scenario_id":"gottlieb_escalating_pasi_progression_probe","scientific_questions":["How do the response time scale and treatment-associated steady state determine PASI dynamics?"],"time_span":{"end":1176,"start":0,"step":24}},{"controls":[{"category":"model parameter","definition":"Effect equilibration time coefficient used by the released system of model equations.","description":"Effect equilibration time coefficient used by the released system of model equations.","key":"Tp_h","label":"Effect equilibration time","max":595.5,"min":198.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"hour","value":397},{"category":"model parameter","definition":"Steady-state PASI score coefficient used by the released system of model equations.","description":"Steady-state PASI score coefficient used by the released system of model equations.","key":"Yss_current_PASI","label":"Steady-state PASI score","max":14.25,"min":4.75,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"dimensionless","value":9.5}],"description":"How do the response time scale and treatment-associated steady state determine PASI dynamics? Explore this biological starting configuration through PASI score, Current PASI response, PASI change rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Gordon 1 mg/kg PASI progression","outputs":[{"classification":"provisional","description":"PASI score over the selected simulation window.","key":"PASI_score","label":"PASI score","unit":"dimensionless"},{"classification":"provisional","description":"Current PASI response over the selected simulation window.","key":"PASI_current","label":"Current PASI response","unit":null},{"classification":"provisional","description":"PASI change rate over the selected simulation window.","key":"pasi_progression_rate_h","label":"PASI change rate","unit":null}],"scenario_id":"gordon_1mgkg_pasi_progression_probe","scientific_questions":["How do the response time scale and treatment-associated steady state determine PASI dynamics?"],"time_span":{"end":1176,"start":0,"step":24}}],"targets":[{"key":"itgal","label":"ITGAL"},{"key":"cd11a","label":"CD11a"},{"key":"lfa_1_alpha","label":"LFA-1 alpha"}],"therapeutics":[{"key":"efalizumab","label":"Efalizumab"},{"key":"efalizumab_hu1124_raptiva","label":"Efalizumab / hu1124 / Raptiva"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced ADC–payload disposition model linking enfortumab vedotin concentration to formation and elimination of the released MMAE payload and their cumulative exposures.","diseases":[{"key":"nectin_4_positive_cancers_and_mmae_drug_drug_interaction_assessment","label":"Nectin-4-positive cancers and MMAE drug–drug interaction assessment"}],"links":{"page":"/modeling/models/choules-2024-enfortumab-vedotin-adc-pbpk-ddi","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb ADC","model_classes":["PBPK","ADC"],"model_id":"choules_2024_enfortumab_vedotin_adc_pbpk_ddi","name":"Enfortumab vedotin and MMAE disposition","outputs":[{"description":"ADC concentration over the selected simulation window.","key":"adc_conc_ug_ml","label":"ADC concentration","unit":"ug/mL"},{"description":"MMAE concentration over the selected simulation window.","key":"mmae_conc_ng_ml","label":"MMAE concentration","unit":"ng/mL"},{"description":"Cumulative ADC exposure over the selected simulation window.","key":"auc_adc_ug_day_ml","label":"Cumulative ADC exposure","unit":"ug*day/mL"},{"description":"Cumulative MMAE exposure over the selected simulation window.","key":"auc_mmae_ng_day_ml","label":"Cumulative MMAE exposure","unit":"ng*day/mL"},{"description":"Elapsed over the selected simulation window.","key":"elapsed_day","label":"Elapsed","unit":"day"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"ADC decay governing first-order loss from the modeled system.","description":"ADC decay governing first-order loss from the modeled system.","key":"adc_decay_day","label":"ADC decay","max":1.1599378881987574,"min":0.3866459627329192,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.7732919254658384},{"category":"model parameter","definition":"MMAE formation governing production or formation in the modeled biological process.","description":"MMAE formation governing production or formation in the modeled biological process.","key":"mmae_formation_ng_ml_day_per_ug_ml","label":"MMAE formation","max":0.1779,"min":0.0593,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"(ng/mL/day)/(ug/mL)","value":0.1186},{"category":"model parameter","definition":"MMAE elimination governing first-order loss from the modeled system.","description":"MMAE elimination governing first-order loss from the modeled system.","key":"mmae_elimination_day","label":"MMAE elimination","max":0.3408846621,"min":0.1136282207,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.2272564414}],"description":"How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure? Explore this intervention regimen through Enfortumab vedotin concentration, MMAE concentration, Cumulative ADC exposure, Cumulative MMAE exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"EV 1.25 mg/kg single dose reduced","outputs":[{"classification":"provisional","description":"ADC concentration over the selected simulation window.","key":"adc_conc_ug_ml","label":"ADC concentration","unit":"ug/mL"},{"classification":"provisional","description":"MMAE concentration over the selected simulation window.","key":"mmae_conc_ng_ml","label":"MMAE concentration","unit":"ng/mL"},{"classification":"provisional","description":"Cumulative ADC exposure over the selected simulation window.","key":"auc_adc_ug_day_ml","label":"Cumulative ADC exposure","unit":"ug*day/mL"},{"classification":"provisional","description":"Cumulative MMAE exposure over the selected simulation window.","key":"auc_mmae_ng_day_ml","label":"Cumulative MMAE exposure","unit":"ng*day/mL"}],"scenario_id":"ev_1p25_single_dose_reduced_ode","scientific_questions":["How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure?"],"time_span":{"end":7,"start":0,"step":0.05}},{"controls":[{"category":"model parameter","definition":"ADC decay governing first-order loss from the modeled system.","description":"ADC decay governing first-order loss from the modeled system.","key":"adc_decay_day","label":"ADC decay","max":1.1574074074074074,"min":0.38580246913580246,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.7716049382716049},{"category":"model parameter","definition":"MMAE formation governing production or formation in the modeled biological process.","description":"MMAE formation governing production or formation in the modeled biological process.","key":"mmae_formation_ng_ml_day_per_ug_ml","label":"MMAE formation","max":0.183,"min":0.061,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"(ng/mL/day)/(ug/mL)","value":0.122},{"category":"model parameter","definition":"MMAE elimination governing first-order loss from the modeled system.","description":"MMAE elimination governing first-order loss from the modeled system.","key":"mmae_elimination_day","label":"MMAE elimination","max":0.3408846621,"min":0.1136282207,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.2272564414}],"description":"How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure? Explore this intervention regimen through Enfortumab vedotin concentration, MMAE concentration, Cumulative ADC exposure, Cumulative MMAE exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"EV 1.25 mg/kg days 1, 8, and 15 reduced","outputs":[{"classification":"provisional","description":"ADC concentration over the selected simulation window.","key":"adc_conc_ug_ml","label":"ADC concentration","unit":"ug/mL"},{"classification":"provisional","description":"MMAE concentration over the selected simulation window.","key":"mmae_conc_ng_ml","label":"MMAE concentration","unit":"ng/mL"},{"classification":"provisional","description":"Cumulative ADC exposure over the selected simulation window.","key":"auc_adc_ug_day_ml","label":"Cumulative ADC exposure","unit":"ug*day/mL"},{"classification":"provisional","description":"Cumulative MMAE exposure over the selected simulation window.","key":"auc_mmae_ng_day_ml","label":"Cumulative MMAE exposure","unit":"ng*day/mL"}],"scenario_id":"ev_1p25_multiple_dose_reduced_ode","scientific_questions":["How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure?"],"time_span":{"end":28,"start":0,"step":0.05}},{"controls":[{"category":"model parameter","definition":"ADC decay governing first-order loss from the modeled system.","description":"ADC decay governing first-order loss from the modeled system.","key":"adc_decay_day","label":"ADC decay","max":1.1599378881987574,"min":0.3866459627329192,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.7732919254658384},{"category":"model parameter","definition":"MMAE formation governing production or formation in the modeled biological process.","description":"MMAE formation governing production or formation in the modeled biological process.","key":"mmae_formation_ng_ml_day_per_ug_ml","label":"MMAE formation","max":0.1779,"min":0.0593,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"(ng/mL/day)/(ug/mL)","value":0.1186},{"category":"model parameter","definition":"MMAE elimination governing first-order loss from the modeled system.","description":"MMAE elimination governing first-order loss from the modeled system.","key":"mmae_elimination_day","label":"MMAE elimination","max":0.7252865151063831,"min":0.2417621717021277,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.4835243434042554}],"description":"How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure? Explore this intervention regimen through Enfortumab vedotin concentration, MMAE concentration, Cumulative ADC exposure, Cumulative MMAE exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"EV plus rifampin MMAE DDI reduced","outputs":[{"classification":"provisional","description":"ADC concentration over the selected simulation window.","key":"adc_conc_ug_ml","label":"ADC concentration","unit":"ug/mL"},{"classification":"provisional","description":"MMAE concentration over the selected simulation window.","key":"mmae_conc_ng_ml","label":"MMAE concentration","unit":"ng/mL"},{"classification":"provisional","description":"Cumulative ADC exposure over the selected simulation window.","key":"auc_adc_ug_day_ml","label":"Cumulative ADC exposure","unit":"ug*day/mL"},{"classification":"provisional","description":"Cumulative MMAE exposure over the selected simulation window.","key":"auc_mmae_ng_day_ml","label":"Cumulative MMAE exposure","unit":"ng*day/mL"}],"scenario_id":"ev_mmae_rifampin_ddi_reduced_ode","scientific_questions":["How does enfortumab vedotin disposition drive MMAE formation, concentration, and cumulative exposure?"],"time_span":{"end":7,"start":0,"step":0.05}}],"targets":[{"key":"pvrl4","label":"PVRL4"},{"key":"nectin_4","label":"Nectin-4"}],"therapeutics":[{"key":"enfortumab_vedotin","label":"Enfortumab vedotin"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model with intramuscular absorption for the long-acting antibody combination tixagevimab–cilgavimab and covariate-dependent bioavailability and disposition.","diseases":[{"key":"sars_cov_2_pre_exposure_prophylaxis","label":"SARS-CoV-2 pre-exposure prophylaxis"}],"links":{"page":"/modeling/models/clegg-2024-azd7442-tixagevimab-cilgavimab-poppk","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"whole monoclonal antibody combination","model_classes":["PopPK"],"model_id":"clegg_2024_azd7442_tixagevimab_cilgavimab_poppk","name":"Tixagevimab–cilgavimab intramuscular PK","outputs":[{"description":"Central antibody concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central antibody concentration","unit":null},{"description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral antibody concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"description":"Effective absorption rate over the selected simulation window.","key":"ka_eff_1_day","label":"Effective absorption rate","unit":null},{"description":"Central-compartment drug amount over the selected simulation window.","key":"A_central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":0.0756,"min":0.0252,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/day","value":0.0504},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":5.04,"min":1.68,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.36},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":0.5925,"min":0.1975,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.395},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":2.745,"min":0.915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.83},{"category":"model parameter","definition":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","description":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","key":"fim_fraction","label":"Intramuscular bioavailability fraction","max":1.0065,"min":0.3355,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.671}],"description":"How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Cumulative antibody exposure, Effective absorption rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"AZD7442 600 mg IM typical gluteal","outputs":[{"classification":"provisional","description":"Central antibody concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central antibody concentration","unit":null},{"classification":"provisional","description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral antibody concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Effective absorption rate over the selected simulation window.","key":"ka_eff_1_day","label":"Effective absorption rate","unit":null}],"scenario_id":"fig4_typical_600mg_gluteal_azd7442","scientific_questions":["How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure?"],"time_span":{"end":1000,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":0.0756,"min":0.0252,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/day","value":0.0504},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":5.04,"min":1.68,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.36},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":0.5925,"min":0.1975,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.395},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":2.745,"min":0.915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.83},{"category":"model parameter","definition":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","description":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","key":"fim_fraction","label":"Intramuscular bioavailability fraction","max":1.0065,"min":0.3355,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.671}],"description":"How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Cumulative antibody exposure, Effective absorption rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"AZD7442 600 mg IM 95th-percentile body weight","outputs":[{"classification":"provisional","description":"Central antibody concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central antibody concentration","unit":null},{"classification":"provisional","description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral antibody concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Effective absorption rate over the selected simulation window.","key":"ka_eff_1_day","label":"Effective absorption rate","unit":null}],"scenario_id":"fig4_high_weight_600mg_gluteal_azd7442","scientific_questions":["How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure?"],"time_span":{"end":1000,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":0.0756,"min":0.0252,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/day","value":0.0504},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":5.04,"min":1.68,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.36},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":0.5925,"min":0.1975,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.395},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":2.745,"min":0.915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.83},{"category":"model parameter","definition":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","description":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","key":"fim_fraction","label":"Intramuscular bioavailability fraction","max":1.0065,"min":0.3355,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.671}],"description":"How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Cumulative antibody exposure, Effective absorption rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"AZD7442 300 mg IM single-dose PrEP","outputs":[{"classification":"provisional","description":"Central antibody concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central antibody concentration","unit":null},{"classification":"provisional","description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral antibody concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Effective absorption rate over the selected simulation window.","key":"ka_eff_1_day","label":"Effective absorption rate","unit":null}],"scenario_id":"fig5_prep_300mg_single_azd7442","scientific_questions":["How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure?"],"time_span":{"end":365,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":0.0756,"min":0.0252,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/day","value":0.0504},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":5.04,"min":1.68,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.36},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":0.5925,"min":0.1975,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.395},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":2.745,"min":0.915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.83},{"category":"model parameter","definition":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","description":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","key":"fim_fraction","label":"Intramuscular bioavailability fraction","max":1.0065,"min":0.3355,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.671}],"description":"How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Cumulative antibody exposure, Effective absorption rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"AZD7442 300 mg IM adolescent 40 kg extrapolation","outputs":[{"classification":"provisional","description":"Central antibody concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central antibody concentration","unit":null},{"classification":"provisional","description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral antibody concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Effective absorption rate over the selected simulation window.","key":"ka_eff_1_day","label":"Effective absorption rate","unit":null}],"scenario_id":"fig5_adolescent_40kg_300mg_azd7442","scientific_questions":["How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure?"],"time_span":{"end":365,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":0.0684,"min":0.0228,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/day","value":0.0456},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.755,"min":1.585,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.17},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":0.648,"min":0.216,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.432},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vp_l","label":"Peripheral distribution volume","max":2.6550000000000002,"min":0.885,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.77},{"category":"model parameter","definition":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","description":"Intramuscular bioavailability fraction represented as a dimensionless fraction in the released equations.","key":"fim_fraction","label":"Intramuscular bioavailability fraction","max":0.9225,"min":0.3075,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.615}],"description":"How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Cumulative antibody exposure, Effective absorption rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Cilgavimab 150 mg typical gluteal","outputs":[{"classification":"provisional","description":"Central antibody concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central antibody concentration","unit":null},{"classification":"provisional","description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral antibody concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Effective absorption rate over the selected simulation window.","key":"ka_eff_1_day","label":"Effective absorption rate","unit":null}],"scenario_id":"cilgavimab_150mg_typical_gluteal_ode","scientific_questions":["How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure?"],"time_span":{"end":1000,"start":0,"step":1}}],"targets":[{"key":"sars_cov_2_spike_rbd","label":"SARS-CoV-2 Spike RBD"}],"therapeutics":[{"key":"tixagevimab_and_cilgavimab","label":"Tixagevimab and cilgavimab"},{"key":"azd7442","label":"AZD7442"},{"key":"tixagevimab","label":"tixagevimab"},{"key":"cilgavimab","label":"cilgavimab"},{"key":"evusheld","label":"Evusheld"},{"key":"tixagevimab_cilgavimab","label":"tixagevimab/cilgavimab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced subcutaneous PK model representing certolizumab pegol absorption from a depot, systemic elimination, blood concentration, and cumulative exposure.","diseases":[{"key":"plaque_psoriasis","label":"Plaque psoriasis"}],"links":{"page":"/modeling/models/coto-segura-2023-certolizumab-pegol-psoriasis-qsp","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"PEGylated Fab anti-TNF","model_classes":["Other/Unclassified"],"model_id":"coto_segura_2023_certolizumab_pegol_psoriasis_qsp","name":"Certolizumab pegol subcutaneous PK","outputs":[{"description":"Blood certolizumab concentration over the selected simulation window.","key":"blood_concentration_mg_l","label":"Blood certolizumab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"},{"description":"Apparent half-life over the selected simulation window.","key":"derived_half_life_h","label":"Apparent half-life","unit":null},{"description":"Blood certolizumab concentration over the selected simulation window.","key":"blood_concentration_ug_ml","label":"Blood certolizumab concentration","unit":null},{"description":"Blood-compartment drug amount over the selected simulation window.","key":"blood_mg","label":"Blood-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Bioavailability represented as a dimensionless fraction in the released equations.","description":"Bioavailability represented as a dimensionless fraction in the released equations.","key":"bioavailability_fraction","label":"Bioavailability","max":1.2000000000000002,"min":0.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.8},{"category":"model parameter","definition":"Effective distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Effective distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"effective_volume_l","label":"Effective distribution volume","max":5.73148441032189,"min":1.9104948034406302,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.8209896068812603},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.716863860921737,"min":0.23895462030724568,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.47790924061449136},{"category":"model parameter","definition":"Elimination rate constant governing first-order loss from the modeled system.","description":"Elimination rate constant governing first-order loss from the modeled system.","key":"kel_1_day","label":"Elimination rate constant","max":0.09628269995855195,"min":0.032094233319517315,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.06418846663903463}],"description":"How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure? Explore this intervention regimen through Blood certolizumab concentration, Cumulative certolizumab exposure, Apparent half-life.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"400 mg single-dose PBPK","outputs":[{"classification":"provisional","description":"Blood certolizumab concentration over the selected simulation window.","key":"blood_concentration_mg_l","label":"Blood certolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"},{"classification":"provisional","description":"Apparent half-life over the selected simulation window.","key":"derived_half_life_h","label":"Apparent half-life","unit":null}],"scenario_id":"single_400mg_pbpk_ode_endpoint_overlay","scientific_questions":["How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure?"],"time_span":{"end":14.125,"start":0,"step":0.2}},{"controls":[{"category":"model parameter","definition":"Bioavailability represented as a dimensionless fraction in the released equations.","description":"Bioavailability represented as a dimensionless fraction in the released equations.","key":"bioavailability_fraction","label":"Bioavailability","max":1.2000000000000002,"min":0.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.8},{"category":"model parameter","definition":"Effective distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Effective distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"effective_volume_l","label":"Effective distribution volume","max":5.73148441032189,"min":1.9104948034406302,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.8209896068812603},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.716863860921737,"min":0.23895462030724568,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.47790924061449136},{"category":"model parameter","definition":"Elimination rate constant governing first-order loss from the modeled system.","description":"Elimination rate constant governing first-order loss from the modeled system.","key":"kel_1_day","label":"Elimination rate constant","max":0.09628269995855195,"min":0.032094233319517315,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.06418846663903463}],"description":"How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure? Explore this intervention regimen through Blood certolizumab concentration, Cumulative certolizumab exposure, Apparent half-life.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"400 mg loading then 200 mg every 2 weeks PBPK","outputs":[{"classification":"provisional","description":"Blood certolizumab concentration over the selected simulation window.","key":"blood_concentration_mg_l","label":"Blood certolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"},{"classification":"provisional","description":"Apparent half-life over the selected simulation window.","key":"derived_half_life_h","label":"Apparent half-life","unit":null}],"scenario_id":"label_loading_200mg_q2w_pbpk_endpoint_overlay","scientific_questions":["How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure?"],"time_span":{"end":112,"start":0,"step":0.5}}],"targets":[{"key":"tnf","label":"TNF / TNFA"},{"key":"p01375","label":"P01375"}],"therapeutics":[{"key":"certolizumab_pegol","label":"Certolizumab pegol"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A subcutaneous population PK model representing envafolimab absorption, systemic concentration, renal-function covariates, and time-varying clearance.","diseases":[{"key":"pd_l1_positive_solid_tumors","label":"PD-L1-positive solid tumors"}],"links":{"page":"/modeling/models/cui-2024-envafolimab-sc-pdl1-midd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"single-domain PD-L1 antibody Fc fusion protein","model_classes":["PopPK"],"model_id":"cui_2024_envafolimab_sc_pdl1_midd","name":"Envafolimab subcutaneous population PK","outputs":[{"description":"Envafolimab concentration over the selected simulation window.","key":"envafolimab_concentration_ng_ml","label":"Envafolimab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"},{"description":"Individual clearance over the selected simulation window.","key":"cl_l_hr_individual","label":"Individual clearance","unit":null},{"description":"Absorption rate constant over the selected simulation window.","key":"ka_day","label":"Absorption rate constant","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_l","label":"Exposure (AUC)","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_hr","label":"Absorption rate constant","max":0.02205,"min":0.00735,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/hr","value":0.0147},{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"theta_cl_l_hr","label":"Typical clearance","max":0.0717,"min":0.0239,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/hr","value":0.0478},{"category":"model parameter","definition":"Apparent distribution volume coefficient used by the released system of model equations.","description":"Apparent distribution volume coefficient used by the released system of model equations.","key":"v_l","label":"Apparent distribution volume","max":23.25,"min":7.75,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"L","value":15.5},{"category":"model parameter","definition":"Time to half-maximal change coefficient used by the released system of model equations.","description":"Time to half-maximal change coefficient used by the released system of model equations.","key":"t50_day","label":"Time to half-maximal change","max":51,"min":17,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":34},{"category":"model parameter","definition":"Creatinine clearance coefficient used by the released system of model equations.","description":"Creatinine clearance coefficient used by the released system of model equations.","key":"crcl_ml_min","label":"Creatinine clearance","max":142.71,"min":47.57,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mL/min","value":95.14}],"description":"How do dosing interval, renal function, and time-varying clearance change envafolimab exposure? Explore this intervention regimen through Envafolimab concentration, Cumulative envafolimab exposure, Individual clearance, Absorption rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Final model 150 mg QW for 20 weeks","outputs":[{"classification":"provisional","description":"Envafolimab concentration over the selected simulation window.","key":"envafolimab_concentration_ng_ml","label":"Envafolimab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"},{"classification":"provisional","description":"Individual clearance over the selected simulation window.","key":"cl_l_hr_individual","label":"Individual clearance","unit":null},{"classification":"provisional","description":"Absorption rate constant over the selected simulation window.","key":"ka_day","label":"Absorption rate constant","unit":null}],"scenario_id":"final_model_150mg_qw_20wk_ode_overlay","scientific_questions":["How do dosing interval, renal function, and time-varying clearance change envafolimab exposure?"],"time_span":{"end":140,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_hr","label":"Absorption rate constant","max":0.02205,"min":0.00735,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/hr","value":0.0147},{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"theta_cl_l_hr","label":"Typical clearance","max":0.0717,"min":0.0239,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/hr","value":0.0478},{"category":"model parameter","definition":"Apparent distribution volume coefficient used by the released system of model equations.","description":"Apparent distribution volume coefficient used by the released system of model equations.","key":"v_l","label":"Apparent distribution volume","max":23.25,"min":7.75,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"L","value":15.5},{"category":"model parameter","definition":"Time to half-maximal change coefficient used by the released system of model equations.","description":"Time to half-maximal change coefficient used by the released system of model equations.","key":"t50_day","label":"Time to half-maximal change","max":51,"min":17,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":34},{"category":"model parameter","definition":"Creatinine clearance coefficient used by the released system of model equations.","description":"Creatinine clearance coefficient used by the released system of model equations.","key":"crcl_ml_min","label":"Creatinine clearance","max":142.71,"min":47.57,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mL/min","value":95.14}],"description":"How do dosing interval, renal function, and time-varying clearance change envafolimab exposure? Explore this intervention regimen through Envafolimab concentration, Cumulative envafolimab exposure, Individual clearance, Absorption rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Final model 300 mg every 2 weeks for 20 weeks","outputs":[{"classification":"provisional","description":"Envafolimab concentration over the selected simulation window.","key":"envafolimab_concentration_ng_ml","label":"Envafolimab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"},{"classification":"provisional","description":"Individual clearance over the selected simulation window.","key":"cl_l_hr_individual","label":"Individual clearance","unit":null},{"classification":"provisional","description":"Absorption rate constant over the selected simulation window.","key":"ka_day","label":"Absorption rate constant","unit":null}],"scenario_id":"final_model_300mg_q2w_20wk_ode_overlay","scientific_questions":["How do dosing interval, renal function, and time-varying clearance change envafolimab exposure?"],"time_span":{"end":140,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_hr","label":"Absorption rate constant","max":0.02205,"min":0.00735,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/hr","value":0.0147},{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"theta_cl_l_hr","label":"Typical clearance","max":0.0717,"min":0.0239,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/hr","value":0.0478},{"category":"model parameter","definition":"Apparent distribution volume coefficient used by the released system of model equations.","description":"Apparent distribution volume coefficient used by the released system of model equations.","key":"v_l","label":"Apparent distribution volume","max":23.25,"min":7.75,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"L","value":15.5},{"category":"model parameter","definition":"Time to half-maximal change coefficient used by the released system of model equations.","description":"Time to half-maximal change coefficient used by the released system of model equations.","key":"t50_day","label":"Time to half-maximal change","max":51,"min":17,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":34},{"category":"model parameter","definition":"Creatinine clearance coefficient used by the released system of model equations.","description":"Creatinine clearance coefficient used by the released system of model equations.","key":"crcl_ml_min","label":"Creatinine clearance","max":142.71,"min":47.57,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mL/min","value":95.14}],"description":"How do dosing interval, renal function, and time-varying clearance change envafolimab exposure? Explore this intervention regimen through Envafolimab concentration, Cumulative envafolimab exposure, Individual clearance, Absorption rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Final model 2.5 mg/kg QW for 20 weeks using mean body weight","outputs":[{"classification":"provisional","description":"Envafolimab concentration over the selected simulation window.","key":"envafolimab_concentration_ng_ml","label":"Envafolimab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"},{"classification":"provisional","description":"Individual clearance over the selected simulation window.","key":"cl_l_hr_individual","label":"Individual clearance","unit":null},{"classification":"provisional","description":"Absorption rate constant over the selected simulation window.","key":"ka_day","label":"Absorption rate constant","unit":null}],"scenario_id":"final_model_2p5mgkg_qw_20wk_endpoint_overlay","scientific_questions":["How do dosing interval, renal function, and time-varying clearance change envafolimab exposure?"],"time_span":{"end":140,"start":0,"step":0.25}}],"targets":[{"key":"pdl1","label":"PD-L1 / CD274"}],"therapeutics":[{"key":"envafolimab","label":"Envafolimab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A translational PK/PD model coupling zenocutuzumab distribution and nonlinear clearance to concentration-dependent tumor-cell death and net tumor-volume dynamics.","diseases":[{"key":"her2_her3_driven_preclinical_tumors_and_first_in_human_translation","label":"HER2/HER3-driven preclinical tumors and first-in-human translation"}],"links":{"page":"/modeling/models/de-vries-2018-mcla128-zenocutuzumab-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Bispecific mAb","model_classes":["PKPD","TCE/BsAb"],"model_id":"de_vries_2018_mcla128_zenocutuzumab_pkpd","name":"Zenocutuzumab PK and tumor-growth dynamics","outputs":[{"description":"Central zenocutuzumab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central zenocutuzumab concentration","unit":null},{"description":"Peripheral zenocutuzumab concentration over the selected simulation window.","key":"peripheral_conc_mg_L","label":"Peripheral zenocutuzumab concentration","unit":null},{"description":"Tumor volume over the selected simulation window.","key":"tumor_mm3","label":"Tumor volume","unit":"millimeter**3"},{"description":"Drug modified tumor growth over the selected simulation window.","key":"growth_effect","label":"Drug modified tumor growth","unit":"dimensionless"},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":0.018750000000000003,"min":0.00625,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0125},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":4.755,"min":1.585,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.17},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"Vmax_mg_h","label":"Maximum elimination rate","max":0.75,"min":0.25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/h","value":0.5},{"category":"model parameter","definition":"Michaelis constant coefficient used by the released system of model equations.","description":"Michaelis constant coefficient used by the released system of model equations.","key":"Km_mg_L","label":"Michaelis constant","max":0.3285,"min":0.1095,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/L","value":0.219},{"category":"model parameter","definition":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_KD_mg_L","label":"Tumor-kill half-maximal concentration","max":1.53e-05,"min":5.1e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"mg/L","value":1.02e-05}],"description":"How does zenocutuzumab exposure translate into tumor-growth inhibition over time? Explore this intervention regimen through Central zenocutuzumab concentration, Peripheral zenocutuzumab concentration, Tumor volume, Drug-modified tumor growth, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Human 360 mg every 3 weeks receptor occupancy","outputs":[{"classification":"provisional","description":"Central zenocutuzumab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Peripheral zenocutuzumab concentration over the selected simulation window.","key":"peripheral_conc_mg_L","label":"Peripheral zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Tumor volume over the selected simulation window.","key":"tumor_mm3","label":"Tumor volume","unit":"millimeter**3"},{"classification":"provisional","description":"Drug modified tumor growth over the selected simulation window.","key":"growth_effect","label":"Drug modified tumor growth","unit":"dimensionless"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"human_360mg_q3wk_ro_probe","scientific_questions":["How does zenocutuzumab exposure translate into tumor-growth inhibition over time?"],"time_span":{"end":504,"start":0,"step":24}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":4.125e-05,"min":1.375e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"L/h","value":2.75e-05},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":0.001359,"min":0.000453,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L","value":0.000906},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"Vmax_mg_h","label":"Maximum elimination rate","max":0.00165,"min":0.00055,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"mg/h","value":0.0011},{"category":"model parameter","definition":"Michaelis constant coefficient used by the released system of model equations.","description":"Michaelis constant coefficient used by the released system of model equations.","key":"Km_mg_L","label":"Michaelis constant","max":0.3285,"min":0.1095,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/L","value":0.219},{"category":"model parameter","definition":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_KD_mg_L","label":"Tumor-kill half-maximal concentration","max":1.53e-05,"min":5.1e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"mg/L","value":1.02e-05}],"description":"How does zenocutuzumab exposure translate into tumor-growth inhibition over time? Explore this intervention regimen through Central zenocutuzumab concentration, Peripheral zenocutuzumab concentration, Tumor volume, Drug-modified tumor growth, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Mouse 2.5 mg/kg every 1 weeks tumor","outputs":[{"classification":"provisional","description":"Central zenocutuzumab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Peripheral zenocutuzumab concentration over the selected simulation window.","key":"peripheral_conc_mg_L","label":"Peripheral zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Tumor volume over the selected simulation window.","key":"tumor_mm3","label":"Tumor volume","unit":"millimeter**3"},{"classification":"provisional","description":"Drug modified tumor growth over the selected simulation window.","key":"growth_effect","label":"Drug modified tumor growth","unit":"dimensionless"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"mouse_2p5mgkg_q1wk_tumor_probe","scientific_questions":["How does zenocutuzumab exposure translate into tumor-growth inhibition over time?"],"time_span":{"end":1440,"start":0,"step":24}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":4.125e-05,"min":1.375e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"L/h","value":2.75e-05},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":0.001359,"min":0.000453,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L","value":0.000906},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"Vmax_mg_h","label":"Maximum elimination rate","max":0.00165,"min":0.00055,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"mg/h","value":0.0011},{"category":"model parameter","definition":"Michaelis constant coefficient used by the released system of model equations.","description":"Michaelis constant coefficient used by the released system of model equations.","key":"Km_mg_L","label":"Michaelis constant","max":0.3285,"min":0.1095,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/L","value":0.219},{"category":"model parameter","definition":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_KD_mg_L","label":"Tumor-kill half-maximal concentration","max":1.53e-05,"min":5.1e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"mg/L","value":1.02e-05}],"description":"How does zenocutuzumab exposure translate into tumor-growth inhibition over time? Explore this intervention regimen through Central zenocutuzumab concentration, Peripheral zenocutuzumab concentration, Tumor volume, Drug-modified tumor growth, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Mouse 25 mg/kg every 1 weeks tumor","outputs":[{"classification":"provisional","description":"Central zenocutuzumab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Peripheral zenocutuzumab concentration over the selected simulation window.","key":"peripheral_conc_mg_L","label":"Peripheral zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Tumor volume over the selected simulation window.","key":"tumor_mm3","label":"Tumor volume","unit":"millimeter**3"},{"classification":"provisional","description":"Drug modified tumor growth over the selected simulation window.","key":"growth_effect","label":"Drug modified tumor growth","unit":"dimensionless"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"mouse_25mgkg_q1wk_tumor_probe","scientific_questions":["How does zenocutuzumab exposure translate into tumor-growth inhibition over time?"],"time_span":{"end":1440,"start":0,"step":24}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":4.125e-05,"min":1.375e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"L/h","value":2.75e-05},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":0.001359,"min":0.000453,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L","value":0.000906},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"Vmax_mg_h","label":"Maximum elimination rate","max":0.00165,"min":0.00055,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"mg/h","value":0.0011},{"category":"model parameter","definition":"Michaelis constant coefficient used by the released system of model equations.","description":"Michaelis constant coefficient used by the released system of model equations.","key":"Km_mg_L","label":"Michaelis constant","max":0.3285,"min":0.1095,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/L","value":0.219},{"category":"model parameter","definition":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_KD_mg_L","label":"Tumor-kill half-maximal concentration","max":1.53e-05,"min":5.1e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"mg/L","value":1.02e-05}],"description":"How does zenocutuzumab exposure translate into tumor-growth inhibition over time? Explore this intervention regimen through Central zenocutuzumab concentration, Peripheral zenocutuzumab concentration, Tumor volume, Drug-modified tumor growth, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Mouse 9.5 mg/kg every 1 weeks tumor","outputs":[{"classification":"provisional","description":"Central zenocutuzumab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Peripheral zenocutuzumab concentration over the selected simulation window.","key":"peripheral_conc_mg_L","label":"Peripheral zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Tumor volume over the selected simulation window.","key":"tumor_mm3","label":"Tumor volume","unit":"millimeter**3"},{"classification":"provisional","description":"Drug modified tumor growth over the selected simulation window.","key":"growth_effect","label":"Drug modified tumor growth","unit":"dimensionless"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"mouse_9p5mgkg_q1wk_tumor_probe","scientific_questions":["How does zenocutuzumab exposure translate into tumor-growth inhibition over time?"],"time_span":{"end":840,"start":0,"step":24}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":4.125e-05,"min":1.375e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"L/h","value":2.75e-05},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":0.001359,"min":0.000453,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L","value":0.000906},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"Vmax_mg_h","label":"Maximum elimination rate","max":0.00165,"min":0.00055,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"mg/h","value":0.0011},{"category":"model parameter","definition":"Michaelis constant coefficient used by the released system of model equations.","description":"Michaelis constant coefficient used by the released system of model equations.","key":"Km_mg_L","label":"Michaelis constant","max":0.3285,"min":0.1095,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/L","value":0.219},{"category":"model parameter","definition":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Tumor-kill half-maximal concentration at which the corresponding modeled effect reaches half of its maximum.","key":"EC50_KD_mg_L","label":"Tumor-kill half-maximal concentration","max":1.53e-05,"min":5.1e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-07,"unit":"mg/L","value":1.02e-05}],"description":"How does zenocutuzumab exposure translate into tumor-growth inhibition over time? Explore this intervention regimen through Central zenocutuzumab concentration, Peripheral zenocutuzumab concentration, Tumor volume, Drug-modified tumor growth, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Mouse 24 mg/kg every 1 weeks tumor","outputs":[{"classification":"provisional","description":"Central zenocutuzumab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Peripheral zenocutuzumab concentration over the selected simulation window.","key":"peripheral_conc_mg_L","label":"Peripheral zenocutuzumab concentration","unit":null},{"classification":"provisional","description":"Tumor volume over the selected simulation window.","key":"tumor_mm3","label":"Tumor volume","unit":"millimeter**3"},{"classification":"provisional","description":"Drug modified tumor growth over the selected simulation window.","key":"growth_effect","label":"Drug modified tumor growth","unit":"dimensionless"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"mouse_24mgkg_q1wk_tumor_probe","scientific_questions":["How does zenocutuzumab exposure translate into tumor-growth inhibition over time?"],"time_span":{"end":840,"start":0,"step":24}}],"targets":[{"key":"erbb3","label":"ERBB3"},{"key":"her3","label":"HER3"},{"key":"her2","label":"HER2 / ERBB2"}],"therapeutics":[{"key":"zenocutuzumab","label":"Zenocutuzumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A PK/PD model coupling dabigatran systemic and bypass-circuit disposition to effect-site concentration and idarucizumab exposure during cardiopulmonary bypass.","diseases":[{"key":"preclinical_anticoagulation_reversal_during_cardiopulmonary_bypass","label":"Preclinical anticoagulation reversal during cardiopulmonary bypass"}],"links":{"page":"/modeling/models/eaton-2025-dabigatran-idarucizumab-sheep-cpb-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Humanized monoclonal antibody fragment","model_classes":["PKPD"],"model_id":"eaton_2025_dabigatran_idarucizumab_sheep_cpb_pkpd","name":"Dabigatran–idarucizumab reversal during cardiopulmonary bypass","outputs":[{"description":"Central dabigatran concentration over the selected simulation window.","key":"dabigatran_conc_mg_l","label":"Central dabigatran concentration","unit":null},{"description":"Effect-site concentration over the selected simulation window.","key":"effect_conc_mg_l","label":"Effect-site concentration","unit":"mg/L"},{"description":"Bypass circuit dabigatran concentration over the selected simulation window.","key":"pump_conc_mg_l","label":"Bypass circuit dabigatran concentration","unit":null},{"description":"Idarucizumab concentration over the selected simulation window.","key":"idarucizumab_conc_mg_l","label":"Idarucizumab concentration","unit":null},{"description":"Mean bypass dabigatran concentration over the selected simulation window.","key":"cpb_mean_dabigatran_mg_l","label":"Mean bypass dabigatran concentration","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Standardized systemic clearance governing removal of modeled material from the relevant compartment.","description":"Standardized systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_std_l_min_70kg","label":"Standardized systemic clearance","max":0.07635,"min":0.02545,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/minute","value":0.0509},{"category":"model parameter","definition":"Standardized central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Standardized central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"v1_std_l_70kg","label":"Standardized central distribution volume","max":5.835,"min":1.945,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.89},{"category":"model parameter","definition":"Circuit flow rate coefficient used by the released system of model equations.","description":"Circuit flow rate coefficient used by the released system of model equations.","key":"flow_l_min","label":"Circuit flow rate","max":2.73,"min":0.91,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/min","value":1.82},{"category":"model parameter","definition":"Idarucizumab clearance governing removal of modeled material from the relevant compartment.","description":"Idarucizumab clearance governing removal of modeled material from the relevant compartment.","key":"cl_ida_l_min","label":"Idarucizumab clearance","max":0.0591,"min":0.0197,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/min","value":0.0394},{"category":"model parameter","definition":"Idarucizumab loading dose defining the modeled treatment input for the explored scenario.","description":"Idarucizumab loading dose defining the modeled treatment input for the explored scenario.","key":"ida_loading_mg_kg","label":"Idarucizumab loading dose","max":75,"min":25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mg/kg","value":50}],"description":"How do bypass-circuit exchange and idarucizumab exposure change dabigatran concentration and effect-site reversal? Explore this biological starting configuration through Central dabigatran concentration, Dabigatran effect-site concentration, Bypass-circuit dabigatran concentration, Idarucizumab concentration, Mean bypass dabigatran concentration.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"CPB dabigatran and idarucizumab reversal","outputs":[{"classification":"provisional","description":"Central dabigatran concentration over the selected simulation window.","key":"dabigatran_conc_mg_l","label":"Central dabigatran concentration","unit":null},{"classification":"provisional","description":"Effect-site concentration over the selected simulation window.","key":"effect_conc_mg_l","label":"Effect-site concentration","unit":"mg/L"},{"classification":"provisional","description":"Bypass circuit dabigatran concentration over the selected simulation window.","key":"pump_conc_mg_l","label":"Bypass circuit dabigatran concentration","unit":null},{"classification":"provisional","description":"Idarucizumab concentration over the selected simulation window.","key":"idarucizumab_conc_mg_l","label":"Idarucizumab concentration","unit":null},{"classification":"provisional","description":"Mean bypass dabigatran concentration over the selected simulation window.","key":"cpb_mean_dabigatran_mg_l","label":"Mean bypass dabigatran concentration","unit":null}],"scenario_id":"cpb_idarucizumab_reversal_overlay","scientific_questions":["How do bypass-circuit exchange and idarucizumab exposure change dabigatran concentration and effect-site reversal?"],"time_span":{"end":1440,"start":0,"step":1}}],"targets":[{"key":"thrombin","label":"Thrombin","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1177/02676591251406086","locator":"Primary publication introduction: dabigatran is a direct thrombin inhibitor.","relationship":"Dabigatran pharmacologic target; not an explicit state in the released equations."}},{"key":"dabigatran","label":"Dabigatran","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1177/02676591251406086","locator":"Primary publication introduction: idarucizumab forms complexes with free or thrombin-bound dabigatran.","relationship":"Idarucizumab binding target; the public release panel separately discloses whether binding is represented in the equations."}}],"therapeutics":[{"key":"dabigatran_and_idarucizumab","label":"Dabigatran and idarucizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A PK/PD model coupling dabigatran central, peripheral, and effect-site disposition to idarucizumab-associated reversal of the anticoagulation response in sheep.","diseases":[{"key":"preclinical_reversal_of_dabigatran_anticoagulation","label":"Preclinical reversal of dabigatran anticoagulation"}],"links":{"page":"/modeling/models/eaton-2025-idarucizumab-dabigatran-sheep-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Fab","model_classes":["PKPD"],"model_id":"eaton_2025_idarucizumab_dabigatran_sheep_pkpd","name":"Idarucizumab reversal of dabigatran in sheep","outputs":[{"description":"Effect-site concentration over the selected simulation window.","key":"effect_conc_mg_l","label":"Effect-site concentration","unit":"mg/L"},{"description":"Idarucizumab reversal effect over the selected simulation window.","key":"idarucizumab_effect_unit","label":"Idarucizumab reversal effect","unit":"dimensionless"},{"description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"description":"Circuit dabigatran amount over the selected simulation window.","key":"cpb_circuit_mg","label":"Circuit dabigatran amount","unit":"mg"},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_min_l","label":"Exposure (AUC)","unit":"mg*min/L"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Standardized systemic clearance governing removal of modeled material from the relevant compartment.","description":"Standardized systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_std_l_min_70kg","label":"Standardized systemic clearance","max":0.06795,"min":0.02265,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/min","value":0.0453},{"category":"model parameter","definition":"Standardized central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Standardized central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"v1_std_l_70kg","label":"Standardized central distribution volume","max":4.41,"min":1.47,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.94},{"category":"model parameter","definition":"Standardized intercompartmental clearance governing exchange between model compartments.","description":"Standardized intercompartmental clearance governing exchange between model compartments.","key":"q_std_l_min_70kg","label":"Standardized intercompartmental clearance","max":0.402,"min":0.134,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/min","value":0.268},{"category":"model parameter","definition":"Effect-compartment half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Effect-compartment half-life controlling the time required for the corresponding quantity to decrease by half.","key":"t12_keo_min","label":"Effect-compartment half-life","max":1.56,"min":0.52,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"min","value":1.04},{"category":"model parameter","definition":"Idarucizumab binding rate coefficient used by the released system of model equations.","description":"Idarucizumab binding rate coefficient used by the released system of model equations.","key":"k_ida_per_min","label":"Idarucizumab binding rate","max":0.0327,"min":0.0109,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/min","value":0.0218}],"description":"How do dabigatran effect-site kinetics and idarucizumab administration determine reversal timing? Explore this intervention regimen through Dabigatran effect-site concentration, Idarucizumab reversal effect, Central dabigatran amount, Circuit dabigatran amount, Cumulative dabigatran exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"4 mg/kg dabigatran sheep PK-PD","outputs":[{"classification":"provisional","description":"Effect-site concentration over the selected simulation window.","key":"effect_conc_mg_l","label":"Effect-site concentration","unit":"mg/L"},{"classification":"provisional","description":"Idarucizumab reversal effect over the selected simulation window.","key":"idarucizumab_effect_unit","label":"Idarucizumab reversal effect","unit":"dimensionless"},{"classification":"provisional","description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"classification":"provisional","description":"Circuit dabigatran amount over the selected simulation window.","key":"cpb_circuit_mg","label":"Circuit dabigatran amount","unit":"mg"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_min_l","label":"Exposure (AUC)","unit":"mg*min/L"}],"scenario_id":"dabigatran_4mgkg_sheep_pkpd","scientific_questions":["How do dabigatran effect-site kinetics and idarucizumab administration determine reversal timing?"],"time_span":{"end":1440,"start":0,"step":5}},{"controls":[{"category":"model parameter","definition":"Standardized systemic clearance governing removal of modeled material from the relevant compartment.","description":"Standardized systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_std_l_min_70kg","label":"Standardized systemic clearance","max":0.06795,"min":0.02265,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/min","value":0.0453},{"category":"model parameter","definition":"Standardized central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Standardized central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"v1_std_l_70kg","label":"Standardized central distribution volume","max":4.41,"min":1.47,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.94},{"category":"model parameter","definition":"Standardized intercompartmental clearance governing exchange between model compartments.","description":"Standardized intercompartmental clearance governing exchange between model compartments.","key":"q_std_l_min_70kg","label":"Standardized intercompartmental clearance","max":0.402,"min":0.134,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/min","value":0.268},{"category":"model parameter","definition":"Effect-compartment half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Effect-compartment half-life controlling the time required for the corresponding quantity to decrease by half.","key":"t12_keo_min","label":"Effect-compartment half-life","max":1.56,"min":0.52,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"min","value":1.04},{"category":"model parameter","definition":"Idarucizumab binding rate coefficient used by the released system of model equations.","description":"Idarucizumab binding rate coefficient used by the released system of model equations.","key":"k_ida_per_min","label":"Idarucizumab binding rate","max":0.0327,"min":0.0109,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/min","value":0.0218}],"description":"How do dabigatran effect-site kinetics and idarucizumab administration determine reversal timing? Explore this intervention regimen through Dabigatran effect-site concentration, Idarucizumab reversal effect, Central dabigatran amount, Circuit dabigatran amount, Cumulative dabigatran exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"target concentration dosing","outputs":[{"classification":"provisional","description":"Effect-site concentration over the selected simulation window.","key":"effect_conc_mg_l","label":"Effect-site concentration","unit":"mg/L"},{"classification":"provisional","description":"Idarucizumab reversal effect over the selected simulation window.","key":"idarucizumab_effect_unit","label":"Idarucizumab reversal effect","unit":"dimensionless"},{"classification":"provisional","description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"classification":"provisional","description":"Circuit dabigatran amount over the selected simulation window.","key":"cpb_circuit_mg","label":"Circuit dabigatran amount","unit":"mg"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_min_l","label":"Exposure (AUC)","unit":"mg*min/L"}],"scenario_id":"target_infusion_90min_figure4","scientific_questions":["How do dabigatran effect-site kinetics and idarucizumab administration determine reversal timing?"],"time_span":{"end":90,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Standardized systemic clearance governing removal of modeled material from the relevant compartment.","description":"Standardized systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_std_l_min_70kg","label":"Standardized systemic clearance","max":0.06795,"min":0.02265,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/min","value":0.0453},{"category":"model parameter","definition":"Standardized central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Standardized central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"v1_std_l_70kg","label":"Standardized central distribution volume","max":4.41,"min":1.47,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.94},{"category":"model parameter","definition":"Standardized intercompartmental clearance governing exchange between model compartments.","description":"Standardized intercompartmental clearance governing exchange between model compartments.","key":"q_std_l_min_70kg","label":"Standardized intercompartmental clearance","max":0.402,"min":0.134,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/min","value":0.268},{"category":"model parameter","definition":"Effect-compartment half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Effect-compartment half-life controlling the time required for the corresponding quantity to decrease by half.","key":"t12_keo_min","label":"Effect-compartment half-life","max":1.56,"min":0.52,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"min","value":1.04},{"category":"model parameter","definition":"Idarucizumab binding rate coefficient used by the released system of model equations.","description":"Idarucizumab binding rate coefficient used by the released system of model equations.","key":"k_ida_per_min","label":"Idarucizumab binding rate","max":0.0327,"min":0.0109,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/min","value":0.0218}],"description":"How do dabigatran effect-site kinetics and idarucizumab administration determine reversal timing? Explore this biological starting configuration through Dabigatran effect-site concentration, Idarucizumab reversal effect, Central dabigatran amount, Circuit dabigatran amount, Cumulative dabigatran exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Idarucizumab 5 min reversal endpoint","outputs":[{"classification":"provisional","description":"Effect-site concentration over the selected simulation window.","key":"effect_conc_mg_l","label":"Effect-site concentration","unit":"mg/L"},{"classification":"provisional","description":"Idarucizumab reversal effect over the selected simulation window.","key":"idarucizumab_effect_unit","label":"Idarucizumab reversal effect","unit":"dimensionless"},{"classification":"provisional","description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"classification":"provisional","description":"Circuit dabigatran amount over the selected simulation window.","key":"cpb_circuit_mg","label":"Circuit dabigatran amount","unit":"mg"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_min_l","label":"Exposure (AUC)","unit":"mg*min/L"}],"scenario_id":"idarucizumab_reversal_5min","scientific_questions":["How do dabigatran effect-site kinetics and idarucizumab administration determine reversal timing?"],"time_span":{"end":5,"start":0,"step":0.25}}],"targets":[{"key":"thrombin","label":"Thrombin","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1177/02676591231226291","locator":"Primary publication introduction: dabigatran reversibly binds the active site of thrombin.","relationship":"Dabigatran pharmacologic target; not an explicit state in the released equations."}},{"key":"dabigatran","label":"Dabigatran","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1177/02676591231226291","locator":"Primary publication introduction: idarucizumab reverses the anticoagulant effect by decreasing unbound dabigatran.","relationship":"Idarucizumab binding target; the released equations expose an independent reversal signal rather than explicit binding."}}],"therapeutics":[{"key":"dabigatran_challenge_and_idarucizumab_reversal","label":"Dabigatran challenge and idarucizumab reversal"},{"key":"idarucizumab","label":"Idarucizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment PK/PD model coupling sutimlimab linear and nonlinear disposition to concentration-dependent recovery and turnover of hemoglobin.","diseases":[{"key":"cold_agglutinin_disease","label":"Cold agglutinin disease"}],"links":{"page":"/modeling/models/frank-2023-sutimlimab-cad-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":null,"model_classes":["PKPD"],"model_id":"frank_2023_sutimlimab_cad_pkpd","name":"Sutimlimab exposure and hemoglobin response","outputs":[{"description":"Central sutimlimab concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central sutimlimab concentration","unit":null},{"description":"Hemoglobin concentration over the selected simulation window.","key":"hb_g_dl","label":"Hemoglobin concentration","unit":"g/dL"},{"description":"Sutimlimab pharmacodynamic effect over the selected simulation window.","key":"drug_effect_fraction","label":"Sutimlimab pharmacodynamic effect","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_ml","label":"Exposure (AUC)","unit":"h*ug/mL"},{"description":"Below 100 proxy percent over the selected simulation window.","key":"below_100_proxy_percent","label":"Below 100 proxy percent","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"table3_cl_ml_h","label":"Systemic clearance","max":8.535,"min":2.845,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mL/hour","value":5.69},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"table3_vc_l","label":"Central distribution volume","max":5.745,"min":1.915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.83},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"table3_vmax_mg_h","label":"Maximum elimination rate","max":14.774999999999999,"min":4.925,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mg/hour","value":9.85},{"category":"model parameter","definition":"Half-maximal effect concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Half-maximal effect concentration at which the corresponding modeled effect reaches half of its maximum.","key":"table4_ec50_ug_ml","label":"Half-maximal effect concentration","max":232.5,"min":77.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"ug/mL","value":155},{"category":"model parameter","definition":"Turnover time coefficient used by the released system of model equations.","description":"Turnover time coefficient used by the released system of model equations.","key":"table4_turnover_time_h","label":"Turnover time","max":282,"min":94,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"hour","value":188}],"description":"How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response? Explore this intervention regimen through Central sutimlimab concentration, Hemoglobin, Sutimlimab pharmacodynamic effect, Cumulative sutimlimab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Approved 6.5 g regimen, 65 kg","outputs":[{"classification":"provisional","description":"Central sutimlimab concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central sutimlimab concentration","unit":null},{"classification":"provisional","description":"Hemoglobin concentration over the selected simulation window.","key":"hb_g_dl","label":"Hemoglobin concentration","unit":"g/dL"},{"classification":"provisional","description":"Sutimlimab pharmacodynamic effect over the selected simulation window.","key":"drug_effect_fraction","label":"Sutimlimab pharmacodynamic effect","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_ml","label":"Exposure (AUC)","unit":"h*ug/mL"}],"scenario_id":"approved_65kg_6p5g_q2w","scientific_questions":["How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response?"],"time_span":{"end":25032,"start":0,"step":24}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"table3_cl_ml_h","label":"Systemic clearance","max":8.535,"min":2.845,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mL/hour","value":5.69},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"table3_vc_l","label":"Central distribution volume","max":5.745,"min":1.915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.83},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"table3_vmax_mg_h","label":"Maximum elimination rate","max":14.774999999999999,"min":4.925,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mg/hour","value":9.85},{"category":"model parameter","definition":"Half-maximal effect concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Half-maximal effect concentration at which the corresponding modeled effect reaches half of its maximum.","key":"table4_ec50_ug_ml","label":"Half-maximal effect concentration","max":232.5,"min":77.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"ug/mL","value":155},{"category":"model parameter","definition":"Turnover time coefficient used by the released system of model equations.","description":"Turnover time coefficient used by the released system of model equations.","key":"table4_turnover_time_h","label":"Turnover time","max":282,"min":94,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"hour","value":188}],"description":"How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response? Explore this intervention regimen through Central sutimlimab concentration, Hemoglobin, Sutimlimab pharmacodynamic effect, Cumulative sutimlimab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Approved 7.5 g regimen, 80 kg","outputs":[{"classification":"provisional","description":"Central sutimlimab concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central sutimlimab concentration","unit":null},{"classification":"provisional","description":"Hemoglobin concentration over the selected simulation window.","key":"hb_g_dl","label":"Hemoglobin concentration","unit":"g/dL"},{"classification":"provisional","description":"Sutimlimab pharmacodynamic effect over the selected simulation window.","key":"drug_effect_fraction","label":"Sutimlimab pharmacodynamic effect","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_ml","label":"Exposure (AUC)","unit":"h*ug/mL"}],"scenario_id":"approved_80kg_7p5g_q2w","scientific_questions":["How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response?"],"time_span":{"end":25032,"start":0,"step":24}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"table3_cl_ml_h","label":"Systemic clearance","max":8.535,"min":2.845,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mL/hour","value":5.69},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"table3_vc_l","label":"Central distribution volume","max":5.745,"min":1.915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.83},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"table3_vmax_mg_h","label":"Maximum elimination rate","max":14.774999999999999,"min":4.925,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mg/hour","value":9.85},{"category":"model parameter","definition":"Half-maximal effect concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Half-maximal effect concentration at which the corresponding modeled effect reaches half of its maximum.","key":"table4_ec50_ug_ml","label":"Half-maximal effect concentration","max":232.5,"min":77.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"ug/mL","value":155},{"category":"model parameter","definition":"Turnover time coefficient used by the released system of model equations.","description":"Turnover time coefficient used by the released system of model equations.","key":"table4_turnover_time_h","label":"Turnover time","max":282,"min":94,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"hour","value":188}],"description":"How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response? Explore this intervention regimen through Central sutimlimab concentration, Hemoglobin, Sutimlimab pharmacodynamic effect, Cumulative sutimlimab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Approved regimen population endpoint proxy","outputs":[{"classification":"provisional","description":"Central sutimlimab concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central sutimlimab concentration","unit":null},{"classification":"provisional","description":"Hemoglobin concentration over the selected simulation window.","key":"hb_g_dl","label":"Hemoglobin concentration","unit":"g/dL"},{"classification":"provisional","description":"Sutimlimab pharmacodynamic effect over the selected simulation window.","key":"drug_effect_fraction","label":"Sutimlimab pharmacodynamic effect","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_ml","label":"Exposure (AUC)","unit":"h*ug/mL"}],"scenario_id":"approved_all_source_limited_population","scientific_questions":["How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response?"],"time_span":{"end":25032,"start":0,"step":24}}],"targets":[{"key":"c1s","label":"Complement C1s","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1124/jpet.122.001511","locator":"Primary publication mechanism context: sutimlimab inhibits complement C1s and the classical complement pathway.","relationship":"Therapeutic target; the released model represents its effect empirically rather than as an explicit C1s state."}}],"therapeutics":[{"key":"sutimlimab","label":"Sutimlimab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model linking pembrolizumab dosing, body-size effects on disposition, central and peripheral antibody amounts, concentration, and cumulative exposure.","diseases":[{"key":"oncology_indications_treated_with_pembrolizumab","label":"Oncology indications treated with pembrolizumab"}],"links":{"page":"/modeling/models/freshwater-2017-pembrolizumab-dosing-strategy-poppk","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PopPK"],"model_id":"freshwater_2017_pembrolizumab_dosing_strategy_poppk","name":"Pembrolizumab population PK and exposure","outputs":[{"description":"Central pembrolizumab concentration over the selected simulation window.","key":"central_concentration_ug_mL","label":"Central pembrolizumab concentration","unit":null},{"description":"Peripheral pembrolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_mL","label":"Peripheral pembrolizumab concentration","unit":null},{"description":"Cumulative pembrolizumab exposure over the selected simulation window.","key":"cumulative_auc_ug_day_mL","label":"Cumulative pembrolizumab exposure","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"description":"Body weight over the selected simulation window.","key":"body_weight_kg","label":"Body weight","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Clearance governing removal of modeled material from the relevant compartment.","description":"Clearance governing removal of modeled material from the relevant compartment.","key":"exploratory_clearance_L_day","label":"Clearance","max":0.30509472,"min":0.10169824,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.20339648},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"exploratory_central_volume_L","label":"Central volume","max":4.938396915,"min":1.646132305,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.29226461},{"category":"model parameter","definition":"Intercompartmental clearance governing removal of modeled material from the relevant compartment.","description":"Intercompartmental clearance governing removal of modeled material from the relevant compartment.","key":"exploratory_intercompartmental_clearance_L_day","label":"Intercompartmental clearance","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.4},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"exploratory_peripheral_volume_L","label":"Peripheral volume","max":5.578630185,"min":1.859543395,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.71908679},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":115.80000000000001,"min":38.6,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":77.2}],"description":"How do dose regimen and body size change pembrolizumab concentration and cumulative exposure? Explore this intervention regimen through Central pembrolizumab concentration, Peripheral pembrolizumab concentration, Cumulative pembrolizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"2 mg/kg every 3 weeks, 77.2 kg","outputs":[{"classification":"provisional","description":"Central pembrolizumab concentration over the selected simulation window.","key":"central_concentration_ug_mL","label":"Central pembrolizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral pembrolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_mL","label":"Peripheral pembrolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative pembrolizumab exposure over the selected simulation window.","key":"cumulative_auc_ug_day_mL","label":"Cumulative pembrolizumab exposure","unit":null}],"scenario_id":"exploratory_calibrated_2mgkg_q3w_77p2kg","scientific_questions":["How do dose regimen and body size change pembrolizumab concentration and cumulative exposure?"],"time_span":{"end":378,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Clearance governing removal of modeled material from the relevant compartment.","description":"Clearance governing removal of modeled material from the relevant compartment.","key":"exploratory_clearance_L_day","label":"Clearance","max":0.30509472,"min":0.10169824,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.20339648},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"exploratory_central_volume_L","label":"Central volume","max":4.938396915,"min":1.646132305,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.29226461},{"category":"model parameter","definition":"Intercompartmental clearance governing removal of modeled material from the relevant compartment.","description":"Intercompartmental clearance governing removal of modeled material from the relevant compartment.","key":"exploratory_intercompartmental_clearance_L_day","label":"Intercompartmental clearance","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.4},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"exploratory_peripheral_volume_L","label":"Peripheral volume","max":5.578630185,"min":1.859543395,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.71908679},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":107.69999999999999,"min":35.9,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":71.8}],"description":"How do dose regimen and body size change pembrolizumab concentration and cumulative exposure? Explore this intervention regimen through Central pembrolizumab concentration, Peripheral pembrolizumab concentration, Cumulative pembrolizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"200 mg every 3 weeks, 71.8 kg","outputs":[{"classification":"provisional","description":"Central pembrolizumab concentration over the selected simulation window.","key":"central_concentration_ug_mL","label":"Central pembrolizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral pembrolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_mL","label":"Peripheral pembrolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative pembrolizumab exposure over the selected simulation window.","key":"cumulative_auc_ug_day_mL","label":"Cumulative pembrolizumab exposure","unit":null}],"scenario_id":"exploratory_calibrated_200mg_q3w_71p8kg","scientific_questions":["How do dose regimen and body size change pembrolizumab concentration and cumulative exposure?"],"time_span":{"end":378,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Clearance governing removal of modeled material from the relevant compartment.","description":"Clearance governing removal of modeled material from the relevant compartment.","key":"exploratory_clearance_L_day","label":"Clearance","max":0.30509472,"min":0.10169824,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.20339648},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"exploratory_central_volume_L","label":"Central volume","max":4.938396915,"min":1.646132305,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.29226461},{"category":"model parameter","definition":"Intercompartmental clearance governing removal of modeled material from the relevant compartment.","description":"Intercompartmental clearance governing removal of modeled material from the relevant compartment.","key":"exploratory_intercompartmental_clearance_L_day","label":"Intercompartmental clearance","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.4},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"exploratory_peripheral_volume_L","label":"Peripheral volume","max":5.578630185,"min":1.859543395,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.71908679},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":115.80000000000001,"min":38.6,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":77.2}],"description":"How do dose regimen and body size change pembrolizumab concentration and cumulative exposure? Explore this intervention regimen through Central pembrolizumab concentration, Peripheral pembrolizumab concentration, Cumulative pembrolizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"10 mg/kg every 3 weeks, 77.2 kg","outputs":[{"classification":"provisional","description":"Central pembrolizumab concentration over the selected simulation window.","key":"central_concentration_ug_mL","label":"Central pembrolizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral pembrolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_mL","label":"Peripheral pembrolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative pembrolizumab exposure over the selected simulation window.","key":"cumulative_auc_ug_day_mL","label":"Cumulative pembrolizumab exposure","unit":null}],"scenario_id":"exploratory_calibrated_10mgkg_q3w_77p2kg","scientific_questions":["How do dose regimen and body size change pembrolizumab concentration and cumulative exposure?"],"time_span":{"end":378,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Clearance governing removal of modeled material from the relevant compartment.","description":"Clearance governing removal of modeled material from the relevant compartment.","key":"exploratory_clearance_L_day","label":"Clearance","max":0.30509472,"min":0.10169824,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.20339648},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"exploratory_central_volume_L","label":"Central volume","max":4.938396915,"min":1.646132305,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.29226461},{"category":"model parameter","definition":"Intercompartmental clearance governing removal of modeled material from the relevant compartment.","description":"Intercompartmental clearance governing removal of modeled material from the relevant compartment.","key":"exploratory_intercompartmental_clearance_L_day","label":"Intercompartmental clearance","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.4},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"exploratory_peripheral_volume_L","label":"Peripheral volume","max":5.578630185,"min":1.859543395,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.71908679},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":115.80000000000001,"min":38.6,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":77.2}],"description":"How do dose regimen and body size change pembrolizumab concentration and cumulative exposure? Explore this intervention regimen through Central pembrolizumab concentration, Peripheral pembrolizumab concentration, Cumulative pembrolizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"10 mg/kg every 2 weeks, 77.2 kg","outputs":[{"classification":"provisional","description":"Central pembrolizumab concentration over the selected simulation window.","key":"central_concentration_ug_mL","label":"Central pembrolizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral pembrolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_mL","label":"Peripheral pembrolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative pembrolizumab exposure over the selected simulation window.","key":"cumulative_auc_ug_day_mL","label":"Cumulative pembrolizumab exposure","unit":null}],"scenario_id":"exploratory_calibrated_10mgkg_q2w_77p2kg","scientific_questions":["How do dose regimen and body size change pembrolizumab concentration and cumulative exposure?"],"time_span":{"end":378,"start":0,"step":0.25}}],"targets":[{"key":"pd1","label":"PD-1 / PDCD1"}],"therapeutics":[{"key":"pembrolizumab","label":"Pembrolizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model for inotuzumab ozogamicin with linear and time-dependent clearance and clinically relevant body-size and disease covariates.","diseases":[{"key":"b_cell_acute_lymphoblastic_leukemia_and_b_cell_lymphoma","label":"B-cell acute lymphoblastic leukemia and B-cell lymphoma"}],"links":{"page":"/modeling/models/garrett-2019-inotuzumab-ozogamicin-poppk","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb ADC","model_classes":["PopPK","ADC"],"model_id":"garrett_2019_inotuzumab_ozogamicin_poppk","name":"Inotuzumab ozogamicin population PK","outputs":[{"description":"Central inotuzumab ozogamicin over the selected simulation window.","key":"central_concentration_ng_mL","label":"Central inotuzumab ozogamicin","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ng_h_mL","label":"Exposure (AUC)","unit":"ng*h/mL"},{"description":"Total clearance over the selected simulation window.","key":"CL_total_L_h","label":"Total clearance","unit":null},{"description":"Clearance desensitization rate over the selected simulation window.","key":"KDES_1_h","label":"Clearance desensitization rate","unit":null},{"description":"Central-compartment drug amount over the selected simulation window.","key":"A_central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Baseline linear clearance governing removal of modeled material from the relevant compartment.","description":"Baseline linear clearance governing removal of modeled material from the relevant compartment.","key":"CL1_base_L_h","label":"Baseline linear clearance","max":0.1695,"min":0.0565,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/h","value":0.113},{"category":"model parameter","definition":"Baseline time-varying clearance governing removal of modeled material from the relevant compartment.","description":"Baseline time-varying clearance governing removal of modeled material from the relevant compartment.","key":"CL2_base_L_h","label":"Baseline time-varying clearance","max":0.5535,"min":0.1845,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/h","value":0.369},{"category":"model parameter","definition":"Baseline central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Baseline central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_base_L","label":"Baseline central distribution volume","max":10.05,"min":3.35,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":6.7},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_h","label":"Intercompartmental clearance","max":0.06075,"min":0.02025,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0405},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_L","label":"Peripheral distribution volume","max":7.6499999999999995,"min":2.55,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":5.1}],"description":"How do regimen and time-dependent clearance shape inotuzumab ozogamicin concentration and exposure? Explore this intervention regimen through Central inotuzumab ozogamicin, Cumulative ADC exposure, Total clearance, Clearance-desensitization rate.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"ALL 1.8 mg/m2/cycle fractionated regimen dynamic","outputs":[{"classification":"provisional","description":"Central inotuzumab ozogamicin over the selected simulation window.","key":"central_concentration_ng_mL","label":"Central inotuzumab ozogamicin","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ng_h_mL","label":"Exposure (AUC)","unit":"ng*h/mL"},{"classification":"provisional","description":"Total clearance over the selected simulation window.","key":"CL_total_L_h","label":"Total clearance","unit":null},{"classification":"provisional","description":"Clearance desensitization rate over the selected simulation window.","key":"KDES_1_h","label":"Clearance desensitization rate","unit":null}],"scenario_id":"fractionated_all_three_cycle_dynamic_smoke","scientific_questions":["How do regimen and time-dependent clearance shape inotuzumab ozogamicin concentration and exposure?"],"time_span":{"end":1848,"start":0,"step":24}}],"targets":[{"key":"siglec2","label":"SIGLEC2"},{"key":"cd22","label":"CD22"},{"key":"b_cell_receptor_cd22","label":"B-cell receptor CD22"}],"therapeutics":[{"key":"inotuzumab_ozogamicin","label":"Inotuzumab ozogamicin"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A QSS-TMDD model representing intravenous or subcutaneous befovacimab disposition, TFPI turnover, free antibody, and antibody–TFPI complex dynamics.","diseases":[{"key":"translational_hemophilia_prophylaxis","label":"Translational hemophilia prophylaxis"}],"links":{"page":"/modeling/models/gu-2017-bay1093884-tfpi-qss-tmdd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PKPD","TMDD"],"model_id":"gu_2017_bay1093884_tfpi_qss_tmdd","name":"Befovacimab PK and TFPI target binding","outputs":[{"description":"Total central befovacimab over the selected simulation window.","key":"central_total_mg_L","label":"Total central befovacimab","unit":null},{"description":"Free central befovacimab over the selected simulation window.","key":"central_free_nM","label":"Free central befovacimab","unit":null},{"description":"Total target concentration over the selected simulation window.","key":"target_total_nM","label":"Total target concentration","unit":"nM"},{"description":"Befovacimab TFPI complex over the selected simulation window.","key":"complex_nM","label":"Befovacimab TFPI complex","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_L_h_kg","label":"Systemic clearance","max":0.0004305,"min":0.0001435,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.000287},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_L_kg","label":"Central distribution volume","max":0.07365,"min":0.02455,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.0491},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"kss_nM","label":"Quasi-steady-state binding constant","max":348,"min":116,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":232},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_h","label":"Target internalization rate","max":83.1,"min":27.7,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"1/h","value":55.4},{"category":"model parameter","definition":"Target synthesis rate governing production or formation in the modeled biological process.","description":"Target synthesis rate governing production or formation in the modeled biological process.","key":"ksyn_nM_h","label":"Target synthesis rate","max":3.9000000000000004,"min":1.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM/h","value":2.6}],"description":"How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex? Explore this biological starting configuration through Total central befovacimab, Free central befovacimab, Total TFPI, Befovacimab–TFPI complex, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"cynomolgus IV 5 mg/kg QSS-TMDD","outputs":[{"classification":"provisional","description":"Total central befovacimab over the selected simulation window.","key":"central_total_mg_L","label":"Total central befovacimab","unit":null},{"classification":"provisional","description":"Free central befovacimab over the selected simulation window.","key":"central_free_nM","label":"Free central befovacimab","unit":null},{"classification":"provisional","description":"Total target concentration over the selected simulation window.","key":"target_total_nM","label":"Total target concentration","unit":"nM"},{"classification":"provisional","description":"Befovacimab TFPI complex over the selected simulation window.","key":"complex_nM","label":"Befovacimab TFPI complex","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"gu_2017_cyno_iv5mgkg_qss_tmdd_probe","scientific_questions":["How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex?"],"time_span":{"end":720,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_L_h_kg","label":"Systemic clearance","max":0.0004305,"min":0.0001435,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.000287},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_L_kg","label":"Central distribution volume","max":0.07365,"min":0.02455,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.0491},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"kss_nM","label":"Quasi-steady-state binding constant","max":348,"min":116,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":232},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_h","label":"Target internalization rate","max":83.1,"min":27.7,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"1/h","value":55.4},{"category":"model parameter","definition":"Target synthesis rate governing production or formation in the modeled biological process.","description":"Target synthesis rate governing production or formation in the modeled biological process.","key":"ksyn_nM_h","label":"Target synthesis rate","max":3.9000000000000004,"min":1.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM/h","value":2.6}],"description":"How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex? Explore this biological starting configuration through Total central befovacimab, Free central befovacimab, Total TFPI, Befovacimab–TFPI complex, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"cynomolgus IV 20 mg/kg QSS-TMDD","outputs":[{"classification":"provisional","description":"Total central befovacimab over the selected simulation window.","key":"central_total_mg_L","label":"Total central befovacimab","unit":null},{"classification":"provisional","description":"Free central befovacimab over the selected simulation window.","key":"central_free_nM","label":"Free central befovacimab","unit":null},{"classification":"provisional","description":"Total target concentration over the selected simulation window.","key":"target_total_nM","label":"Total target concentration","unit":"nM"},{"classification":"provisional","description":"Befovacimab TFPI complex over the selected simulation window.","key":"complex_nM","label":"Befovacimab TFPI complex","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"gu_2017_cyno_iv20mgkg_qss_tmdd_probe","scientific_questions":["How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex?"],"time_span":{"end":1008,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_L_h_kg","label":"Systemic clearance","max":0.0004305,"min":0.0001435,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.000287},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_L_kg","label":"Central distribution volume","max":0.07365,"min":0.02455,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.0491},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"kss_nM","label":"Quasi-steady-state binding constant","max":348,"min":116,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":232},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_h","label":"Target internalization rate","max":83.1,"min":27.7,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"1/h","value":55.4},{"category":"model parameter","definition":"Target synthesis rate governing production or formation in the modeled biological process.","description":"Target synthesis rate governing production or formation in the modeled biological process.","key":"ksyn_nM_h","label":"Target synthesis rate","max":3.9000000000000004,"min":1.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM/h","value":2.6}],"description":"How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex? Explore this biological starting configuration through Total central befovacimab, Free central befovacimab, Total TFPI, Befovacimab–TFPI complex, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Human 0.4 mg/kg","outputs":[{"classification":"provisional","description":"Total central befovacimab over the selected simulation window.","key":"central_total_mg_L","label":"Total central befovacimab","unit":null},{"classification":"provisional","description":"Free central befovacimab over the selected simulation window.","key":"central_free_nM","label":"Free central befovacimab","unit":null},{"classification":"provisional","description":"Total target concentration over the selected simulation window.","key":"target_total_nM","label":"Total target concentration","unit":"nM"},{"classification":"provisional","description":"Befovacimab TFPI complex over the selected simulation window.","key":"complex_nM","label":"Befovacimab TFPI complex","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"gu_2017_human_0p4mgkg_iv_source_limited","scientific_questions":["How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex?"],"time_span":{"end":168,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_L_h_kg","label":"Systemic clearance","max":0.0004305,"min":0.0001435,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.000287},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_L_kg","label":"Central distribution volume","max":0.07365,"min":0.02455,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.0491},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"kss_nM","label":"Quasi-steady-state binding constant","max":348,"min":116,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":232},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_h","label":"Target internalization rate","max":83.1,"min":27.7,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"1/h","value":55.4},{"category":"model parameter","definition":"Target synthesis rate governing production or formation in the modeled biological process.","description":"Target synthesis rate governing production or formation in the modeled biological process.","key":"ksyn_nM_h","label":"Target synthesis rate","max":3.9000000000000004,"min":1.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM/h","value":2.6}],"description":"How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex? Explore this biological starting configuration through Total central befovacimab, Free central befovacimab, Total TFPI, Befovacimab–TFPI complex, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"cynomolgus SC 5 mg/kg","outputs":[{"classification":"provisional","description":"Total central befovacimab over the selected simulation window.","key":"central_total_mg_L","label":"Total central befovacimab","unit":null},{"classification":"provisional","description":"Free central befovacimab over the selected simulation window.","key":"central_free_nM","label":"Free central befovacimab","unit":null},{"classification":"provisional","description":"Total target concentration over the selected simulation window.","key":"target_total_nM","label":"Total target concentration","unit":"nM"},{"classification":"provisional","description":"Befovacimab TFPI complex over the selected simulation window.","key":"complex_nM","label":"Befovacimab TFPI complex","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"gu_2017_exploratory_calibrated_cyno_sc5mgkg_joint_figures2_4_5_6_table2","scientific_questions":["How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex?"],"time_span":{"end":528,"start":0,"step":0.5}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_L_h_kg","label":"Systemic clearance","max":0.003832851905342577,"min":0.001277617301780859,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/h/kg","value":0.002555234603561718},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_L_kg","label":"Central distribution volume","max":0.07692307692307693,"min":0.025641025641025644,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.05128205128205129},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"kss_nM","label":"Quasi-steady-state binding constant","max":348,"min":116,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":232},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_h","label":"Target internalization rate","max":1,"min":0,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"1/h","value":0},{"category":"model parameter","definition":"Target synthesis rate governing production or formation in the modeled biological process.","description":"Target synthesis rate governing production or formation in the modeled biological process.","key":"ksyn_nM_h","label":"Target synthesis rate","max":9.864,"min":3.2880000000000003,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM/h","value":6.5760000000000005}],"description":"How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex? Explore this biological starting configuration through Total central befovacimab, Free central befovacimab, Total TFPI, Befovacimab–TFPI complex, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"human 0.4 mg/kg endpoints","outputs":[{"classification":"provisional","description":"Total central befovacimab over the selected simulation window.","key":"central_total_mg_L","label":"Total central befovacimab","unit":null},{"classification":"provisional","description":"Free central befovacimab over the selected simulation window.","key":"central_free_nM","label":"Free central befovacimab","unit":null},{"classification":"provisional","description":"Total target concentration over the selected simulation window.","key":"target_total_nM","label":"Total target concentration","unit":"nM"},{"classification":"provisional","description":"Befovacimab TFPI complex over the selected simulation window.","key":"complex_nM","label":"Befovacimab TFPI complex","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_L","label":"Exposure (AUC)","unit":"mg*h/L"}],"scenario_id":"gu_2017_exploratory_calibrated_human_0p4mgkg_endpoints","scientific_questions":["How do route and dose change befovacimab exposure, free antibody, TFPI, and bound complex?"],"time_span":{"end":168,"start":0,"step":0.5}}],"targets":[{"key":"tfpi","label":"TFPI"},{"key":"tissue_factor_pathway_inhibitor","label":"tissue factor pathway inhibitor"}],"therapeutics":[{"key":"befovacimab","label":"Befovacimab"},{"key":"bay_1093884_befovacimab","label":"BAY 1093884 / befovacimab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A mechanistic pharmacodynamic model connecting PROTAC concentration, target and E3-ligase binding, catalytic degradation, protein turnover, and the high-concentration hook effect.","diseases":[{"key":"mechanistic_target_degradation_pharmacology","label":"Mechanistic target-degradation pharmacology"}],"links":{"page":"/modeling/models/haid-2023-protac-mechanistic-pd-framework","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":null,"model_classes":["Other/Unclassified"],"model_id":"haid_2023_protac_mechanistic_pd_framework","name":"PROTAC target-engagement and degradation dynamics","outputs":[{"description":"Relative mechanistic degradation over the selected simulation window.","key":"p_mech_rel","label":"Relative mechanistic degradation","unit":"dimensionless"},{"description":"Relative hook-effect response over the selected simulation window.","key":"p_hook_rel","label":"Relative hook-effect response","unit":"dimensionless"},{"description":"Simplified target engagement over the selected simulation window.","key":"te_simplified","label":"Simplified target engagement","unit":null},{"description":"Steady state maximum degradation over the selected simulation window.","key":"hook_dmax_ss","label":"Steady state maximum degradation","unit":null},{"description":"Elapsed over the selected simulation window.","key":"elapsed_h","label":"Elapsed","unit":"h"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"PROTAC concentration coefficient used by the released system of model equations.","description":"PROTAC concentration coefficient used by the released system of model equations.","key":"protac_conc_nm","label":"PROTAC concentration","max":103.35000000000001,"min":34.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"nM","value":68.9},{"category":"model parameter","definition":"Target–PROTAC dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"Target–PROTAC dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"kd_p_nm","label":"Target–PROTAC dissociation constant","max":207,"min":69,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":138},{"category":"model parameter","definition":"PROTAC–E3 ligase dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"PROTAC–E3 ligase dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"kd_e_nm","label":"PROTAC–E3 ligase dissociation constant","max":4650,"min":1550,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":10,"unit":"nM","value":3100},{"category":"model parameter","definition":"Catalytic degradation rate coefficient used by the released system of model equations.","description":"Catalytic degradation rate coefficient used by the released system of model equations.","key":"kcat_h","label":"Catalytic degradation rate","max":0.75,"min":0.25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/h","value":0.5},{"category":"model parameter","definition":"Target-protein half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Target-protein half-life controlling the time required for the corresponding quantity to decrease by half.","key":"t_half_p_h","label":"Target-protein half-life","max":67.5,"min":22.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"h","value":45}],"description":"How do binding affinity, catalytic rate, and PROTAC concentration determine target degradation and the hook effect? Explore this biological starting configuration through Mechanistic relative target protein, Hook-model relative target protein, Simplified target engagement, Steady-state maximum degradation.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Eq. 14 hook-model 6 h to 24 h RIPK2 degradation","outputs":[{"classification":"provisional","description":"Relative mechanistic degradation over the selected simulation window.","key":"p_mech_rel","label":"Relative mechanistic degradation","unit":"dimensionless"},{"classification":"provisional","description":"Relative hook-effect response over the selected simulation window.","key":"p_hook_rel","label":"Relative hook-effect response","unit":"dimensionless"},{"classification":"provisional","description":"Simplified target engagement over the selected simulation window.","key":"te_simplified","label":"Simplified target engagement","unit":null},{"classification":"provisional","description":"Steady state maximum degradation over the selected simulation window.","key":"hook_dmax_ss","label":"Steady state maximum degradation","unit":null}],"scenario_id":"mares_ripk2_hook_timecourse","scientific_questions":["How do binding affinity, catalytic rate, and PROTAC concentration determine target degradation and the hook effect?"],"time_span":{"end":96,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"PROTAC concentration coefficient used by the released system of model equations.","description":"PROTAC concentration coefficient used by the released system of model equations.","key":"protac_conc_nm","label":"PROTAC concentration","max":150,"min":50,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":100},{"category":"model parameter","definition":"Target–PROTAC dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"Target–PROTAC dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"kd_p_nm","label":"Target–PROTAC dissociation constant","max":207,"min":69,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":138},{"category":"model parameter","definition":"PROTAC–E3 ligase dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"PROTAC–E3 ligase dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"kd_e_nm","label":"PROTAC–E3 ligase dissociation constant","max":4650,"min":1550,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":10,"unit":"nM","value":3100},{"category":"model parameter","definition":"Catalytic degradation rate coefficient used by the released system of model equations.","description":"Catalytic degradation rate coefficient used by the released system of model equations.","key":"kcat_h","label":"Catalytic degradation rate","max":0.75,"min":0.25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/h","value":0.5},{"category":"model parameter","definition":"Target-protein half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Target-protein half-life controlling the time required for the corresponding quantity to decrease by half.","key":"t_half_p_h","label":"Target-protein half-life","max":24,"min":8,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"h","value":16}],"description":"How do binding affinity, catalytic rate, and PROTAC concentration determine target degradation and the hook effect? Explore this biological starting configuration through Mechanistic relative target protein, Hook-model relative target protein, Simplified target engagement, Steady-state maximum degradation.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Mechanistic Eq. 8 target-engagement degradation","outputs":[{"classification":"provisional","description":"Relative mechanistic degradation over the selected simulation window.","key":"p_mech_rel","label":"Relative mechanistic degradation","unit":"dimensionless"},{"classification":"provisional","description":"Relative hook-effect response over the selected simulation window.","key":"p_hook_rel","label":"Relative hook-effect response","unit":"dimensionless"},{"classification":"provisional","description":"Simplified target engagement over the selected simulation window.","key":"te_simplified","label":"Simplified target engagement","unit":null},{"classification":"provisional","description":"Steady state maximum degradation over the selected simulation window.","key":"hook_dmax_ss","label":"Steady state maximum degradation","unit":null}],"scenario_id":"ramos_cpd_i_mechanistic_te_ode","scientific_questions":["How do binding affinity, catalytic rate, and PROTAC concentration determine target degradation and the hook effect?"],"time_span":{"end":48,"start":0,"step":1}}],"targets":[{"key":"generic_poi","label":"generic POI"},{"key":"e3_ligase","label":"E3 ligase"}],"therapeutics":[{"key":"parameterized_protac","label":"Parameterized PROTAC"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced QSP model connecting nivolumab exposure and PD-1 checkpoint inhibition to effector and regulatory T-cell dynamics, tumor-cell burden, and tumor regression.","diseases":[{"key":"resectable_non_small_cell_lung_cancer","label":"Resectable non-small cell lung cancer"}],"links":{"page":"/modeling/models/jafarnejad-2019-nivolumab-neoadjuvant-pd1-nsclc-qsp","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole monoclonal antibody immune-checkpoint inhibitor","model_classes":["QSP"],"model_id":"jafarnejad_2019_nivolumab_neoadjuvant_pd1_nsclc_qsp","name":"Neoadjuvant nivolumab tumor–immune dynamics","outputs":[{"description":"PD 1 blockade over the selected simulation window.","key":"pd1_blockade_fraction","label":"PD 1 blockade","unit":null},{"description":"Effector t over the selected simulation window.","key":"teff_cells","label":"Effector t","unit":"cell"},{"description":"Regulatory t over the selected simulation window.","key":"treg_cells","label":"Regulatory t","unit":"cell"},{"description":"Tumor-cell count over the selected simulation window.","key":"tumor_cells","label":"Tumor-cell count","unit":"cell"},{"description":"Tumor diameter relative to baseline over the selected simulation window.","key":"tumor_diameter_percent_calc","label":"Tumor diameter relative to baseline","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Nivolumab elimination rate governing first-order loss from the modeled system.","description":"Nivolumab elimination rate governing first-order loss from the modeled system.","key":"k_elim_nivo_day","label":"Nivolumab elimination rate","max":0.093,"min":0.031,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.062},{"category":"model parameter","definition":"Nivolumab input rate defining the modeled treatment input for the explored scenario.","description":"Nivolumab input rate defining the modeled treatment input for the explored scenario.","key":"nivo_input_rate_mg_day","label":"Nivolumab input rate","max":25.714285714285715,"min":8.571428571428571,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"mg/day","value":17.142857142857142},{"category":"model parameter","definition":"Checkpoint relaxation coefficient used by the released system of model equations.","description":"Checkpoint relaxation coefficient used by the released system of model equations.","key":"checkpoint_relaxation_day","label":"Checkpoint relaxation","max":3,"min":1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"day","value":2},{"category":"model parameter","definition":"Effector T-cell activation coefficient used by the released system of model equations.","description":"Effector T-cell activation coefficient used by the released system of model equations.","key":"teff_activation_day","label":"Effector T-cell activation","max":0.026999999999999996,"min":0.009,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.018},{"category":"model parameter","definition":"Regulatory T-cell relaxation coefficient used by the released system of model equations.","description":"Regulatory T-cell relaxation coefficient used by the released system of model equations.","key":"treg_relaxation_day","label":"Regulatory T-cell relaxation","max":52.5,"min":17.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":35}],"description":"Explore how a regimen-averaged nivolumab input rate changes PD-1 blockade, effector and regulatory T-cell balance, and tumor regression. The packaged equations use a continuous average input parameter; discrete infusion events are not executed by this reduced model.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Regimen-averaged neoadjuvant nivolumab input","outputs":[{"classification":"provisional","description":"PD 1 blockade over the selected simulation window.","key":"pd1_blockade_fraction","label":"PD 1 blockade","unit":null},{"classification":"provisional","description":"Effector t over the selected simulation window.","key":"teff_cells","label":"Effector t","unit":"cell"},{"classification":"provisional","description":"Regulatory t over the selected simulation window.","key":"treg_cells","label":"Regulatory t","unit":"cell"},{"classification":"provisional","description":"Tumor-cell count over the selected simulation window.","key":"tumor_cells","label":"Tumor-cell count","unit":"cell"},{"classification":"provisional","description":"Tumor diameter relative to baseline over the selected simulation window.","key":"tumor_diameter_percent_calc","label":"Tumor diameter relative to baseline","unit":null}],"scenario_id":"neoadjuvant_two_dose_resection_endpoint","scientific_questions":["How does neoadjuvant PD-1 blockade propagate through T-cell balance to tumor regression?"],"time_span":{"end":40,"start":0,"step":1}}],"targets":[{"key":"pd1","label":"PD-1 / PDCD1"}],"therapeutics":[{"key":"nivolumab","label":"Nivolumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced AUTOTAC PK/PD model linking ATC161 exposure to concentration-dependent degradation and recovery of alpha-synuclein aggregates.","diseases":[{"key":"preclinical_parkinson_disease_and_synucleinopathy_models","label":"Preclinical Parkinson disease and synucleinopathy models"}],"links":{"page":"/modeling/models/lee-2023-atc161-autotac-alpha-syn-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Small-molecule AUTOTAC degrader","model_classes":["PKPD"],"model_id":"lee_2023_atc161_autotac_alpha_syn_pkpd","name":"ATC161 exposure and alpha-synuclein aggregate degradation","outputs":[{"description":"Plasma ATC161 concentration over the selected simulation window.","key":"plasma_atc161_ng_mL","label":"Plasma ATC161 concentration","unit":"ng/mL"},{"description":"ATC161 molar concentration over the selected simulation window.","key":"atc161_concentration_nM","label":"ATC161 molar concentration","unit":null},{"description":"Aggregate degradation effect over the selected simulation window.","key":"degradation_effect_fraction","label":"Aggregate degradation effect","unit":null},{"description":"Alpha synuclein aggregate fraction over the selected simulation window.","key":"aggregate_fraction","label":"Alpha synuclein aggregate fraction","unit":"dimensionless"},{"description":"ATC161 DC50 over the selected simulation window.","key":"atc161_dc50_ng_mL","label":"ATC161 DC50","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Oral ATC161 half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Oral ATC161 half-life controlling the time required for the corresponding quantity to decrease by half.","key":"atc161_po_half_life_h","label":"Oral ATC161 half-life","max":5.550000000000001,"min":1.85,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"h","value":3.7},{"category":"model parameter","definition":"Half-maximal degradation concentration at which the corresponding modeled effect reaches half of its maximum.","description":"Half-maximal degradation concentration at which the corresponding modeled effect reaches half of its maximum.","key":"dc50_nM","label":"Half-maximal degradation concentration","max":150,"min":50,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":100},{"category":"model parameter","definition":"Aggregate degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"Aggregate degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aggregate_degradation_k_h","label":"Aggregate degradation rate","max":0.06,"min":0.02,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/h","value":0.04},{"category":"model parameter","definition":"Aggregate recovery rate coefficient used by the released system of model equations.","description":"Aggregate recovery rate coefficient used by the released system of model equations.","key":"aggregate_recovery_k_h","label":"Aggregate recovery rate","max":0.0015,"min":0.0005,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"1/h","value":0.001},{"category":"model parameter","definition":"Baseline aggregate fraction represented as a dimensionless fraction in the released equations.","description":"Baseline aggregate fraction represented as a dimensionless fraction in the released equations.","key":"baseline_aggregate_fraction","label":"Baseline aggregate fraction","max":1.5,"min":0.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"dimensionless","value":1}],"description":"How does ATC161 exposure control the time course and recovery of alpha-synuclein aggregate reduction? Explore this biological starting configuration through Plasma ATC161, ATC161 molar concentration, Aggregate degradation effect, Alpha-synuclein aggregate fraction.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"PO 20 mg/kg first-order PK/degradation","outputs":[{"classification":"provisional","description":"Plasma ATC161 concentration over the selected simulation window.","key":"plasma_atc161_ng_mL","label":"Plasma ATC161 concentration","unit":"ng/mL"},{"classification":"provisional","description":"ATC161 molar concentration over the selected simulation window.","key":"atc161_concentration_nM","label":"ATC161 molar concentration","unit":null},{"classification":"provisional","description":"Aggregate degradation effect over the selected simulation window.","key":"degradation_effect_fraction","label":"Aggregate degradation effect","unit":null},{"classification":"provisional","description":"Alpha synuclein aggregate fraction over the selected simulation window.","key":"aggregate_fraction","label":"Alpha synuclein aggregate fraction","unit":"dimensionless"}],"scenario_id":"po20mgkg_first_order_pk_degradation_probe","scientific_questions":["How does ATC161 exposure control the time course and recovery of alpha-synuclein aggregate reduction?"],"time_span":{"end":24,"start":0,"step":0.1}}],"targets":[{"key":"alpha_synuclein_aggregates","label":"alpha-synuclein aggregates"},{"key":"snca_aggregates","label":"SNCA aggregates"},{"key":"p62","label":"p62"},{"key":"sqstm1","label":"SQSTM1"}],"therapeutics":[{"key":"atc161","label":"ATC161"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model representing eculizumab or SB12 disposition, body-weight effects, disease-specific central volume, concentration, and cumulative exposure.","diseases":[{"key":"healthy_participants_and_paroxysmal_nocturnal_hemoglobinuria","label":"Healthy participants and paroxysmal nocturnal hemoglobinuria"}],"links":{"page":"/modeling/models/lee-2024-sb12-eculizumab-biosimilar-poppkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":null,"model_classes":["PopPK","PKPD"],"model_id":"lee_2024_sb12_eculizumab_biosimilar_poppkpd","name":"Eculizumab and SB12 population PK","outputs":[{"description":"Central eculizumab or SB12 concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central eculizumab or SB12 concentration","unit":null},{"description":"Peripheral concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_h_ml","label":"Exposure (AUC)","unit":"ug*h/mL"},{"description":"Systemic clearance over the selected simulation window.","key":"cl_l_h","label":"Systemic clearance","unit":null},{"description":"Body weight over the selected simulation window.","key":"body_weight_kg","label":"Body weight","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"PK clearance governing removal of modeled material from the relevant compartment.","description":"PK clearance governing removal of modeled material from the relevant compartment.","key":"pk_cl_l_h","label":"PK clearance","max":0.026099999999999998,"min":0.0087,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0174},{"category":"model parameter","definition":"Central distribution volume — healthy participants used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume — healthy participants used to convert modeled amount to concentration in the relevant compartment.","key":"pk_vc_healthy_l","label":"Central distribution volume — healthy participants","max":5.205,"min":1.735,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.47},{"category":"model parameter","definition":"Central distribution volume — PNH used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume — PNH used to convert modeled amount to concentration in the relevant compartment.","key":"pk_vc_pnh_l","label":"Central distribution volume — PNH","max":8.52,"min":2.84,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":5.68},{"category":"model parameter","definition":"PK intercompartmental clearance governing exchange between model compartments.","description":"PK intercompartmental clearance governing exchange between model compartments.","key":"pk_q_l_h","label":"PK intercompartmental clearance","max":0.0201,"min":0.0067,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0134},{"category":"model parameter","definition":"PK peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"PK peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"pk_vp_l","label":"PK peripheral distribution volume","max":1.185,"min":0.395,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L","value":0.79}],"description":"How do body weight and disease context change eculizumab or SB12 concentration and exposure? Explore this intervention regimen through Central eculizumab or SB12 concentration, Peripheral concentration, Cumulative exposure, Individual clearance.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Healthy 300 mg IV single-dose PK/PD","outputs":[{"classification":"provisional","description":"Central eculizumab or SB12 concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central eculizumab or SB12 concentration","unit":null},{"classification":"provisional","description":"Peripheral concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_h_ml","label":"Exposure (AUC)","unit":"ug*h/mL"},{"classification":"provisional","description":"Systemic clearance over the selected simulation window.","key":"cl_l_h","label":"Systemic clearance","unit":null}],"scenario_id":"healthy_300mg_iv_single_dose_dynamic_overlay","scientific_questions":["How do body weight and disease context change eculizumab or SB12 concentration and exposure?"],"time_span":{"end":672,"start":0,"step":6}},{"controls":[{"category":"model parameter","definition":"PK clearance governing removal of modeled material from the relevant compartment.","description":"PK clearance governing removal of modeled material from the relevant compartment.","key":"pk_cl_l_h","label":"PK clearance","max":0.026099999999999998,"min":0.0087,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0174},{"category":"model parameter","definition":"Central distribution volume — healthy participants used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume — healthy participants used to convert modeled amount to concentration in the relevant compartment.","key":"pk_vc_healthy_l","label":"Central distribution volume — healthy participants","max":5.205,"min":1.735,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.47},{"category":"model parameter","definition":"Central distribution volume — PNH used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume — PNH used to convert modeled amount to concentration in the relevant compartment.","key":"pk_vc_pnh_l","label":"Central distribution volume — PNH","max":8.52,"min":2.84,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":5.68},{"category":"model parameter","definition":"PK intercompartmental clearance governing exchange between model compartments.","description":"PK intercompartmental clearance governing exchange between model compartments.","key":"pk_q_l_h","label":"PK intercompartmental clearance","max":0.0201,"min":0.0067,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0134},{"category":"model parameter","definition":"PK peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"PK peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"pk_vp_l","label":"PK peripheral distribution volume","max":1.185,"min":0.395,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L","value":0.79}],"description":"How do body weight and disease context change eculizumab or SB12 concentration and exposure? Explore this intervention regimen through Central eculizumab or SB12 concentration, Peripheral concentration, Cumulative exposure, Individual clearance.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"PNH labeled regimen PK/PD/LDH","outputs":[{"classification":"provisional","description":"Central eculizumab or SB12 concentration over the selected simulation window.","key":"central_conc_ug_ml","label":"Central eculizumab or SB12 concentration","unit":null},{"classification":"provisional","description":"Peripheral concentration over the selected simulation window.","key":"peripheral_conc_ug_ml","label":"Peripheral concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_h_ml","label":"Exposure (AUC)","unit":"ug*h/mL"},{"classification":"provisional","description":"Systemic clearance over the selected simulation window.","key":"cl_l_h","label":"Systemic clearance","unit":null}],"scenario_id":"pnh_labeled_regimen_dynamic_overlay","scientific_questions":["How do body weight and disease context change eculizumab or SB12 concentration and exposure?"],"time_span":{"end":5040,"start":0,"step":12}}],"targets":[{"key":"c5","label":"Complement C5"}],"therapeutics":[{"key":"eculizumab_or_sb12","label":"Eculizumab or SB12"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"Mechanistic rat QSP coupling whole-body AAV biodistribution, intracellular transduction, transgene-derived anti-TargetX mAb, FcRn-aware protein PBPK, TargetX binding, and detailed brain/CSF transport across 725 explicit scalar states.","diseases":[{"key":"not_disease_specific_preclinical_cns_delivery","label":"Preclinical CNS antibody delivery (not disease-specific)","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1007/s10928-026-10051-w","locator":"Primary publication title and abstract describe AAV-mediated antibody delivery in rat brain without a disease indication.","relationship":"Explicit non-disease-specific context; no disease indication is inferred."}}],"links":{"page":"/modeling/models/liu-2026-aav-mab-targetx-rat-brain-full-qsp","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"AAV-mediated monoclonal antibody gene delivery","model_classes":["PBPK","QSP","TMDD"],"model_id":"liu_2026_aav_mab_targetx_rat_brain_full_qsp","name":"Whole-body AAV–anti-TargetX rat brain QSP","outputs":[{"description":"Whole-blood vector-genome concentration for route and serotype biodistribution comparison.","key":"aav_blood_Vg_mL","label":"AAV in whole blood","unit":"Vg/mL"},{"description":"Volume-weighted vector-genome concentration across modeled brain vascular, barrier, CSF, meningeal, and cellular spaces.","key":"aav_brain_Vg_mL","label":"AAV in total brain","unit":"Vg/mL"},{"description":"Circulating transgene-derived or exogenously dosed antibody.","key":"mab_plasma_nM","label":"Anti target x m ab in plasma","unit":"nM"},{"description":"Volume-weighted modeled antibody across brain vascular, ISF, BBB, BCSFB, and parenchymal endosomal spaces.","key":"mab_brain_nM","label":"Anti target x m ab in total brain","unit":"nM"},{"description":"Free cisterna-magna TargetX normalized to its pre-dose model baseline; this is the Figure 7 CSF mapping.","key":"target_csf_pct_baseline","label":"Free target x in cisterna magna csf","unit":"% baseline"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Unit-normalized six-hour exogenous TargetX bolus disposition. The source does not disclose the administered amount, so only the population-fit curve shape and reported 1.4 h half-life are compared.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"Exogenous TargetX disposition","outputs":[{"classification":"provisional","description":"Modeled free TargetX concentration in plasma.","key":"target_plasma_pM","label":"Free target x in plasma","unit":"pM"}],"scenario_id":"figure3a_exogenous_targetx_shape","scientific_questions":["Does exogenous plasma TargetX show the reported rapid disposition shape?"],"time_span":{"end":6,"start":0,"step":0.1}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Twenty-one-day no-dose TargetX equilibration for the disclosed plasma, brain-ISF, and lateral-ventricle CSF anchors.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"TargetX steady-state calibration","outputs":[{"classification":"qualified","description":"Modeled free TargetX concentration in plasma.","key":"target_plasma_pM","label":"Free target x in plasma","unit":"pM"},{"classification":"qualified","description":"Modeled free TargetX concentration in brain interstitial fluid.","key":"target_isf_pM","label":"Free target x in brain isf","unit":"pM"},{"classification":"qualified","description":"Modeled free TargetX concentration in ventricular cerebrospinal fluid.","key":"target_lv_pM","label":"Free target x in ventricular csf","unit":"pM"}],"scenario_id":"figure3b_targetx_steady_state","scientific_questions":["Do plasma, brain-ISF, and ventricular-CSF TargetX approach the disclosed baselines?"],"time_span":{"end":0,"start":-504,"step":6}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Figure 3C-F 3 mg/kg IV anti-TargetX mAb regimen. Dose amount assumes the disclosed 0.280 kg rat physiology and a 150 kDa IgG conversion; the source does not disclose individual animal weights or administration duration.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"IV anti-TargetX mAb — 3 mg/kg","outputs":[{"classification":"provisional","description":"Plasma concentration after an intravenous anti-TargetX mAb dose.","key":"mab_plasma_ug_mL","label":"Anti target x m ab in plasma","unit":"µg/mL"},{"classification":"provisional","description":"Brain interstitial-fluid concentration after an intravenous anti-TargetX mAb dose.","key":"mab_isf_ug_mL","label":"Anti target x m ab in brain isf","unit":"µg/mL"},{"classification":"provisional","description":"Cerebrospinal-fluid concentration after an intravenous anti-TargetX mAb dose.","key":"mab_csf_ug_mL","label":"Anti target x m ab in csf","unit":"µg/mL"},{"classification":"provisional","description":"Modeled free TargetX concentration in cerebrospinal fluid.","key":"target_csf_pM","label":"Free target x in csf","unit":"pM"}],"scenario_id":"figure3_mab_iv_3mgkg","scientific_questions":["How does an exogenous IV anti-TargetX mAb dose distribute between plasma, brain ISF, and CSF?"],"time_span":{"end":504,"start":-1000,"step":6}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Figure 3C-F 10 mg/kg IV anti-TargetX mAb regimen. Dose amount assumes the disclosed 0.280 kg rat physiology and a 150 kDa IgG conversion; the source does not disclose individual animal weights or administration duration.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"IV anti-TargetX mAb — 10 mg/kg","outputs":[{"classification":"provisional","description":"Plasma concentration after an intravenous anti-TargetX mAb dose.","key":"mab_plasma_ug_mL","label":"Anti target x m ab in plasma","unit":"µg/mL"},{"classification":"provisional","description":"Brain interstitial-fluid concentration after an intravenous anti-TargetX mAb dose.","key":"mab_isf_ug_mL","label":"Anti target x m ab in brain isf","unit":"µg/mL"},{"classification":"provisional","description":"Cerebrospinal-fluid concentration after an intravenous anti-TargetX mAb dose.","key":"mab_csf_ug_mL","label":"Anti target x m ab in csf","unit":"µg/mL"},{"classification":"provisional","description":"Modeled free TargetX concentration in cerebrospinal fluid.","key":"target_csf_pM","label":"Free target x in csf","unit":"pM"}],"scenario_id":"figure3_mab_iv_10mgkg","scientific_questions":["How does an exogenous IV anti-TargetX mAb dose distribute between plasma, brain ISF, and CSF?"],"time_span":{"end":504,"start":-1000,"step":6}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Figure 3C-F 30 mg/kg IV anti-TargetX mAb regimen. Dose amount assumes the disclosed 0.280 kg rat physiology and a 150 kDa IgG conversion; the source does not disclose individual animal weights or administration duration.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"IV anti-TargetX mAb — 30 mg/kg","outputs":[{"classification":"provisional","description":"Plasma concentration after an intravenous anti-TargetX mAb dose.","key":"mab_plasma_ug_mL","label":"Anti target x m ab in plasma","unit":"µg/mL"},{"classification":"provisional","description":"Brain interstitial-fluid concentration after an intravenous anti-TargetX mAb dose.","key":"mab_isf_ug_mL","label":"Anti target x m ab in brain isf","unit":"µg/mL"},{"classification":"provisional","description":"Cerebrospinal-fluid concentration after an intravenous anti-TargetX mAb dose.","key":"mab_csf_ug_mL","label":"Anti target x m ab in csf","unit":"µg/mL"},{"classification":"provisional","description":"Modeled free TargetX concentration in cerebrospinal fluid.","key":"target_csf_pM","label":"Free target x in csf","unit":"pM"}],"scenario_id":"figure3_mab_iv_30mgkg","scientific_questions":["How does an exogenous IV anti-TargetX mAb dose distribute between plasma, brain ISF, and CSF?"],"time_span":{"end":504,"start":-1000,"step":6}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Figure 3C-F 100 mg/kg IV anti-TargetX mAb regimen. Dose amount assumes the disclosed 0.280 kg rat physiology and a 150 kDa IgG conversion; the source does not disclose individual animal weights or administration duration.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"IV anti-TargetX mAb — 100 mg/kg","outputs":[{"classification":"provisional","description":"Plasma concentration after an intravenous anti-TargetX mAb dose.","key":"mab_plasma_ug_mL","label":"Anti target x m ab in plasma","unit":"µg/mL"},{"classification":"provisional","description":"Brain interstitial-fluid concentration after an intravenous anti-TargetX mAb dose.","key":"mab_isf_ug_mL","label":"Anti target x m ab in brain isf","unit":"µg/mL"},{"classification":"provisional","description":"Cerebrospinal-fluid concentration after an intravenous anti-TargetX mAb dose.","key":"mab_csf_ug_mL","label":"Anti target x m ab in csf","unit":"µg/mL"},{"classification":"provisional","description":"Modeled free TargetX concentration in cerebrospinal fluid.","key":"target_csf_pM","label":"Free target x in csf","unit":"pM"}],"scenario_id":"figure3_mab_iv_100mgkg","scientific_questions":["How does an exogenous IV anti-TargetX mAb dose distribute between plasma, brain ISF, and CSF?"],"time_span":{"end":504,"start":-1000,"step":6}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Systemic AAV9 delivery after 1000 h receptor and TargetX pre-equilibration.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"Systemic AAV9 delivery — 5E12 Vg IV","outputs":[{"classification":"provisional","description":"Whole-blood vector-genome concentration for route and serotype biodistribution comparison.","key":"aav_blood_Vg_mL","label":"AAV in whole blood","unit":"Vg/mL"},{"classification":"provisional","description":"Volume-weighted vector-genome concentration across modeled brain vascular, barrier, CSF, meningeal, and cellular spaces.","key":"aav_brain_Vg_mL","label":"AAV in total brain","unit":"Vg/mL"},{"classification":"provisional","description":"Circulating transgene-derived or exogenously dosed antibody.","key":"mab_plasma_nM","label":"Anti target x m ab in plasma","unit":"nM"},{"classification":"provisional","description":"Volume-weighted modeled antibody across brain vascular, ISF, BBB, BCSFB, and parenchymal endosomal spaces.","key":"mab_brain_nM","label":"Anti target x m ab in total brain","unit":"nM"},{"classification":"qualified","description":"Free cisterna-magna TargetX normalized to its pre-dose model baseline; this is the Figure 7 CSF mapping.","key":"target_csf_pct_baseline","label":"Free target x in cisterna magna csf","unit":"% baseline"}],"scenario_id":"iv_5e12_aav9","scientific_questions":["How do route, dose, and serotype shape vector biodistribution, antibody exposure, and free TargetX?"],"time_span":{"end":1344,"start":-1000,"step":24}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Low-dose AAV9 delivery into cisterna-magna CSF.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"Low-dose AAV9 delivery — 5E11 Vg ICM","outputs":[{"classification":"provisional","description":"Whole-blood vector-genome concentration for route and serotype biodistribution comparison.","key":"aav_blood_Vg_mL","label":"AAV in whole blood","unit":"Vg/mL"},{"classification":"provisional","description":"Volume-weighted vector-genome concentration across modeled brain vascular, barrier, CSF, meningeal, and cellular spaces.","key":"aav_brain_Vg_mL","label":"AAV in total brain","unit":"Vg/mL"},{"classification":"provisional","description":"Circulating transgene-derived or exogenously dosed antibody.","key":"mab_plasma_nM","label":"Anti target x m ab in plasma","unit":"nM"},{"classification":"provisional","description":"Volume-weighted modeled antibody across brain vascular, ISF, BBB, BCSFB, and parenchymal endosomal spaces.","key":"mab_brain_nM","label":"Anti target x m ab in total brain","unit":"nM"},{"classification":"qualified","description":"Free cisterna-magna TargetX normalized to its pre-dose model baseline; this is the Figure 7 CSF mapping.","key":"target_csf_pct_baseline","label":"Free target x in cisterna magna csf","unit":"% baseline"}],"scenario_id":"icm_5e11_aav9","scientific_questions":["How do route, dose, and serotype shape vector biodistribution, antibody exposure, and free TargetX?"],"time_span":{"end":1344,"start":-1000,"step":24}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Mid-dose AAV9 delivery into cisterna-magna CSF.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"Mid-dose AAV9 delivery — 1E12 Vg ICM","outputs":[{"classification":"provisional","description":"Whole-blood vector-genome concentration for route and serotype biodistribution comparison.","key":"aav_blood_Vg_mL","label":"AAV in whole blood","unit":"Vg/mL"},{"classification":"provisional","description":"Volume-weighted vector-genome concentration across modeled brain vascular, barrier, CSF, meningeal, and cellular spaces.","key":"aav_brain_Vg_mL","label":"AAV in total brain","unit":"Vg/mL"},{"classification":"provisional","description":"Circulating transgene-derived or exogenously dosed antibody.","key":"mab_plasma_nM","label":"Anti target x m ab in plasma","unit":"nM"},{"classification":"provisional","description":"Volume-weighted modeled antibody across brain vascular, ISF, BBB, BCSFB, and parenchymal endosomal spaces.","key":"mab_brain_nM","label":"Anti target x m ab in total brain","unit":"nM"},{"classification":"qualified","description":"Free cisterna-magna TargetX normalized to its pre-dose model baseline; this is the Figure 7 CSF mapping.","key":"target_csf_pct_baseline","label":"Free target x in cisterna magna csf","unit":"% baseline"}],"scenario_id":"icm_1e12_aav9","scientific_questions":["How do route, dose, and serotype shape vector biodistribution, antibody exposure, and free TargetX?"],"time_span":{"end":1344,"start":-1000,"step":24}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"High-dose AAV9 delivery into cisterna-magna CSF.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"High-dose AAV9 delivery — 5E12 Vg ICM","outputs":[{"classification":"provisional","description":"Whole-blood vector-genome concentration for route and serotype biodistribution comparison.","key":"aav_blood_Vg_mL","label":"AAV in whole blood","unit":"Vg/mL"},{"classification":"provisional","description":"Volume-weighted vector-genome concentration across modeled brain vascular, barrier, CSF, meningeal, and cellular spaces.","key":"aav_brain_Vg_mL","label":"AAV in total brain","unit":"Vg/mL"},{"classification":"provisional","description":"Circulating transgene-derived or exogenously dosed antibody.","key":"mab_plasma_nM","label":"Anti target x m ab in plasma","unit":"nM"},{"classification":"provisional","description":"Volume-weighted modeled antibody across brain vascular, ISF, BBB, BCSFB, and parenchymal endosomal spaces.","key":"mab_brain_nM","label":"Anti target x m ab in total brain","unit":"nM"},{"classification":"qualified","description":"Free cisterna-magna TargetX normalized to its pre-dose model baseline; this is the Figure 7 CSF mapping.","key":"target_csf_pct_baseline","label":"Free target x in cisterna magna csf","unit":"% baseline"}],"scenario_id":"icm_5e12_aav9","scientific_questions":["How do route, dose, and serotype shape vector biodistribution, antibody exposure, and free TargetX?"],"time_span":{"end":1344,"start":-1000,"step":24}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":1.5105,"min":0.5035,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":1.007},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"Local AAV9 delivery into brain interstitial fluid.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"Local AAV9 delivery — 2.5E11 Vg IST","outputs":[{"classification":"provisional","description":"Whole-blood vector-genome concentration for route and serotype biodistribution comparison.","key":"aav_blood_Vg_mL","label":"AAV in whole blood","unit":"Vg/mL"},{"classification":"provisional","description":"Volume-weighted vector-genome concentration across modeled brain vascular, barrier, CSF, meningeal, and cellular spaces.","key":"aav_brain_Vg_mL","label":"AAV in total brain","unit":"Vg/mL"},{"classification":"provisional","description":"Circulating transgene-derived or exogenously dosed antibody.","key":"mab_plasma_nM","label":"Anti target x m ab in plasma","unit":"nM"},{"classification":"provisional","description":"Volume-weighted modeled antibody across brain vascular, ISF, BBB, BCSFB, and parenchymal endosomal spaces.","key":"mab_brain_nM","label":"Anti target x m ab in total brain","unit":"nM"},{"classification":"qualified","description":"Free cisterna-magna TargetX normalized to its pre-dose model baseline; this is the Figure 7 CSF mapping.","key":"target_csf_pct_baseline","label":"Free target x in cisterna magna csf","unit":"% baseline"}],"scenario_id":"ist_2_5e11_aav9","scientific_questions":["How do route, dose, and serotype shape vector biodistribution, antibody exposure, and free TargetX?"],"time_span":{"end":1344,"start":-1000,"step":24}},{"controls":[{"category":"published fixed","definition":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","description":"AAV degradation rate governing loss, degradation, or removal in the modeled biological process.","key":"aav_kdeg_h","label":"AAV degradation rate","max":7.5,"min":2.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":0.01,"unit":"1/h","value":5},{"category":"published fixed","definition":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","description":"Antibody permeability–surface area coefficient coefficient used by the released system of model equations.","key":"ps_mab_L_h","label":"Antibody permeability–surface area coefficient","max":3.93e-07,"min":1.31e-07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Liu 2026 Table 1","step":1e-09,"unit":"L/h","value":2.62e-07}],"description":"AAV5 serotype comparison using the disclosed parameter overrides.","interpretation_guardrails":["Research-only rat forward simulation; do not interpret as a dose recommendation, clinical prediction, or sponsor-fit replay.","Figures 3–6 comparisons use raster-derived sponsor population-fit curves and therefore establish diagnostic public-figure consistency rather than parity to unreleased source coordinates."],"name":"AAV5 serotype comparison — 5E12 Vg ICM","outputs":[{"classification":"provisional","description":"Whole-blood vector-genome concentration for route and serotype biodistribution comparison.","key":"aav_blood_Vg_mL","label":"AAV in whole blood","unit":"Vg/mL"},{"classification":"provisional","description":"Volume-weighted vector-genome concentration across modeled brain vascular, barrier, CSF, meningeal, and cellular spaces.","key":"aav_brain_Vg_mL","label":"AAV in total brain","unit":"Vg/mL"},{"classification":"provisional","description":"Circulating transgene-derived or exogenously dosed antibody.","key":"mab_plasma_nM","label":"Anti target x m ab in plasma","unit":"nM"},{"classification":"provisional","description":"Volume-weighted modeled antibody across brain vascular, ISF, BBB, BCSFB, and parenchymal endosomal spaces.","key":"mab_brain_nM","label":"Anti target x m ab in total brain","unit":"nM"},{"classification":"qualified","description":"Free cisterna-magna TargetX normalized to its pre-dose model baseline; this is the Figure 7 CSF mapping.","key":"target_csf_pct_baseline","label":"Free target x in cisterna magna csf","unit":"% baseline"}],"scenario_id":"icm_5e12_aav5","scientific_questions":["How do route, dose, and serotype shape vector biodistribution, antibody exposure, and free TargetX?"],"time_span":{"end":1344,"start":-1000,"step":24}}],"targets":[{"key":"targetx_anonymized_paper_target","label":"TargetX (anonymized paper target)"}],"therapeutics":[{"key":"aav9_aav5_encoded_anti_targetx_monoclonal_antibody","label":"AAV9/AAV5-encoded anti-TargetX monoclonal antibody"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.1.6"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model coupling panitumumab distribution to parallel linear and saturable Michaelis–Menten elimination.","diseases":[{"key":"cancer_therapy_with_egfr_targeted_panitumumab","label":"Cancer therapy with EGFR-targeted panitumumab"}],"links":{"page":"/modeling/models/lobet-2026-panitumumab-body-composition-poppk","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":null,"model_classes":["PopPK"],"model_id":"lobet_2026_panitumumab_body_composition_poppk","name":"Panitumumab nonlinear population PK","outputs":[{"description":"Central panitumumab concentration over the selected simulation window.","key":"central_conc_mg_l","label":"Central panitumumab concentration","unit":null},{"description":"Peripheral panitumumab concentration over the selected simulation window.","key":"peripheral_conc_mg_l","label":"Peripheral panitumumab concentration","unit":null},{"description":"Linear elimination over the selected simulation window.","key":"linear_elimination_mg_day","label":"Linear elimination","unit":null},{"description":"Saturable elimination over the selected simulation window.","key":"michaelis_menten_elimination_mg_day","label":"Saturable elimination","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_day","label":"Systemic clearance","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.4},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"v1_l","label":"Central distribution volume","max":3.7649999999999997,"min":1.255,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.51},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"q_l_day","label":"Intercompartmental clearance","max":0.255,"min":0.085,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.17},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"v2_l","label":"Peripheral distribution volume","max":4.365,"min":1.455,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.91},{"category":"model parameter","definition":"Maximum elimination rate coefficient used by the released system of model equations.","description":"Maximum elimination rate coefficient used by the released system of model equations.","key":"vmax_mg_day","label":"Maximum elimination rate","max":6.39,"min":2.13,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mg/day","value":4.26}],"description":"How do linear and saturable elimination jointly shape panitumumab concentration and exposure? Explore this intervention regimen through Central panitumumab concentration, Peripheral panitumumab concentration, Linear elimination, Saturable elimination, Cumulative panitumumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Typical FFCD0904 3 mg/kg every 2 weeks with AUC","outputs":[{"classification":"provisional","description":"Central panitumumab concentration over the selected simulation window.","key":"central_conc_mg_l","label":"Central panitumumab concentration","unit":null},{"classification":"provisional","description":"Peripheral panitumumab concentration over the selected simulation window.","key":"peripheral_conc_mg_l","label":"Peripheral panitumumab concentration","unit":null},{"classification":"provisional","description":"Linear elimination over the selected simulation window.","key":"linear_elimination_mg_day","label":"Linear elimination","unit":null},{"classification":"provisional","description":"Saturable elimination over the selected simulation window.","key":"michaelis_menten_elimination_mg_day","label":"Saturable elimination","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_day_l","label":"Exposure (AUC)","unit":"mg*day/L"}],"scenario_id":"ffcd0904_typical_3mgkg_q2w_ode_overlay","scientific_questions":["How do linear and saturable elimination jointly shape panitumumab concentration and exposure?"],"time_span":{"end":70,"start":0,"step":0.25}}],"targets":[{"key":"egfr","label":"EGFR / ERBB1","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1016/j.biopha.2026.119242","locator":"Primary publication introduction: panitumumab is a therapeutic monoclonal antibody directed against EGFR.","relationship":"Therapeutic target; saturable elimination is not presented as an explicit EGFR state."}}],"therapeutics":[{"key":"panitumumab","label":"Panitumumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model representing vedolizumab central and peripheral disposition, prior anti-TNF effects on clearance, concentration, and cumulative exposure.","diseases":[{"key":"inflammatory_bowel_disease","label":"Inflammatory bowel disease"}],"links":{"page":"/modeling/models/markovic-2024-vedolizumab-clearance-remission-poppk","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":null,"model_classes":["PopPK","Exposure-response"],"model_id":"markovic_2024_vedolizumab_clearance_remission_poppk","name":"Vedolizumab clearance and exposure","outputs":[{"description":"Central vedolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central vedolizumab concentration","unit":null},{"description":"Cumulative vedolizumab exposure over the selected simulation window.","key":"AUC_central_ug_day_mL","label":"Cumulative vedolizumab exposure","unit":null},{"description":"Effective clearance over the selected simulation window.","key":"CL_effective_L_day_out","label":"Effective clearance","unit":null},{"description":"AUC central over the selected simulation window.","key":"AUC_central_mg_day_L","label":"AUC central","unit":"mg*day/L"},{"description":"Central-compartment drug amount over the selected simulation window.","key":"A_central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.2385,"min":0.0795,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.159},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L","label":"Central distribution volume","max":4.785,"min":1.595,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.19},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.18,"min":0.06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.12},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L","label":"Peripheral distribution volume","max":2.4899999999999998,"min":0.83,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.66},{"category":"model parameter","definition":"Anti-TNF effect coefficient used by the released system of model equations.","description":"Anti-TNF effect coefficient used by the released system of model equations.","key":"ATNF_effect","label":"Anti-TNF effect","max":0.396,"min":0.132,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.264}],"description":"How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure? Explore this intervention regimen through Central vedolizumab concentration, Cumulative vedolizumab exposure, Effective clearance.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0-2-6w + 10w + every 4 weeks, prior anti-TNF no","outputs":[{"classification":"provisional","description":"Central vedolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central vedolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative vedolizumab exposure over the selected simulation window.","key":"AUC_central_ug_day_mL","label":"Cumulative vedolizumab exposure","unit":null},{"classification":"provisional","description":"Effective clearance over the selected simulation window.","key":"CL_effective_L_day_out","label":"Effective clearance","unit":null}],"scenario_id":"induction_10w_q4w_no_prior_anti_tnf","scientific_questions":["How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure?"],"time_span":{"end":630,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.2385,"min":0.0795,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.159},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L","label":"Central distribution volume","max":4.785,"min":1.595,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.19},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.18,"min":0.06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.12},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L","label":"Peripheral distribution volume","max":2.4899999999999998,"min":0.83,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.66},{"category":"model parameter","definition":"Anti-TNF effect coefficient used by the released system of model equations.","description":"Anti-TNF effect coefficient used by the released system of model equations.","key":"ATNF_effect","label":"Anti-TNF effect","max":0.396,"min":0.132,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.264}],"description":"How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure? Explore this intervention regimen through Central vedolizumab concentration, Cumulative vedolizumab exposure, Effective clearance.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0-2-6w + 14w + every 6 weeks, prior anti-TNF no","outputs":[{"classification":"provisional","description":"Central vedolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central vedolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative vedolizumab exposure over the selected simulation window.","key":"AUC_central_ug_day_mL","label":"Cumulative vedolizumab exposure","unit":null},{"classification":"provisional","description":"Effective clearance over the selected simulation window.","key":"CL_effective_L_day_out","label":"Effective clearance","unit":null}],"scenario_id":"induction_14w_q6w_no_prior_anti_tnf","scientific_questions":["How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure?"],"time_span":{"end":938,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.2385,"min":0.0795,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.159},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L","label":"Central distribution volume","max":4.785,"min":1.595,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.19},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.18,"min":0.06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.12},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L","label":"Peripheral distribution volume","max":2.4899999999999998,"min":0.83,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.66},{"category":"model parameter","definition":"Anti-TNF effect coefficient used by the released system of model equations.","description":"Anti-TNF effect coefficient used by the released system of model equations.","key":"ATNF_effect","label":"Anti-TNF effect","max":0.396,"min":0.132,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.264}],"description":"How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure? Explore this intervention regimen through Central vedolizumab concentration, Cumulative vedolizumab exposure, Effective clearance.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0-2-6w + every 8 weeks, prior anti-TNF no","outputs":[{"classification":"provisional","description":"Central vedolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central vedolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative vedolizumab exposure over the selected simulation window.","key":"AUC_central_ug_day_mL","label":"Cumulative vedolizumab exposure","unit":null},{"classification":"provisional","description":"Effective clearance over the selected simulation window.","key":"CL_effective_L_day_out","label":"Effective clearance","unit":null}],"scenario_id":"induction_q8w_no_prior_anti_tnf","scientific_questions":["How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure?"],"time_span":{"end":1162,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.2385,"min":0.0795,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.159},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L","label":"Central distribution volume","max":4.785,"min":1.595,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.19},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.18,"min":0.06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.12},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L","label":"Peripheral distribution volume","max":2.4899999999999998,"min":0.83,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.66},{"category":"model parameter","definition":"Anti-TNF effect coefficient used by the released system of model equations.","description":"Anti-TNF effect coefficient used by the released system of model equations.","key":"ATNF_effect","label":"Anti-TNF effect","max":0.396,"min":0.132,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.264}],"description":"How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure? Explore this intervention regimen through Central vedolizumab concentration, Cumulative vedolizumab exposure, Effective clearance.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0-2-6w + every 8 weeks, prior anti-TNF yes","outputs":[{"classification":"provisional","description":"Central vedolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central vedolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative vedolizumab exposure over the selected simulation window.","key":"AUC_central_ug_day_mL","label":"Cumulative vedolizumab exposure","unit":null},{"classification":"provisional","description":"Effective clearance over the selected simulation window.","key":"CL_effective_L_day_out","label":"Effective clearance","unit":null}],"scenario_id":"induction_q8w_prior_anti_tnf","scientific_questions":["How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure?"],"time_span":{"end":1162,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.2385,"min":0.0795,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.159},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L","label":"Central distribution volume","max":4.785,"min":1.595,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.19},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.18,"min":0.06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.12},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L","label":"Peripheral distribution volume","max":2.4899999999999998,"min":0.83,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.66},{"category":"model parameter","definition":"Anti-TNF effect coefficient used by the released system of model equations.","description":"Anti-TNF effect coefficient used by the released system of model equations.","key":"ATNF_effect","label":"Anti-TNF effect","max":0.396,"min":0.132,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.264}],"description":"How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure? Explore this intervention regimen through Central vedolizumab concentration, Cumulative vedolizumab exposure, Effective clearance.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0-2-6w + 10w + every 8 weeks, prior anti-TNF yes","outputs":[{"classification":"provisional","description":"Central vedolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central vedolizumab concentration","unit":null},{"classification":"provisional","description":"Cumulative vedolizumab exposure over the selected simulation window.","key":"AUC_central_ug_day_mL","label":"Cumulative vedolizumab exposure","unit":null},{"classification":"provisional","description":"Effective clearance over the selected simulation window.","key":"CL_effective_L_day_out","label":"Effective clearance","unit":null}],"scenario_id":"induction_10w_q8w_prior_anti_tnf","scientific_questions":["How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure?"],"time_span":{"end":1190,"start":0,"step":1}}],"targets":[{"key":"integrin_alpha4beta7","label":"Integrin α4β7","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.3390/pharmaceutics16121629","locator":"Primary publication introduction: vedolizumab is a monoclonal antibody targeting α4β7 integrin.","relationship":"Therapeutic target; the population-PK equations do not contain an explicit α4β7 state."}}],"therapeutics":[{"key":"vedolizumab","label":"Vedolizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment PK model representing eculizumab central and peripheral disposition and cumulative exposure in generalized myasthenia gravis.","diseases":[{"key":"generalized_myasthenia_gravis","label":"Generalized myasthenia gravis"}],"links":{"page":"/modeling/models/monteleone-2021-eculizumab-gmg-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PopPK","PKPD","Exposure-response"],"model_id":"monteleone_2021_eculizumab_gmg_pkpd","name":"Eculizumab exposure in generalized myasthenia gravis","outputs":[{"description":"Central eculizumab concentration over the selected simulation window.","key":"central_conc_ug_mL","label":"Central eculizumab concentration","unit":null},{"description":"Peripheral eculizumab concentration over the selected simulation window.","key":"peripheral_conc_ug_mL","label":"Peripheral eculizumab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_h_mL","label":"Exposure (AUC)","unit":"ug*hour/mL"},{"description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"description":"Elapsed time over the selected simulation window.","key":"elapsed_time_h","label":"Elapsed time","unit":"hour"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0106},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":3.81,"min":1.27,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.54},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_h","label":"Intercompartmental clearance","max":0.3765,"min":0.1255,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/h","value":0.251},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_L","label":"Peripheral distribution volume","max":4.095,"min":1.365,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.73}],"description":"How does the eculizumab regimen determine concentration and cumulative exposure over time? Explore this intervention regimen through Central eculizumab concentration, Peripheral eculizumab concentration, Cumulative eculizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"REGAIN approved 900/1200 mg IV regimen PK/PD context","outputs":[{"classification":"provisional","description":"Central eculizumab concentration over the selected simulation window.","key":"central_conc_ug_mL","label":"Central eculizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral eculizumab concentration over the selected simulation window.","key":"peripheral_conc_ug_mL","label":"Peripheral eculizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_h_mL","label":"Exposure (AUC)","unit":"ug*hour/mL"}],"scenario_id":"regain_900_1200mg_iv_pkpd_context","scientific_questions":["How does the eculizumab regimen determine concentration and cumulative exposure over time?"],"time_span":{"end":4368.583333333333,"start":0,"step":24}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_h","label":"Systemic clearance","max":0.011774999999999999,"min":0.003925,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/h","value":0.00785},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":3.81,"min":1.27,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.54},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_h","label":"Intercompartmental clearance","max":0.3765,"min":0.1255,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/h","value":0.251},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_L","label":"Peripheral distribution volume","max":4.095,"min":1.365,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.73}],"description":"How does the eculizumab regimen determine concentration and cumulative exposure over time? Explore this intervention regimen through Central eculizumab concentration, Peripheral eculizumab concentration, Cumulative eculizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"median-clearance PK/PD context","outputs":[{"classification":"provisional","description":"Central eculizumab concentration over the selected simulation window.","key":"central_conc_ug_mL","label":"Central eculizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral eculizumab concentration over the selected simulation window.","key":"peripheral_conc_ug_mL","label":"Peripheral eculizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_h_mL","label":"Exposure (AUC)","unit":"ug*hour/mL"}],"scenario_id":"exploratory_calibrated_fig1_median_clearance_pkpd_context","scientific_questions":["How does the eculizumab regimen determine concentration and cumulative exposure over time?"],"time_span":{"end":4368.583333333333,"start":0,"step":24}}],"targets":[{"key":"c5","label":"Complement C5"}],"therapeutics":[{"key":"eculizumab","label":"Eculizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced PK/PD model linking ravulizumab exposure to concentration-dependent suppression and recovery of free complement C5.","diseases":[{"key":"neuromyelitis_optica_spectrum_disorder","label":"Neuromyelitis optica spectrum disorder"}],"links":{"page":"/modeling/models/ortiz-2024-ravulizumab-nmosd-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PKPD"],"model_id":"ortiz_2024_ravulizumab_nmosd_pkpd","name":"Ravulizumab exposure and free C5 suppression","outputs":[{"description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"description":"Free complement C5 over the selected simulation window.","key":"free_c5_ug_ml","label":"Free complement C5","unit":"ug/mL"},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"description":"Ada baseline positive count over the selected simulation window.","key":"out__ada_baseline_positive_count","label":"Ada baseline positive count","unit":null},{"description":"Ada baseline positive pct over the selected simulation window.","key":"out__ada_baseline_positive_pct","label":"Ada baseline positive pct","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Apparent distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Apparent distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"apparent_volume_l","label":"Apparent distribution volume","max":3.7062304061593005,"min":1.2354101353864335,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.470820270772867},{"category":"model parameter","definition":"Elimination rate constant governing first-order loss from the modeled system.","description":"Elimination rate constant governing first-order loss from the modeled system.","key":"kel_per_day","label":"Elimination rate constant","max":0.0236319152730413,"min":0.007877305091013767,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.015754610182027534},{"category":"model parameter","definition":"C5 suppression rate coefficient used by the released system of model equations.","description":"C5 suppression rate coefficient used by the released system of model equations.","key":"k_c5_suppression_per_day","label":"C5 suppression rate","max":13.0077,"min":4.3359,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"1/day","value":8.6718}],"description":"How do weight-based ravulizumab regimens maintain exposure and suppression of free C5? Explore this intervention regimen through Central ravulizumab amount, Free complement C5, Cumulative ravulizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Body weight 40 to <60 kg week-50 PK/free-C5","outputs":[{"classification":"provisional","description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"classification":"provisional","description":"Free complement C5 over the selected simulation window.","key":"free_c5_ug_ml","label":"Free complement C5","unit":"ug/mL"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"}],"scenario_id":"week50_40_60_pk_free_c5_ode","scientific_questions":["How do weight-based ravulizumab regimens maintain exposure and suppression of free C5?"],"time_span":{"end":352,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Apparent distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Apparent distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"apparent_volume_l","label":"Apparent distribution volume","max":4.313398177711291,"min":1.4377993925704304,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.875598785140861},{"category":"model parameter","definition":"Elimination rate constant governing first-order loss from the modeled system.","description":"Elimination rate constant governing first-order loss from the modeled system.","key":"kel_per_day","label":"Elimination rate constant","max":0.02505504963567834,"min":0.00835168321189278,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.01670336642378556},{"category":"model parameter","definition":"C5 suppression rate coefficient used by the released system of model equations.","description":"C5 suppression rate coefficient used by the released system of model equations.","key":"k_c5_suppression_per_day","label":"C5 suppression rate","max":13.0077,"min":4.3359,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"1/day","value":8.6718}],"description":"How do weight-based ravulizumab regimens maintain exposure and suppression of free C5? Explore this intervention regimen through Central ravulizumab amount, Free complement C5, Cumulative ravulizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Body weight 60 to <100 kg week-50 PK/free-C5","outputs":[{"classification":"provisional","description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"classification":"provisional","description":"Free complement C5 over the selected simulation window.","key":"free_c5_ug_ml","label":"Free complement C5","unit":"ug/mL"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"}],"scenario_id":"week50_60_100_pk_free_c5_ode","scientific_questions":["How do weight-based ravulizumab regimens maintain exposure and suppression of free C5?"],"time_span":{"end":352,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Apparent distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Apparent distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"apparent_volume_l","label":"Apparent distribution volume","max":5.785635121229319,"min":1.928545040409773,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.857090080819546},{"category":"model parameter","definition":"Elimination rate constant governing first-order loss from the modeled system.","description":"Elimination rate constant governing first-order loss from the modeled system.","key":"kel_per_day","label":"Elimination rate constant","max":0.028306130557426538,"min":0.009435376852475513,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.018870753704951025},{"category":"model parameter","definition":"C5 suppression rate coefficient used by the released system of model equations.","description":"C5 suppression rate coefficient used by the released system of model equations.","key":"k_c5_suppression_per_day","label":"C5 suppression rate","max":13.0077,"min":4.3359,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"1/day","value":8.6718}],"description":"How do weight-based ravulizumab regimens maintain exposure and suppression of free C5? Explore this intervention regimen through Central ravulizumab amount, Free complement C5, Cumulative ravulizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Body weight >=100 kg week-50 PK/free-C5","outputs":[{"classification":"provisional","description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"},{"classification":"provisional","description":"Free complement C5 over the selected simulation window.","key":"free_c5_ug_ml","label":"Free complement C5","unit":"ug/mL"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"}],"scenario_id":"week50_ge100_pk_free_c5_ode","scientific_questions":["How do weight-based ravulizumab regimens maintain exposure and suppression of free C5?"],"time_span":{"end":352,"start":0,"step":1}}],"targets":[{"key":"c5","label":"Complement C5"}],"therapeutics":[{"key":"ravulizumab","label":"Ravulizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced pediatric PBPK model connecting body-size-dependent antibody disposition to central and peripheral exposure and optional target binding.","diseases":[{"key":"pediatric_therapeutic_protein_dose_and_exposure_scaling","label":"Pediatric therapeutic-protein dose and exposure scaling"}],"links":{"page":"/modeling/models/pan-2020-pediatric-tp-pbpk-pk-sim","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PBPK"],"model_id":"pan_2020_pediatric_tp_pbpk_pk_sim","name":"Pediatric therapeutic-protein PBPK scaling","outputs":[{"description":"Central antibody concentration over the selected simulation window.","key":"central_concentration_ug_ml","label":"Central antibody concentration","unit":null},{"description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_concentration_ug_ml","label":"Peripheral antibody concentration","unit":null},{"description":"Free target concentration over the selected simulation window.","key":"target_free_uM","label":"Free target concentration","unit":"uM"},{"description":"Drug–target complex concentration over the selected simulation window.","key":"complex_uM","label":"Drug–target complex concentration","unit":"uM"},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_ml_day","label":"Exposure (AUC)","unit":"ug/mL*day"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":10.5,"min":3.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"kg","value":7},{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_mL_day_70kg","label":"Systemic clearance","max":297,"min":99,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"mL/day","value":198},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L_70kg","label":"Central distribution volume","max":6.135,"min":2.045,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":4.09},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_mL_day_70kg","label":"Intercompartmental clearance","max":1318.5,"min":439.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"mL/day","value":879},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L_70kg","label":"Peripheral distribution volume","max":3.3449999999999998,"min":1.115,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.23}],"description":"How does pediatric growth change therapeutic-protein disposition, exposure, and target binding? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Free target, Drug–target complex, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Palivizumab 15 mg/kg nominal-age growth","outputs":[{"classification":"provisional","description":"Central antibody concentration over the selected simulation window.","key":"central_concentration_ug_ml","label":"Central antibody concentration","unit":null},{"classification":"provisional","description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_concentration_ug_ml","label":"Peripheral antibody concentration","unit":null},{"classification":"provisional","description":"Free target concentration over the selected simulation window.","key":"target_free_uM","label":"Free target concentration","unit":"uM"},{"classification":"provisional","description":"Drug–target complex concentration over the selected simulation window.","key":"complex_uM","label":"Drug–target complex concentration","unit":"uM"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_ml_day","label":"Exposure (AUC)","unit":"ug/mL*day"}],"scenario_id":"palivizumab_15mgkg_nominal_growth_table3_smoke","scientific_questions":["How does pediatric growth change therapeutic-protein disposition, exposure, and target binding?"],"time_span":{"end":120,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":67.5,"min":22.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":45},{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_mL_day_70kg","label":"Systemic clearance","max":356.4,"min":118.8,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"mL/day","value":237.6},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L_70kg","label":"Central distribution volume","max":4.275,"min":1.425,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.85},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_mL_day_70kg","label":"Intercompartmental clearance","max":1008,"min":336,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"mL/day","value":672},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L_70kg","label":"Peripheral distribution volume","max":3.846,"min":1.282,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.564}],"description":"How does pediatric growth change therapeutic-protein disposition, exposure, and target binding? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Free target, Drug–target complex, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Bevacizumab 15 mg/kg 13-year growth","outputs":[{"classification":"provisional","description":"Central antibody concentration over the selected simulation window.","key":"central_concentration_ug_ml","label":"Central antibody concentration","unit":null},{"classification":"provisional","description":"Peripheral antibody concentration over the selected simulation window.","key":"peripheral_concentration_ug_ml","label":"Peripheral antibody concentration","unit":null},{"classification":"provisional","description":"Free target concentration over the selected simulation window.","key":"target_free_uM","label":"Free target concentration","unit":"uM"},{"classification":"provisional","description":"Drug–target complex concentration over the selected simulation window.","key":"complex_uM","label":"Drug–target complex concentration","unit":"uM"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_ml_day","label":"Exposure (AUC)","unit":"ug/mL*day"}],"scenario_id":"bevacizumab_15mgkg_13y_growth_table4_smoke","scientific_questions":["How does pediatric growth change therapeutic-protein disposition, exposure, and target binding?"],"time_span":{"end":120,"start":0,"step":1}}],"targets":[{"key":"rsv_f_protein","label":"RSV F protein"},{"key":"vegfa","label":"VEGFA"},{"key":"fcrn","label":"FcRn"}],"therapeutics":[{"key":"palivizumab_or_bevacizumab","label":"Palivizumab or bevacizumab"},{"key":"palivizumab_bevacizumab","label":"palivizumab; bevacizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A population QSS-TMDD model coupling bevacizumab disposition to VEGF165 turnover, free antibody, target-bound complex, and total circulating VEGF165.","diseases":[{"key":"metastatic_colorectal_cancer","label":"Metastatic colorectal cancer"}],"links":{"page":"/modeling/models/panoilia-2015-bevacizumab-vegf165-qss-tmdd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PopPK","TMDD"],"model_id":"panoilia_2015_bevacizumab_vegf165_qss_tmdd","name":"Bevacizumab PK and VEGF165 target binding","outputs":[{"description":"Total bevacizumab over the selected simulation window.","key":"total_bevacizumab_mg_L","label":"Total bevacizumab","unit":null},{"description":"Free bevacizumab over the selected simulation window.","key":"free_bevacizumab_mg_L","label":"Free bevacizumab","unit":null},{"description":"Bevacizumab VEGF165 complex over the selected simulation window.","key":"complex_nM","label":"Bevacizumab VEGF165 complex","unit":null},{"description":"Total VEGF165 over the selected simulation window.","key":"total_vegf165_nM","label":"Total VEGF165","unit":null},{"description":"Cumulative total exposure over the selected simulation window.","key":"AUC_total_mg_day_L","label":"Cumulative total exposure","unit":"mg*day/L"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.27,"min":0.09,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.18},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":4.845,"min":1.615,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.23},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":2.07,"min":0.69,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/day","value":1.38},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"Kss_nM","label":"Quasi-steady-state binding constant","max":400.5,"min":133.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":267},{"category":"model parameter","definition":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","description":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","key":"kout_1_day","label":"Turnover loss rate","max":0.6015,"min":0.2005,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.401}],"description":"How do bevacizumab exposure and VEGF165 turnover determine free drug, target, and complex concentrations? Explore this intervention regimen through Total bevacizumab, Free bevacizumab, Bevacizumab–VEGF165 complex, Total VEGF165, Cumulative total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"5 mg/kg every 2 weeks 70 kg deterministic simulation","outputs":[{"classification":"provisional","description":"Total bevacizumab over the selected simulation window.","key":"total_bevacizumab_mg_L","label":"Total bevacizumab","unit":null},{"classification":"provisional","description":"Free bevacizumab over the selected simulation window.","key":"free_bevacizumab_mg_L","label":"Free bevacizumab","unit":null},{"classification":"provisional","description":"Bevacizumab VEGF165 complex over the selected simulation window.","key":"complex_nM","label":"Bevacizumab VEGF165 complex","unit":null},{"classification":"provisional","description":"Total VEGF165 over the selected simulation window.","key":"total_vegf165_nM","label":"Total VEGF165","unit":null},{"classification":"provisional","description":"Cumulative total exposure over the selected simulation window.","key":"AUC_total_mg_day_L","label":"Cumulative total exposure","unit":"mg*day/L"}],"scenario_id":"fig3_5mgkg_q2w_70kg_dynamic","scientific_questions":["How do bevacizumab exposure and VEGF165 turnover determine free drug, target, and complex concentrations?"],"time_span":{"end":126,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.27,"min":0.09,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.18},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_L","label":"Central distribution volume","max":4.845,"min":1.615,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.23},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":2.07,"min":0.69,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/day","value":1.38},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"Kss_nM","label":"Quasi-steady-state binding constant","max":400.5,"min":133.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"nM","value":267},{"category":"model parameter","definition":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","description":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","key":"kout_1_day","label":"Turnover loss rate","max":0.6015,"min":0.2005,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.401}],"description":"How do bevacizumab exposure and VEGF165 turnover determine free drug, target, and complex concentrations? Explore this intervention regimen through Total bevacizumab, Free bevacizumab, Bevacizumab–VEGF165 complex, Total VEGF165, Cumulative total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"7.5 mg/kg every 3 weeks 70 kg deterministic simulation","outputs":[{"classification":"provisional","description":"Total bevacizumab over the selected simulation window.","key":"total_bevacizumab_mg_L","label":"Total bevacizumab","unit":null},{"classification":"provisional","description":"Free bevacizumab over the selected simulation window.","key":"free_bevacizumab_mg_L","label":"Free bevacizumab","unit":null},{"classification":"provisional","description":"Bevacizumab VEGF165 complex over the selected simulation window.","key":"complex_nM","label":"Bevacizumab VEGF165 complex","unit":null},{"classification":"provisional","description":"Total VEGF165 over the selected simulation window.","key":"total_vegf165_nM","label":"Total VEGF165","unit":null},{"classification":"provisional","description":"Cumulative total exposure over the selected simulation window.","key":"AUC_total_mg_day_L","label":"Cumulative total exposure","unit":"mg*day/L"}],"scenario_id":"fig3_7p5mgkg_q3w_70kg_dynamic","scientific_questions":["How do bevacizumab exposure and VEGF165 turnover determine free drug, target, and complex concentrations?"],"time_span":{"end":126,"start":0,"step":1}}],"targets":[{"key":"vegfa","label":"VEGFA"},{"key":"vegf165","label":"VEGF165"},{"key":"vascular_endothelial_growth_factor_a","label":"vascular endothelial growth factor A"}],"therapeutics":[{"key":"bevacizumab","label":"Bevacizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A coupled subcutaneous or intravenous PK/PD model linking mepolizumab absorption and distribution to concentration-dependent suppression and turnover of circulating eosinophils.","diseases":[{"key":"eosinophilic_asthma","label":"Eosinophilic asthma"}],"links":{"page":"/modeling/models/pouliquen-2015-mepolizumab-eosinophil-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PKPD"],"model_id":"pouliquen_2015_mepolizumab_eosinophil_pkpd","name":"Mepolizumab exposure and blood eosinophils","outputs":[{"description":"Mepolizumab concentration over the selected simulation window.","key":"central_concentration_ng_mL","label":"Mepolizumab concentration","unit":null},{"description":"Blood eosinophil concentration over the selected simulation window.","key":"blood_eosinophils_GI_L","label":"Blood eosinophil concentration","unit":"Gcell/L"},{"description":"Eosinophil inhibition over the selected simulation window.","key":"eosinophil_inhibition_fraction","label":"Eosinophil inhibition","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"description":"Central-compartment drug amount over the selected simulation window.","key":"A_central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Clearance intravenous governing removal of modeled material from the relevant compartment.","description":"Clearance intravenous governing removal of modeled material from the relevant compartment.","key":"CL_iv_L_day","label":"Clearance intravenous","max":0.315,"min":0.105,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.21},{"category":"model parameter","definition":"Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_iv_L","label":"Central distribution volume intravenous","max":5.4,"min":1.8,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.6},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"KA_1_day","label":"Absorption rate constant","max":0.29100000000000004,"min":0.097,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.194},{"category":"model parameter","definition":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","description":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","key":"IC50_ng_mL","label":"Half-maximal inhibitory concentration","max":1891.5,"min":630.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":10,"unit":"ng/mL","value":1261},{"category":"model parameter","definition":"Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"IMAX_fraction","label":"Imax fraction","max":1.3920000000000001,"min":0.464,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.928}],"description":"How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression? Explore this intervention regimen through Mepolizumab concentration, Blood eosinophils, Eosinophil inhibition, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"12.5 mg SC every 4 weeks, three doses","outputs":[{"classification":"provisional","description":"Mepolizumab concentration over the selected simulation window.","key":"central_concentration_ng_mL","label":"Mepolizumab concentration","unit":null},{"classification":"provisional","description":"Blood eosinophil concentration over the selected simulation window.","key":"blood_eosinophils_GI_L","label":"Blood eosinophil concentration","unit":"Gcell/L"},{"classification":"provisional","description":"Eosinophil inhibition over the selected simulation window.","key":"eosinophil_inhibition_fraction","label":"Eosinophil inhibition","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"}],"scenario_id":"sc_12_5mg_q4w_three_doses","scientific_questions":["How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?"],"time_span":{"end":140,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Clearance intravenous governing removal of modeled material from the relevant compartment.","description":"Clearance intravenous governing removal of modeled material from the relevant compartment.","key":"CL_iv_L_day","label":"Clearance intravenous","max":0.315,"min":0.105,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.21},{"category":"model parameter","definition":"Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_iv_L","label":"Central distribution volume intravenous","max":5.4,"min":1.8,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.6},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"KA_1_day","label":"Absorption rate constant","max":0.29100000000000004,"min":0.097,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.194},{"category":"model parameter","definition":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","description":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","key":"IC50_ng_mL","label":"Half-maximal inhibitory concentration","max":1891.5,"min":630.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":10,"unit":"ng/mL","value":1261},{"category":"model parameter","definition":"Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"IMAX_fraction","label":"Imax fraction","max":1.3920000000000001,"min":0.464,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.928}],"description":"How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression? Explore this intervention regimen through Mepolizumab concentration, Blood eosinophils, Eosinophil inhibition, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"125 mg SC every 4 weeks, three doses","outputs":[{"classification":"provisional","description":"Mepolizumab concentration over the selected simulation window.","key":"central_concentration_ng_mL","label":"Mepolizumab concentration","unit":null},{"classification":"provisional","description":"Blood eosinophil concentration over the selected simulation window.","key":"blood_eosinophils_GI_L","label":"Blood eosinophil concentration","unit":"Gcell/L"},{"classification":"provisional","description":"Eosinophil inhibition over the selected simulation window.","key":"eosinophil_inhibition_fraction","label":"Eosinophil inhibition","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"}],"scenario_id":"sc_125mg_q4w_three_doses","scientific_questions":["How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?"],"time_span":{"end":140,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Clearance intravenous governing removal of modeled material from the relevant compartment.","description":"Clearance intravenous governing removal of modeled material from the relevant compartment.","key":"CL_iv_L_day","label":"Clearance intravenous","max":0.315,"min":0.105,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.21},{"category":"model parameter","definition":"Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_iv_L","label":"Central distribution volume intravenous","max":5.4,"min":1.8,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.6},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"KA_1_day","label":"Absorption rate constant","max":0.29100000000000004,"min":0.097,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.194},{"category":"model parameter","definition":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","description":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","key":"IC50_ng_mL","label":"Half-maximal inhibitory concentration","max":1891.5,"min":630.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":10,"unit":"ng/mL","value":1261},{"category":"model parameter","definition":"Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"IMAX_fraction","label":"Imax fraction","max":1.3920000000000001,"min":0.464,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.928}],"description":"How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression? Explore this intervention regimen through Mepolizumab concentration, Blood eosinophils, Eosinophil inhibition, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"250 mg SC every 4 weeks, three doses","outputs":[{"classification":"provisional","description":"Mepolizumab concentration over the selected simulation window.","key":"central_concentration_ng_mL","label":"Mepolizumab concentration","unit":null},{"classification":"provisional","description":"Blood eosinophil concentration over the selected simulation window.","key":"blood_eosinophils_GI_L","label":"Blood eosinophil concentration","unit":"Gcell/L"},{"classification":"provisional","description":"Eosinophil inhibition over the selected simulation window.","key":"eosinophil_inhibition_fraction","label":"Eosinophil inhibition","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"}],"scenario_id":"sc_250mg_q4w_three_doses","scientific_questions":["How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?"],"time_span":{"end":140,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Clearance intravenous governing removal of modeled material from the relevant compartment.","description":"Clearance intravenous governing removal of modeled material from the relevant compartment.","key":"CL_iv_L_day","label":"Clearance intravenous","max":0.315,"min":0.105,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.21},{"category":"model parameter","definition":"Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_iv_L","label":"Central distribution volume intravenous","max":5.4,"min":1.8,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.6},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"KA_1_day","label":"Absorption rate constant","max":0.29100000000000004,"min":0.097,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.194},{"category":"model parameter","definition":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","description":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","key":"IC50_ng_mL","label":"Half-maximal inhibitory concentration","max":1891.5,"min":630.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":10,"unit":"ng/mL","value":1261},{"category":"model parameter","definition":"Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"IMAX_fraction","label":"Imax fraction","max":1.3920000000000001,"min":0.464,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"dimensionless","value":0.928}],"description":"How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression? Explore this intervention regimen through Mepolizumab concentration, Blood eosinophils, Eosinophil inhibition, Cumulative exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"75 mg IV every 4 weeks, three doses","outputs":[{"classification":"provisional","description":"Mepolizumab concentration over the selected simulation window.","key":"central_concentration_ng_mL","label":"Mepolizumab concentration","unit":null},{"classification":"provisional","description":"Blood eosinophil concentration over the selected simulation window.","key":"blood_eosinophils_GI_L","label":"Blood eosinophil concentration","unit":"Gcell/L"},{"classification":"provisional","description":"Eosinophil inhibition over the selected simulation window.","key":"eosinophil_inhibition_fraction","label":"Eosinophil inhibition","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"}],"scenario_id":"iv_75mg_q4w_three_doses","scientific_questions":["How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?"],"time_span":{"end":140,"start":0,"step":1}}],"targets":[{"key":"il5","label":"IL5"},{"key":"il_5","label":"IL-5"}],"therapeutics":[{"key":"mepolizumab","label":"Mepolizumab"},{"key":"nucala","label":"Nucala"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A PK/PD exposure-response model linking intravenous dazukibart disposition and IFN-beta binding to delayed changes in cutaneous, muscle, functional, and global disease assessments.","diseases":[{"key":"dermatomyositis","label":"Dermatomyositis"}],"links":{"page":"/modeling/models/prybylski-2026-dazukibart-ifnb-dm-er","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":null,"model_classes":["PKPD","Exposure-response"],"model_id":"prybylski_2026_dazukibart_ifnb_dm_er","name":"Dazukibart IFN-beta and dermatomyositis response","outputs":[{"description":"Dazukibart concentration over the selected simulation window.","key":"out__central_conc_ug_ml","label":"Dazukibart concentration","unit":null},{"description":"Free ifn beta over the selected simulation window.","key":"out__ifn_free_pg_ml","label":"Free ifn beta","unit":null},{"description":"Cdasi activity response over the selected simulation window.","key":"end_cdasi_a","label":"Cdasi activity response","unit":"dimensionless"},{"description":"Mmt 8 response over the selected simulation window.","key":"end_mmt8","label":"Mmt 8 response","unit":"dimensionless"},{"description":"Physician global response over the selected simulation window.","key":"end_phga","label":"Physician global response","unit":"dimensionless"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_week","label":"Systemic clearance","max":1.6959600000000001,"min":0.56532,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/week","value":1.13064},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.574999999999999,"min":1.525,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.05},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_week","label":"Absorption rate constant","max":2.6712000000000002,"min":0.8904000000000001,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"1/week","value":1.7808000000000002},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"kss_pm","label":"Quasi-steady-state binding constant","max":120.30000000000001,"min":40.1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pM","value":80.2},{"category":"model parameter","definition":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","description":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","key":"kout_week","label":"Turnover loss rate","max":0.3675,"min":0.1225,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/week","value":0.245}],"description":"How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures? Explore this intervention regimen through Dazukibart concentration, Free IFN-beta, CDASI activity response, MMT-8 response, Physician global response.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Stage 1 600 mg IV every 4 weeks x3","outputs":[{"classification":"provisional","description":"Dazukibart concentration over the selected simulation window.","key":"out__central_conc_ug_ml","label":"Dazukibart concentration","unit":null},{"classification":"provisional","description":"Free ifn beta over the selected simulation window.","key":"out__ifn_free_pg_ml","label":"Free ifn beta","unit":null},{"classification":"provisional","description":"Cdasi activity response over the selected simulation window.","key":"end_cdasi_a","label":"Cdasi activity response","unit":"dimensionless"},{"classification":"provisional","description":"Mmt 8 response over the selected simulation window.","key":"end_mmt8","label":"Mmt 8 response","unit":"dimensionless"},{"classification":"provisional","description":"Physician global response over the selected simulation window.","key":"end_phga","label":"Physician global response","unit":"dimensionless"}],"scenario_id":"stage1_600mg_q4w_cdasi_tis","scientific_questions":["How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures?"],"time_span":{"end":12,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_week","label":"Systemic clearance","max":1.6959600000000001,"min":0.56532,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/week","value":1.13064},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.574999999999999,"min":1.525,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.05},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_week","label":"Absorption rate constant","max":2.6712000000000002,"min":0.8904000000000001,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"1/week","value":1.7808000000000002},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"kss_pm","label":"Quasi-steady-state binding constant","max":120.30000000000001,"min":40.1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pM","value":80.2},{"category":"model parameter","definition":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","description":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","key":"kout_week","label":"Turnover loss rate","max":0.3675,"min":0.1225,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/week","value":0.245}],"description":"How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures? Explore this intervention regimen through Dazukibart concentration, Free IFN-beta, CDASI activity response, MMT-8 response, Physician global response.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Stage 2 150 mg IV every 4 weeks x3","outputs":[{"classification":"provisional","description":"Dazukibart concentration over the selected simulation window.","key":"out__central_conc_ug_ml","label":"Dazukibart concentration","unit":null},{"classification":"provisional","description":"Free ifn beta over the selected simulation window.","key":"out__ifn_free_pg_ml","label":"Free ifn beta","unit":null},{"classification":"provisional","description":"Cdasi activity response over the selected simulation window.","key":"end_cdasi_a","label":"Cdasi activity response","unit":"dimensionless"},{"classification":"provisional","description":"Mmt 8 response over the selected simulation window.","key":"end_mmt8","label":"Mmt 8 response","unit":"dimensionless"},{"classification":"provisional","description":"Physician global response over the selected simulation window.","key":"end_phga","label":"Physician global response","unit":"dimensionless"}],"scenario_id":"stage2_150mg_q4w_cdasi","scientific_questions":["How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures?"],"time_span":{"end":12,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_l_week","label":"Systemic clearance","max":1.6959600000000001,"min":0.56532,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/week","value":1.13064},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"vc_l","label":"Central distribution volume","max":4.574999999999999,"min":1.525,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.05},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_week","label":"Absorption rate constant","max":2.6712000000000002,"min":0.8904000000000001,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"1/week","value":1.7808000000000002},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"kss_pm","label":"Quasi-steady-state binding constant","max":120.30000000000001,"min":40.1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"pM","value":80.2},{"category":"model parameter","definition":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","description":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","key":"kout_week","label":"Turnover loss rate","max":0.3675,"min":0.1225,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/week","value":0.245}],"description":"How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures? Explore this biological starting configuration through Dazukibart concentration, Free IFN-beta, CDASI activity response, MMT-8 response, Physician global response.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Placebo week-12 endpoint turnover","outputs":[{"classification":"provisional","description":"Dazukibart concentration over the selected simulation window.","key":"out__central_conc_ug_ml","label":"Dazukibart concentration","unit":null},{"classification":"provisional","description":"Free ifn beta over the selected simulation window.","key":"out__ifn_free_pg_ml","label":"Free ifn beta","unit":null},{"classification":"provisional","description":"Cdasi activity response over the selected simulation window.","key":"end_cdasi_a","label":"Cdasi activity response","unit":"dimensionless"},{"classification":"provisional","description":"Mmt 8 response over the selected simulation window.","key":"end_mmt8","label":"Mmt 8 response","unit":"dimensionless"},{"classification":"provisional","description":"Physician global response over the selected simulation window.","key":"end_phga","label":"Physician global response","unit":"dimensionless"}],"scenario_id":"placebo_week12_endpoint_turnover","scientific_questions":["How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures?"],"time_span":{"end":12,"start":0,"step":0.25}}],"targets":[{"key":"ifnb1","label":"IFNB1"},{"key":"interferon_beta","label":"interferon-beta"}],"therapeutics":[{"key":"dazukibart","label":"Dazukibart"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model connecting pertuzumab dosing and lean-body-weight and albumin covariates to concentration and cumulative exposure during neoadjuvant therapy.","diseases":[{"key":"her2_positive_early_breast_cancer","label":"HER2-positive early breast cancer"}],"links":{"page":"/modeling/models/quartino-2017-pertuzumab-neoadjuvant-pk-er","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PopPK","Exposure-response"],"model_id":"quartino_2017_pertuzumab_neoadjuvant_pk_er","name":"Pertuzumab neoadjuvant population PK","outputs":[{"description":"Pertuzumab concentration over the selected simulation window.","key":"pertuzumab_concentration_ug_mL","label":"Pertuzumab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"description":"Covariate adjusted clearance over the selected simulation window.","key":"CL_cov_L_day","label":"Covariate adjusted clearance","unit":null},{"description":"Covariate adjusted central volume over the selected simulation window.","key":"Vc_cov_L","label":"Covariate adjusted central volume","unit":null},{"description":"Central-compartment drug amount over the selected simulation window.","key":"A_central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.3525,"min":0.1175,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.235},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L","label":"Central distribution volume","max":4.665,"min":1.555,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.11},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.801,"min":0.267,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.534},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L","label":"Peripheral distribution volume","max":3.69,"min":1.23,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.46},{"category":"model parameter","definition":"Lean body weight used for body-size scaling in the model.","description":"Lean body weight used for body-size scaling in the model.","key":"lean_body_weight_kg","label":"Lean body weight","max":66.9,"min":22.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":44.6}],"description":"How do regimen, lean body weight, and albumin change pertuzumab concentration and exposure? Explore this intervention regimen through Pertuzumab concentration, Cumulative pertuzumab exposure, Covariate-adjusted clearance, Covariate-adjusted central volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Typical NeoSphere 840/420 mg every 3 weeks four-cycle PK shell","outputs":[{"classification":"provisional","description":"Pertuzumab concentration over the selected simulation window.","key":"pertuzumab_concentration_ug_mL","label":"Pertuzumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Covariate adjusted clearance over the selected simulation window.","key":"CL_cov_L_day","label":"Covariate adjusted clearance","unit":null},{"classification":"provisional","description":"Covariate adjusted central volume over the selected simulation window.","key":"Vc_cov_L","label":"Covariate adjusted central volume","unit":null}],"scenario_id":"typical_neosphere_840_420_q3w_4cycles","scientific_questions":["How do regimen, lean body weight, and albumin change pertuzumab concentration and exposure?"],"time_span":{"end":84,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.3525,"min":0.1175,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.235},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_L","label":"Central distribution volume","max":4.665,"min":1.555,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.11},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.801,"min":0.267,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.534},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vp_L","label":"Peripheral distribution volume","max":3.69,"min":1.23,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.46},{"category":"model parameter","definition":"Lean body weight used for body-size scaling in the model.","description":"Lean body weight used for body-size scaling in the model.","key":"lean_body_weight_kg","label":"Lean body weight","max":73.80000000000001,"min":24.6,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":49.2}],"description":"How do regimen, lean body weight, and albumin change pertuzumab concentration and exposure? Explore this intervention regimen through Pertuzumab concentration, Cumulative pertuzumab exposure, Covariate-adjusted clearance, Covariate-adjusted central volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Historical reference covariates 840/420 mg every 3 weeks","outputs":[{"classification":"provisional","description":"Pertuzumab concentration over the selected simulation window.","key":"pertuzumab_concentration_ug_mL","label":"Pertuzumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Covariate adjusted clearance over the selected simulation window.","key":"CL_cov_L_day","label":"Covariate adjusted clearance","unit":null},{"classification":"provisional","description":"Covariate adjusted central volume over the selected simulation window.","key":"Vc_cov_L","label":"Covariate adjusted central volume","unit":null}],"scenario_id":"historical_reference_840_420_q3w_4cycles","scientific_questions":["How do regimen, lean body weight, and albumin change pertuzumab concentration and exposure?"],"time_span":{"end":84,"start":0,"step":1}}],"targets":[{"key":"her2","label":"HER2 / ERBB2"}],"therapeutics":[{"key":"pertuzumab","label":"Pertuzumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A subcutaneous PK/PD model linking secukinumab absorption and distribution to IL-17A pathway inhibition, delayed PASI response, and tolerance dynamics.","diseases":[{"key":"moderate_to_severe_plaque_psoriasis","label":"Moderate-to-severe plaque psoriasis"}],"links":{"page":"/modeling/models/rodriguez-fernandez-2024-secukinumab-psoriasis-mipd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PopPK","PKPD","MIPD/TDM"],"model_id":"rodriguez_fernandez_2024_secukinumab_psoriasis_mipd","name":"Secukinumab exposure and PASI dynamics","outputs":[{"description":"Central secukinumab concentration over the selected simulation window.","key":"central_concentration_mg_l","label":"Central secukinumab concentration","unit":null},{"description":"PASI score over the selected simulation window.","key":"pasi","label":"PASI score","unit":"dimensionless"},{"description":"Il 17 a pathway drug effect over the selected simulation window.","key":"drug_effect_fraction","label":"Il 17 a pathway drug effect","unit":null},{"description":"Tolerance drive over the selected simulation window.","key":"tolerance_drive","label":"Tolerance drive","unit":null},{"description":"Cumulative concentration exposure over the selected simulation window.","key":"AUC_conc_day","label":"Cumulative concentration exposure","unit":"mg*day/L"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.22499999999999998,"min":0.075,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.15},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_L","label":"Peripheral distribution volume","max":5.58,"min":1.86,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.72},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.30000000000000004,"min":0.1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.2},{"category":"model parameter","definition":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","description":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","key":"ic50_mg_l","label":"Half-maximal inhibitory concentration","max":14.024999999999999,"min":4.675,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mg/L","value":9.35},{"category":"model parameter","definition":"Maximum inhibitory effect defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Maximum inhibitory effect defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"imax","label":"Maximum inhibitory effect","max":1.755,"min":0.585,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"dimensionless","value":1.17}],"description":"How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance? Explore this intervention regimen through Central secukinumab concentration, PASI score, IL-17A pathway drug effect, Tolerance drive, Cumulative concentration exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Subject 1 300 mg every 4 weeks 20-cycle","outputs":[{"classification":"provisional","description":"Central secukinumab concentration over the selected simulation window.","key":"central_concentration_mg_l","label":"Central secukinumab concentration","unit":null},{"classification":"provisional","description":"PASI score over the selected simulation window.","key":"pasi","label":"PASI score","unit":"dimensionless"},{"classification":"provisional","description":"Il 17 a pathway drug effect over the selected simulation window.","key":"drug_effect_fraction","label":"Il 17 a pathway drug effect","unit":null},{"classification":"provisional","description":"Tolerance drive over the selected simulation window.","key":"tolerance_drive","label":"Tolerance drive","unit":null},{"classification":"provisional","description":"Cumulative concentration exposure over the selected simulation window.","key":"AUC_conc_day","label":"Cumulative concentration exposure","unit":"mg*day/L"}],"scenario_id":"subject1_300mg_q4w_20cycle_ode_probe","scientific_questions":["How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance?"],"time_span":{"end":616,"start":0,"step":7}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.39,"min":0.13,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.26},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_L","label":"Peripheral distribution volume","max":6.8999999999999995,"min":2.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":4.6},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.27,"min":0.09,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.18},{"category":"model parameter","definition":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","description":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","key":"ic50_mg_l","label":"Half-maximal inhibitory concentration","max":14.024999999999999,"min":4.675,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mg/L","value":9.35},{"category":"model parameter","definition":"Maximum inhibitory effect defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Maximum inhibitory effect defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"imax","label":"Maximum inhibitory effect","max":1.755,"min":0.585,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"dimensionless","value":1.17}],"description":"How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance? Explore this intervention regimen through Central secukinumab concentration, PASI score, IL-17A pathway drug effect, Tolerance drive, Cumulative concentration exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Subject 5 300 mg every 4 weeks 20-cycle","outputs":[{"classification":"provisional","description":"Central secukinumab concentration over the selected simulation window.","key":"central_concentration_mg_l","label":"Central secukinumab concentration","unit":null},{"classification":"provisional","description":"PASI score over the selected simulation window.","key":"pasi","label":"PASI score","unit":"dimensionless"},{"classification":"provisional","description":"Il 17 a pathway drug effect over the selected simulation window.","key":"drug_effect_fraction","label":"Il 17 a pathway drug effect","unit":null},{"classification":"provisional","description":"Tolerance drive over the selected simulation window.","key":"tolerance_drive","label":"Tolerance drive","unit":null},{"classification":"provisional","description":"Cumulative concentration exposure over the selected simulation window.","key":"AUC_conc_day","label":"Cumulative concentration exposure","unit":"mg*day/L"}],"scenario_id":"subject5_300mg_q4w_20cycle_ode_probe","scientific_questions":["How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance?"],"time_span":{"end":616,"start":0,"step":7}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_L_day","label":"Systemic clearance","max":0.21000000000000002,"min":0.07,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.14},{"category":"model parameter","definition":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_L","label":"Peripheral distribution volume","max":4.199999999999999,"min":1.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.8},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.27,"min":0.09,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.18},{"category":"model parameter","definition":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","description":"Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.","key":"ic50_mg_l","label":"Half-maximal inhibitory concentration","max":14.024999999999999,"min":4.675,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mg/L","value":9.35},{"category":"model parameter","definition":"Maximum inhibitory effect defining the limiting magnitude of the corresponding pharmacodynamic effect.","description":"Maximum inhibitory effect defining the limiting magnitude of the corresponding pharmacodynamic effect.","key":"imax","label":"Maximum inhibitory effect","max":1.6350000000000002,"min":0.545,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"dimensionless","value":1.09}],"description":"How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance? Explore this intervention regimen through Central secukinumab concentration, PASI score, IL-17A pathway drug effect, Tolerance drive, Cumulative concentration exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Subject 8 150 mg every 6 weeks 20-cycle","outputs":[{"classification":"provisional","description":"Central secukinumab concentration over the selected simulation window.","key":"central_concentration_mg_l","label":"Central secukinumab concentration","unit":null},{"classification":"provisional","description":"PASI score over the selected simulation window.","key":"pasi","label":"PASI score","unit":"dimensionless"},{"classification":"provisional","description":"Il 17 a pathway drug effect over the selected simulation window.","key":"drug_effect_fraction","label":"Il 17 a pathway drug effect","unit":null},{"classification":"provisional","description":"Tolerance drive over the selected simulation window.","key":"tolerance_drive","label":"Tolerance drive","unit":null},{"classification":"provisional","description":"Cumulative concentration exposure over the selected simulation window.","key":"AUC_conc_day","label":"Cumulative concentration exposure","unit":"mg*day/L"}],"scenario_id":"subject8_150mg_q6w_20cycle_ode_probe","scientific_questions":["How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance?"],"time_span":{"end":616,"start":0,"step":7}}],"targets":[{"key":"il17a","label":"IL17A"},{"key":"il_17a","label":"IL-17A"}],"therapeutics":[{"key":"secukinumab","label":"Secukinumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A coupled PK/PD model linking circulating rituximab to CD19-positive B-cell depletion, cell-dependent drug loss, and gradual B-cell repopulation.","diseases":[{"key":"multiple_sclerosis","label":"Multiple sclerosis"}],"links":{"page":"/modeling/models/serkland-2025-rituximab-ms-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PKPD","TMDD"],"model_id":"serkland_2025_rituximab_ms_pkpd","name":"Rituximab exposure and CD19-positive B-cell dynamics","outputs":[{"description":"Rituximab concentration over the selected simulation window.","key":"rituximab_concentration_mg_l","label":"Rituximab concentration","unit":"mg/L"},{"description":"CD19 positive b over the selected simulation window.","key":"cd19_cells_mm3","label":"CD19 positive b","unit":"cell/millimeter^3"},{"description":"Linear rituximab loss over the selected simulation window.","key":"linear_clearance_component_mg_l_day","label":"Linear rituximab loss","unit":"mg/L/day"},{"description":"B cell dependent rituximab loss over the selected simulation window.","key":"tmdd_clearance_component_mg_l_day","label":"B cell dependent rituximab loss","unit":"mg/L/day"},{"description":"Drug concentration over the selected simulation window.","key":"C","label":"Drug concentration","unit":"mg/L"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_day","label":"Systemic clearance","max":0.045561551834203504,"min":0.0151871839447345,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.030374367889469},{"category":"model parameter","definition":"Concentration-dependent B-cell depletion rate governing loss, degradation, or removal in the modeled biological process.","description":"Concentration-dependent B-cell depletion rate governing loss, degradation, or removal in the modeled biological process.","key":"kdeg1_mm3_mg_day","label":"Concentration-dependent B-cell depletion rate","max":0.00453693171307614,"min":0.00151231057102538,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"millimeter^3/(cell*day)","value":0.00302462114205076},{"category":"model parameter","definition":"Exposure-dependent B-cell depletion rate governing loss, degradation, or removal in the modeled biological process.","description":"Exposure-dependent B-cell depletion rate governing loss, degradation, or removal in the modeled biological process.","key":"kdeg2_l_mg_day","label":"Exposure-dependent B-cell depletion rate","max":0.00468859287963375,"min":0.00156286429321125,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/(mg*day)","value":0.0031257285864225},{"category":"model parameter","definition":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","description":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","key":"kout_day","label":"Turnover loss rate","max":0.00061555502517258,"min":0.00020518500839086,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"1/day","value":0.00041037001678172},{"category":"model parameter","definition":"Baseline B-cell concentration coefficient used by the released system of model equations.","description":"Baseline B-cell concentration coefficient used by the released system of model equations.","key":"L0_cells_mm3","label":"Baseline B-cell concentration","max":299.355,"min":99.785,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"cell/millimeter^3","value":199.57}],"description":"How does rituximab exposure control the depth and duration of B-cell depletion and repopulation? Explore this biological starting configuration through Rituximab concentration, CD19-positive B cells, Linear rituximab loss, B-cell-dependent rituximab loss.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Typical 1000 mg exposure and B-cell response","outputs":[{"classification":"provisional","description":"Rituximab concentration over the selected simulation window.","key":"rituximab_concentration_mg_l","label":"Rituximab concentration","unit":"mg/L"},{"classification":"provisional","description":"CD19 positive b over the selected simulation window.","key":"cd19_cells_mm3","label":"CD19 positive b","unit":"cell/millimeter^3"},{"classification":"provisional","description":"Linear rituximab loss over the selected simulation window.","key":"linear_clearance_component_mg_l_day","label":"Linear rituximab loss","unit":"mg/L/day"},{"classification":"provisional","description":"B cell dependent rituximab loss over the selected simulation window.","key":"tmdd_clearance_component_mg_l_day","label":"B cell dependent rituximab loss","unit":"mg/L/day"}],"scenario_id":"population_typical_1000mg_full_ode","scientific_questions":["How does rituximab exposure control the depth and duration of B-cell depletion and repopulation?"],"time_span":{"end":200,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Systemic clearance governing removal of modeled material from the relevant compartment.","description":"Systemic clearance governing removal of modeled material from the relevant compartment.","key":"cl_day","label":"Systemic clearance","max":0.0272688,"min":0.0090896,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.0181792},{"category":"model parameter","definition":"Concentration-dependent B-cell depletion rate governing loss, degradation, or removal in the modeled biological process.","description":"Concentration-dependent B-cell depletion rate governing loss, degradation, or removal in the modeled biological process.","key":"kdeg1_mm3_mg_day","label":"Concentration-dependent B-cell depletion rate","max":0.003721095,"min":0.001240365,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"millimeter^3/(cell*day)","value":0.00248073},{"category":"model parameter","definition":"Exposure-dependent B-cell depletion rate governing loss, degradation, or removal in the modeled biological process.","description":"Exposure-dependent B-cell depletion rate governing loss, degradation, or removal in the modeled biological process.","key":"kdeg2_l_mg_day","label":"Exposure-dependent B-cell depletion rate","max":0.005154135000000001,"min":0.001718045,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/(mg*day)","value":0.00343609},{"category":"model parameter","definition":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","description":"Turnover loss rate governing loss, degradation, or removal in the modeled biological process.","key":"kout_day","label":"Turnover loss rate","max":0.0015865049999999998,"min":0.000528835,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"1/day","value":0.00105767},{"category":"model parameter","definition":"Baseline B-cell concentration coefficient used by the released system of model equations.","description":"Baseline B-cell concentration coefficient used by the released system of model equations.","key":"L0_cells_mm3","label":"Baseline B-cell concentration","max":246.25350000000003,"min":82.0845,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1,"unit":"cell/millimeter^3","value":164.169}],"description":"How does rituximab exposure control the depth and duration of B-cell depletion and repopulation? Explore this biological starting configuration through Rituximab concentration, CD19-positive B cells, Linear rituximab loss, B-cell-dependent rituximab loss.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Individualized exposure and B-cell response","outputs":[{"classification":"provisional","description":"Rituximab concentration over the selected simulation window.","key":"rituximab_concentration_mg_l","label":"Rituximab concentration","unit":"mg/L"},{"classification":"provisional","description":"CD19 positive b over the selected simulation window.","key":"cd19_cells_mm3","label":"CD19 positive b","unit":"cell/millimeter^3"},{"classification":"provisional","description":"Linear rituximab loss over the selected simulation window.","key":"linear_clearance_component_mg_l_day","label":"Linear rituximab loss","unit":"mg/L/day"},{"classification":"provisional","description":"B cell dependent rituximab loss over the selected simulation window.","key":"tmdd_clearance_component_mg_l_day","label":"B cell dependent rituximab loss","unit":"mg/L/day"}],"scenario_id":"subject1_saem_full_ode_overlay","scientific_questions":["How does rituximab exposure control the depth and duration of B-cell depletion and repopulation?"],"time_span":{"end":186.05,"start":0,"step":1}}],"targets":[{"key":"cd20","label":"CD20 / MS4A1"}],"therapeutics":[{"key":"rituximab","label":"Rituximab"},{"key":"rtx","label":"RTX"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model representing pediatric atezolizumab exposure with body weight, albumin, tumor burden, and anti-drug-antibody effects on disposition.","diseases":[{"key":"pediatric_and_young_adult_malignancies","label":"Pediatric and young-adult malignancies"}],"links":{"page":"/modeling/models/shemesh-2019-atezolizumab-pediatric-poppk-safety","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PopPK"],"model_id":"shemesh_2019_atezolizumab_pediatric_poppk_safety","name":"Atezolizumab pediatric population PK","outputs":[{"description":"Central atezolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central atezolizumab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"description":"Systemic clearance over the selected simulation window.","key":"CL_L_day","label":"Systemic clearance","unit":null},{"description":"Central distribution volume over the selected simulation window.","key":"V1_L","label":"Central distribution volume","unit":null},{"description":"Central-compartment drug amount over the selected simulation window.","key":"A_central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.3255,"min":0.1085,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.217},{"category":"model parameter","definition":"Reference central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Reference central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_ref_L","label":"Reference central distribution volume","max":4.515,"min":1.505,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.01},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.27449999999999997,"min":0.0915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.183},{"category":"model parameter","definition":"Reference peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Reference peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_ref_L","label":"Reference peripheral distribution volume","max":2.04,"min":0.68,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.36},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":33.75,"min":11.25,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":22.5}],"description":"How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Cumulative atezolizumab exposure, Individual clearance, Individual central volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Child <30 kg, 15 mg/kg every 3 weeks dynamic scenario","outputs":[{"classification":"provisional","description":"Central atezolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Systemic clearance over the selected simulation window.","key":"CL_L_day","label":"Systemic clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"V1_L","label":"Central distribution volume","unit":null}],"scenario_id":"child_lt30kg_15mgkg_q3w_source_limited","scientific_questions":["How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure?"],"time_span":{"end":210,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.3255,"min":0.1085,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.217},{"category":"model parameter","definition":"Reference central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Reference central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_ref_L","label":"Reference central distribution volume","max":4.515,"min":1.505,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.01},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.27449999999999997,"min":0.0915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.183},{"category":"model parameter","definition":"Reference peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Reference peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_ref_L","label":"Reference peripheral distribution volume","max":2.04,"min":0.68,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.36},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":76.65,"min":25.55,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":51.1}],"description":"How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Cumulative atezolizumab exposure, Individual clearance, Individual central volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Pediatric >=45 kg, 15 mg/kg every 3 weeks dynamic scenario","outputs":[{"classification":"provisional","description":"Central atezolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Systemic clearance over the selected simulation window.","key":"CL_L_day","label":"Systemic clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"V1_L","label":"Central distribution volume","unit":null}],"scenario_id":"adolescent_ge45kg_15mgkg_q3w_source_limited","scientific_questions":["How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure?"],"time_span":{"end":210,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.3255,"min":0.1085,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.217},{"category":"model parameter","definition":"Reference central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Reference central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_ref_L","label":"Reference central distribution volume","max":4.515,"min":1.505,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.01},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.27449999999999997,"min":0.0915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.183},{"category":"model parameter","definition":"Reference peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Reference peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_ref_L","label":"Reference peripheral distribution volume","max":2.04,"min":0.68,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.36},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":91.5,"min":30.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":61}],"description":"How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Cumulative atezolizumab exposure, Individual clearance, Individual central volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Young adult 57-65 kg, 1200 mg every 3 weeks dynamic scenario","outputs":[{"classification":"provisional","description":"Central atezolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Systemic clearance over the selected simulation window.","key":"CL_L_day","label":"Systemic clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"V1_L","label":"Central distribution volume","unit":null}],"scenario_id":"young_adult_57to65kg_1200mg_q3w_source_limited","scientific_questions":["How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure?"],"time_span":{"end":210,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.3255,"min":0.1085,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.217},{"category":"model parameter","definition":"Reference central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Reference central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_ref_L","label":"Reference central distribution volume","max":4.515,"min":1.505,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.01},{"category":"model parameter","definition":"Intercompartmental clearance governing exchange between model compartments.","description":"Intercompartmental clearance governing exchange between model compartments.","key":"Q_L_day","label":"Intercompartmental clearance","max":0.27449999999999997,"min":0.0915,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.183},{"category":"model parameter","definition":"Reference peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Reference peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_ref_L","label":"Reference peripheral distribution volume","max":2.04,"min":0.68,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.36},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":13.649999999999999,"min":4.55,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"kg","value":9.1}],"description":"How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Cumulative atezolizumab exposure, Individual clearance, Individual central volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"<2 years typical-patient 15 mg/kg every 3 weeks scenario","outputs":[{"classification":"provisional","description":"Central atezolizumab concentration over the selected simulation window.","key":"C_central_ug_mL","label":"Central atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_mL","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Systemic clearance over the selected simulation window.","key":"CL_L_day","label":"Systemic clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"V1_L","label":"Central distribution volume","unit":null}],"scenario_id":"infant_lt2_15mgkg_q3w_figure2_source_limited","scientific_questions":["How do pediatric body size and clinical covariates alter atezolizumab concentration and exposure?"],"time_span":{"end":210,"start":0,"step":0.25}}],"targets":[{"key":"pdl1","label":"PD-L1 / CD274"}],"therapeutics":[{"key":"atezolizumab","label":"Atezolizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A reduced dose–exposure model for the CD37-directed ADC naratuximab emtansine, representing plasma decline and cumulative exposure across dose levels.","diseases":[{"key":"relapsed_or_refractory_b_cell_non_hodgkin_lymphoma","label":"Relapsed or refractory B-cell non-Hodgkin lymphoma"}],"links":{"page":"/modeling/models/stathis-2018-imgn529-cd37-adc-phase1-nca","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Antibody-drug conjugate","model_classes":["ADC"],"model_id":"stathis_2018_imgn529_cd37_adc_phase1_nca","name":"Naratuximab emtansine dose and plasma exposure","outputs":[{"description":"Plasma naratuximab emtansine over the selected simulation window.","key":"plasma_imgn529_ug_mL","label":"Plasma naratuximab emtansine","unit":"ug/mL"},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_mL","label":"Exposure (AUC)","unit":"h*ug/mL"},{"description":"Peak ADC concentration over the selected simulation window.","key":"calibrated_cmax_ug_mL","label":"Peak ADC concentration","unit":null},{"description":"Extrapolated total exposure over the selected simulation window.","key":"calibrated_aucinf_h_ug_mL","label":"Extrapolated total exposure","unit":null},{"description":"Calibrated clearance linear over the selected simulation window.","key":"calibrated_cl_linear_per_kg","label":"Calibrated clearance linear","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Selected dose defining the modeled treatment input for the explored scenario.","description":"Selected dose defining the modeled treatment input for the explored scenario.","key":"selected_dose_mg_kg","label":"Selected dose","max":0.15000000000000002,"min":0.05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/kg","value":0.1},{"category":"model parameter","definition":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","key":"selected_half_life_h","label":"Selected half-life","max":7.3500000000000005,"min":2.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"h","value":4.9},{"category":"model parameter","definition":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_linear_per_kg","label":"Calibrated clearance linear","max":0.0010407232164085355,"min":0.00034690773880284516,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.0006938154776056903},{"category":"model parameter","definition":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_tmdd_per_kg","label":"Calibrated clearance tmdd","max":0.02292657888031449,"min":0.007642192960104831,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h/kg","value":0.015284385920209661},{"category":"model parameter","definition":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"calibrated_ec50_mg_kg","label":"Calibrated EC50","max":0.1227999093230796,"min":0.0409333031076932,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"mg/kg","value":0.0818666062153864}],"description":"How does dose level change naratuximab emtansine plasma concentration and cumulative exposure? Explore this biological starting configuration through Plasma naratuximab emtansine, Cumulative ADC exposure, Peak ADC concentration, Extrapolated total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0.1 mg/kg exponential","outputs":[{"classification":"provisional","description":"Plasma naratuximab emtansine over the selected simulation window.","key":"plasma_imgn529_ug_mL","label":"Plasma naratuximab emtansine","unit":"ug/mL"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_mL","label":"Exposure (AUC)","unit":"h*ug/mL"},{"classification":"provisional","description":"Peak ADC concentration over the selected simulation window.","key":"calibrated_cmax_ug_mL","label":"Peak ADC concentration","unit":null},{"classification":"provisional","description":"Extrapolated total exposure over the selected simulation window.","key":"calibrated_aucinf_h_ug_mL","label":"Extrapolated total exposure","unit":null}],"scenario_id":"stathis_dose_0p1_exponential_probe","scientific_questions":["How does dose level change naratuximab emtansine plasma concentration and cumulative exposure?"],"time_span":{"end":504,"start":0,"step":2}},{"controls":[{"category":"model parameter","definition":"Selected dose defining the modeled treatment input for the explored scenario.","description":"Selected dose defining the modeled treatment input for the explored scenario.","key":"selected_dose_mg_kg","label":"Selected dose","max":1.2000000000000002,"min":0.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/kg","value":0.8},{"category":"model parameter","definition":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","key":"selected_half_life_h","label":"Selected half-life","max":59.550000000000004,"min":19.85,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"h","value":39.7},{"category":"model parameter","definition":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_linear_per_kg","label":"Calibrated clearance linear","max":0.0010407232164085355,"min":0.00034690773880284516,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.0006938154776056903},{"category":"model parameter","definition":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_tmdd_per_kg","label":"Calibrated clearance tmdd","max":0.02292657888031449,"min":0.007642192960104831,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h/kg","value":0.015284385920209661},{"category":"model parameter","definition":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"calibrated_ec50_mg_kg","label":"Calibrated EC50","max":0.1227999093230796,"min":0.0409333031076932,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"mg/kg","value":0.0818666062153864}],"description":"How does dose level change naratuximab emtansine plasma concentration and cumulative exposure? Explore this biological starting configuration through Plasma naratuximab emtansine, Cumulative ADC exposure, Peak ADC concentration, Extrapolated total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0.8 mg/kg exponential","outputs":[{"classification":"provisional","description":"Plasma naratuximab emtansine over the selected simulation window.","key":"plasma_imgn529_ug_mL","label":"Plasma naratuximab emtansine","unit":"ug/mL"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_mL","label":"Exposure (AUC)","unit":"h*ug/mL"},{"classification":"provisional","description":"Peak ADC concentration over the selected simulation window.","key":"calibrated_cmax_ug_mL","label":"Peak ADC concentration","unit":null},{"classification":"provisional","description":"Extrapolated total exposure over the selected simulation window.","key":"calibrated_aucinf_h_ug_mL","label":"Extrapolated total exposure","unit":null}],"scenario_id":"stathis_dose_0p8_exponential_probe","scientific_questions":["How does dose level change naratuximab emtansine plasma concentration and cumulative exposure?"],"time_span":{"end":504,"start":0,"step":2}},{"controls":[{"category":"model parameter","definition":"Selected dose defining the modeled treatment input for the explored scenario.","description":"Selected dose defining the modeled treatment input for the explored scenario.","key":"selected_dose_mg_kg","label":"Selected dose","max":0.15000000000000002,"min":0.05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/kg","value":0.1},{"category":"model parameter","definition":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","key":"selected_half_life_h","label":"Selected half-life","max":7.3500000000000005,"min":2.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"h","value":4.9},{"category":"model parameter","definition":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_linear_per_kg","label":"Calibrated clearance linear","max":0.0010407232164085355,"min":0.00034690773880284516,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.0006938154776056903},{"category":"model parameter","definition":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_tmdd_per_kg","label":"Calibrated clearance tmdd","max":0.02292657888031449,"min":0.007642192960104831,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h/kg","value":0.015284385920209661},{"category":"model parameter","definition":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"calibrated_ec50_mg_kg","label":"Calibrated EC50","max":0.1227999093230796,"min":0.0409333031076932,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"mg/kg","value":0.0818666062153864}],"description":"How does dose level change naratuximab emtansine plasma concentration and cumulative exposure? Explore this biological starting configuration through Plasma naratuximab emtansine, Cumulative ADC exposure, Peak ADC concentration, Extrapolated total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0.1 mg/kg joint calibration","outputs":[{"classification":"provisional","description":"Plasma naratuximab emtansine over the selected simulation window.","key":"plasma_imgn529_ug_mL","label":"Plasma naratuximab emtansine","unit":"ug/mL"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_mL","label":"Exposure (AUC)","unit":"h*ug/mL"},{"classification":"provisional","description":"Peak ADC concentration over the selected simulation window.","key":"calibrated_cmax_ug_mL","label":"Peak ADC concentration","unit":null},{"classification":"provisional","description":"Extrapolated total exposure over the selected simulation window.","key":"calibrated_aucinf_h_ug_mL","label":"Extrapolated total exposure","unit":null}],"scenario_id":"stathis_exploratory_calibrated_dose_0p1_joint_table4","scientific_questions":["How does dose level change naratuximab emtansine plasma concentration and cumulative exposure?"],"time_span":{"end":504,"start":0,"step":2}},{"controls":[{"category":"model parameter","definition":"Selected dose defining the modeled treatment input for the explored scenario.","description":"Selected dose defining the modeled treatment input for the explored scenario.","key":"selected_dose_mg_kg","label":"Selected dose","max":1.0499999999999998,"min":0.35,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"mg/kg","value":0.7},{"category":"model parameter","definition":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","key":"selected_half_life_h","label":"Selected half-life","max":31.349999999999998,"min":10.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"h","value":20.9},{"category":"model parameter","definition":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_linear_per_kg","label":"Calibrated clearance linear","max":0.0010407232164085355,"min":0.00034690773880284516,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.0006938154776056903},{"category":"model parameter","definition":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_tmdd_per_kg","label":"Calibrated clearance tmdd","max":0.02292657888031449,"min":0.007642192960104831,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h/kg","value":0.015284385920209661},{"category":"model parameter","definition":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"calibrated_ec50_mg_kg","label":"Calibrated EC50","max":0.1227999093230796,"min":0.0409333031076932,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"mg/kg","value":0.0818666062153864}],"description":"How does dose level change naratuximab emtansine plasma concentration and cumulative exposure? Explore this biological starting configuration through Plasma naratuximab emtansine, Cumulative ADC exposure, Peak ADC concentration, Extrapolated total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"0.7 mg/kg joint calibration","outputs":[{"classification":"provisional","description":"Plasma naratuximab emtansine over the selected simulation window.","key":"plasma_imgn529_ug_mL","label":"Plasma naratuximab emtansine","unit":"ug/mL"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_mL","label":"Exposure (AUC)","unit":"h*ug/mL"},{"classification":"provisional","description":"Peak ADC concentration over the selected simulation window.","key":"calibrated_cmax_ug_mL","label":"Peak ADC concentration","unit":null},{"classification":"provisional","description":"Extrapolated total exposure over the selected simulation window.","key":"calibrated_aucinf_h_ug_mL","label":"Extrapolated total exposure","unit":null}],"scenario_id":"stathis_exploratory_calibrated_dose_0p7_joint_table4","scientific_questions":["How does dose level change naratuximab emtansine plasma concentration and cumulative exposure?"],"time_span":{"end":504,"start":0,"step":2}},{"controls":[{"category":"model parameter","definition":"Selected dose defining the modeled treatment input for the explored scenario.","description":"Selected dose defining the modeled treatment input for the explored scenario.","key":"selected_dose_mg_kg","label":"Selected dose","max":2.7,"min":0.9,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"mg/kg","value":1.8},{"category":"model parameter","definition":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","description":"Selected half-life controlling the time required for the corresponding quantity to decrease by half.","key":"selected_half_life_h","label":"Selected half-life","max":50.849999999999994,"min":16.95,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"h","value":33.9},{"category":"model parameter","definition":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance linear governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_linear_per_kg","label":"Calibrated clearance linear","max":0.0010407232164085355,"min":0.00034690773880284516,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":1e-06,"unit":"L/h/kg","value":0.0006938154776056903},{"category":"model parameter","definition":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","description":"Calibrated clearance tmdd governing removal of modeled material from the relevant compartment.","key":"calibrated_cl_tmdd_per_kg","label":"Calibrated clearance tmdd","max":0.02292657888031449,"min":0.007642192960104831,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h/kg","value":0.015284385920209661},{"category":"model parameter","definition":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","description":"Calibrated EC50 at which the corresponding modeled effect reaches half of its maximum.","key":"calibrated_ec50_mg_kg","label":"Calibrated EC50","max":0.1227999093230796,"min":0.0409333031076932,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"mg/kg","value":0.0818666062153864}],"description":"How does dose level change naratuximab emtansine plasma concentration and cumulative exposure? Explore this biological starting configuration through Plasma naratuximab emtansine, Cumulative ADC exposure, Peak ADC concentration, Extrapolated total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"1.8 mg/kg joint calibration","outputs":[{"classification":"provisional","description":"Plasma naratuximab emtansine over the selected simulation window.","key":"plasma_imgn529_ug_mL","label":"Plasma naratuximab emtansine","unit":"ug/mL"},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_h_ug_mL","label":"Exposure (AUC)","unit":"h*ug/mL"},{"classification":"provisional","description":"Peak ADC concentration over the selected simulation window.","key":"calibrated_cmax_ug_mL","label":"Peak ADC concentration","unit":null},{"classification":"provisional","description":"Extrapolated total exposure over the selected simulation window.","key":"calibrated_aucinf_h_ug_mL","label":"Extrapolated total exposure","unit":null}],"scenario_id":"stathis_exploratory_calibrated_dose_1p8_joint_table4","scientific_questions":["How does dose level change naratuximab emtansine plasma concentration and cumulative exposure?"],"time_span":{"end":504,"start":0,"step":2}}],"targets":[{"key":"cd37","label":"CD37"}],"therapeutics":[{"key":"naratuximab_emtansine","label":"Naratuximab emtansine"},{"key":"naratuximab_k7153a","label":"Naratuximab / K7153A"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A minimal PBPK model connecting body-weight-scaled bevacizumab clearance and compartment volumes to central and peripheral antibody exposure.","diseases":[{"key":"pediatric_to_adult_bevacizumab_exposure_bridging","label":"Pediatric-to-adult bevacizumab exposure bridging"}],"links":{"page":"/modeling/models/sule-2025-bevacizumab-minimal-pbpk-pediatric-bridge","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"whole monoclonal antibody","model_classes":["PBPK"],"model_id":"sule_2025_bevacizumab_minimal_pbpk_pediatric_bridge","name":"Pediatric bevacizumab minimal PBPK","outputs":[{"description":"Central bevacizumab concentration over the selected simulation window.","key":"out__central_conc_mg_l","label":"Central bevacizumab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_l","label":"Exposure (AUC)","unit":"mg*h/L"},{"description":"Total bevacizumab clearance over the selected simulation window.","key":"out__total_cl_l_h","label":"Total bevacizumab clearance","unit":null},{"description":"Central distribution volume over the selected simulation window.","key":"out__central_volume_l","label":"Central distribution volume","unit":null},{"description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":93,"min":31,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":62},{"category":"model parameter","definition":"Catabolic clearance governing removal of modeled material from the relevant compartment.","description":"Catabolic clearance governing removal of modeled material from the relevant compartment.","key":"CLcat_L_h","label":"Catabolic clearance","max":0.026250000000000002,"min":0.00875,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0175},{"category":"model parameter","definition":"Additional clearance governing removal of modeled material from the relevant compartment.","description":"Additional clearance governing removal of modeled material from the relevant compartment.","key":"CLadd_L_h","label":"Additional clearance","max":0.00417,"min":0.00139,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/h","value":0.00278},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"central_volume_l_per_kg","label":"Central volume","max":0.05717988792741967,"min":0.019059962642473224,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.03811992528494645},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"peripheral_volume_l_per_kg","label":"Peripheral volume","max":0.04288491594556475,"min":0.014294971981854917,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.028589943963709834}],"description":"How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure? Explore this intervention regimen through Central bevacizumab concentration, Cumulative bevacizumab exposure, Total bevacizumab clearance, Central distribution volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Female >=18 10 mg/kg every 2 weeks","outputs":[{"classification":"provisional","description":"Central bevacizumab concentration over the selected simulation window.","key":"out__central_conc_mg_l","label":"Central bevacizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_l","label":"Exposure (AUC)","unit":"mg*h/L"},{"classification":"provisional","description":"Total bevacizumab clearance over the selected simulation window.","key":"out__total_cl_l_h","label":"Total bevacizumab clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"out__central_volume_l","label":"Central distribution volume","unit":null}],"scenario_id":"adult_female_ge18_10mgkg_q2w_ode_endpoint_overlay","scientific_questions":["How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure?"],"time_span":{"end":3024,"start":0,"step":4}},{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":16.5,"min":5.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":11},{"category":"model parameter","definition":"Catabolic clearance governing removal of modeled material from the relevant compartment.","description":"Catabolic clearance governing removal of modeled material from the relevant compartment.","key":"CLcat_L_h","label":"Catabolic clearance","max":0.026250000000000002,"min":0.00875,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0175},{"category":"model parameter","definition":"Additional clearance governing removal of modeled material from the relevant compartment.","description":"Additional clearance governing removal of modeled material from the relevant compartment.","key":"CLadd_L_h","label":"Additional clearance","max":0.00417,"min":0.00139,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/h","value":0.00278},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"central_volume_l_per_kg","label":"Central volume","max":0.07146260123868509,"min":0.023820867079561693,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.047641734159123386},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"peripheral_volume_l_per_kg","label":"Peripheral volume","max":0.053596950929013815,"min":0.01786565030967127,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.03573130061934254}],"description":"How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure? Explore this intervention regimen through Central bevacizumab concentration, Cumulative bevacizumab exposure, Total bevacizumab clearance, Central distribution volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Female 0.5-2 years 10 mg/kg every 2 weeks","outputs":[{"classification":"provisional","description":"Central bevacizumab concentration over the selected simulation window.","key":"out__central_conc_mg_l","label":"Central bevacizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_l","label":"Exposure (AUC)","unit":"mg*h/L"},{"classification":"provisional","description":"Total bevacizumab clearance over the selected simulation window.","key":"out__total_cl_l_h","label":"Total bevacizumab clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"out__central_volume_l","label":"Central distribution volume","unit":null}],"scenario_id":"female_0p5_2y_10mgkg_q2w_ode_endpoint_overlay","scientific_questions":["How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure?"],"time_span":{"end":3024,"start":0,"step":4}},{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":52.5,"min":17.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":35},{"category":"model parameter","definition":"Catabolic clearance governing removal of modeled material from the relevant compartment.","description":"Catabolic clearance governing removal of modeled material from the relevant compartment.","key":"CLcat_L_h","label":"Catabolic clearance","max":0.026250000000000002,"min":0.00875,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0175},{"category":"model parameter","definition":"Additional clearance governing removal of modeled material from the relevant compartment.","description":"Additional clearance governing removal of modeled material from the relevant compartment.","key":"CLadd_L_h","label":"Additional clearance","max":0.00417,"min":0.00139,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/h","value":0.00278},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"central_volume_l_per_kg","label":"Central volume","max":0.06898137502874224,"min":0.022993791676247415,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.04598758335249483},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"peripheral_volume_l_per_kg","label":"Peripheral volume","max":0.05173603127155668,"min":0.01724534375718556,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.03449068751437112}],"description":"How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure? Explore this intervention regimen through Central bevacizumab concentration, Cumulative bevacizumab exposure, Total bevacizumab clearance, Central distribution volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Female 6-12 years 10 mg/kg every 2 weeks","outputs":[{"classification":"provisional","description":"Central bevacizumab concentration over the selected simulation window.","key":"out__central_conc_mg_l","label":"Central bevacizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_l","label":"Exposure (AUC)","unit":"mg*h/L"},{"classification":"provisional","description":"Total bevacizumab clearance over the selected simulation window.","key":"out__total_cl_l_h","label":"Total bevacizumab clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"out__central_volume_l","label":"Central distribution volume","unit":null}],"scenario_id":"female_6_12y_10mgkg_q2w_ode_endpoint_overlay","scientific_questions":["How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure?"],"time_span":{"end":3024,"start":0,"step":4}},{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":28.5,"min":9.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":19},{"category":"model parameter","definition":"Catabolic clearance governing removal of modeled material from the relevant compartment.","description":"Catabolic clearance governing removal of modeled material from the relevant compartment.","key":"CLcat_L_h","label":"Catabolic clearance","max":0.026250000000000002,"min":0.00875,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0175},{"category":"model parameter","definition":"Additional clearance governing removal of modeled material from the relevant compartment.","description":"Additional clearance governing removal of modeled material from the relevant compartment.","key":"CLadd_L_h","label":"Additional clearance","max":0.008805,"min":0.002935,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/h","value":0.00587},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"central_volume_l_per_kg","label":"Central volume","max":0.07159562789365662,"min":0.02386520929788554,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.04773041859577108},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"peripheral_volume_l_per_kg","label":"Peripheral volume","max":0.05369672092024246,"min":0.017898906973414154,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.03579781394682831}],"description":"How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure? Explore this intervention regimen through Central bevacizumab concentration, Cumulative bevacizumab exposure, Total bevacizumab clearance, Central distribution volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Male 2-6 years 10 mg/kg every 2 weeks","outputs":[{"classification":"provisional","description":"Central bevacizumab concentration over the selected simulation window.","key":"out__central_conc_mg_l","label":"Central bevacizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_l","label":"Exposure (AUC)","unit":"mg*h/L"},{"classification":"provisional","description":"Total bevacizumab clearance over the selected simulation window.","key":"out__total_cl_l_h","label":"Total bevacizumab clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"out__central_volume_l","label":"Central distribution volume","unit":null}],"scenario_id":"male_2_6y_10mgkg_q2w_ode_endpoint_overlay","scientific_questions":["How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure?"],"time_span":{"end":3024,"start":0,"step":4}},{"controls":[{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":90,"min":30,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":60},{"category":"model parameter","definition":"Catabolic clearance governing removal of modeled material from the relevant compartment.","description":"Catabolic clearance governing removal of modeled material from the relevant compartment.","key":"CLcat_L_h","label":"Catabolic clearance","max":0.026250000000000002,"min":0.00875,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/h","value":0.0175},{"category":"model parameter","definition":"Additional clearance governing removal of modeled material from the relevant compartment.","description":"Additional clearance governing removal of modeled material from the relevant compartment.","key":"CLadd_L_h","label":"Additional clearance","max":0.008805,"min":0.002935,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-06,"unit":"L/h","value":0.00587},{"category":"model parameter","definition":"Central volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central volume used to convert modeled amount to concentration in the relevant compartment.","key":"central_volume_l_per_kg","label":"Central volume","max":0.06728871343979903,"min":0.022429571146599676,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.04485914229319935},{"category":"model parameter","definition":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","description":"Peripheral volume used to convert modeled amount to concentration in the relevant compartment.","key":"peripheral_volume_l_per_kg","label":"Peripheral volume","max":0.05046653507984927,"min":0.016822178359949758,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"L/kg","value":0.033644356719899515}],"description":"How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure? Explore this intervention regimen through Central bevacizumab concentration, Cumulative bevacizumab exposure, Total bevacizumab clearance, Central distribution volume.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Male 12-18 years 10 mg/kg every 2 weeks","outputs":[{"classification":"provisional","description":"Central bevacizumab concentration over the selected simulation window.","key":"out__central_conc_mg_l","label":"Central bevacizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_mg_h_l","label":"Exposure (AUC)","unit":"mg*h/L"},{"classification":"provisional","description":"Total bevacizumab clearance over the selected simulation window.","key":"out__total_cl_l_h","label":"Total bevacizumab clearance","unit":null},{"classification":"provisional","description":"Central distribution volume over the selected simulation window.","key":"out__central_volume_l","label":"Central distribution volume","unit":null}],"scenario_id":"male_12_18y_10mgkg_q2w_ode_endpoint_overlay","scientific_questions":["How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure?"],"time_span":{"end":3024,"start":0,"step":4}}],"targets":[{"key":"vegfa","label":"VEGF-A","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1208/s12248-025-01120-y","locator":"Primary publication introduction: bevacizumab binds vascular endothelial growth factor A (VEGF-A).","relationship":"Therapeutic target; target-mediated disposition is explicitly outside this minimal-PBPK model."}}],"therapeutics":[{"key":"bevacizumab","label":"Bevacizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"Mechanistic QSP model for an intravenously dosed biologic designed to remain closed systemically and open after engaging a tumor-enriched gate. It connects three-compartment disposition, reversible cargo accessibility, tumor retention, and central-versus-tumor receptor occupancy using transparent UBI-authored equations and synthetic exploratory assumptions.","diseases":[{"key":"solid_tumors_with_an_accessible_tumor_enriched_gate_target","label":"Solid tumors with an accessible tumor-enriched gate target"}],"links":{"page":"/modeling/models/ubi-2026-target-gated-cargo-qsp","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"conditionally active targeted biologic","model_classes":["QSP","TMDD"],"model_id":"ubi_2026_target_gated_cargo_qsp","name":"Target-Gated Cargo QSP","outputs":[{"description":"Central occupancy predicted from assumed receptor capacity and synthetic kinetic priors; not a safety threshold or clinical biomarker.","key":"central_receptor_occupancy_percent","label":"Systemic cargo receptor occupancy","unit":"%"},{"description":"Tumor occupancy predicted from gate retention, opening, and cargo-receptor engagement; not a clinical efficacy claim.","key":"tumor_receptor_occupancy_percent","label":"Tumor cargo receptor occupancy","unit":"%"},{"description":"Fraction of the assumed accessible gate capacity occupied by construct.","key":"tumor_gate_occupancy_percent","label":"Tumor gate target occupancy","unit":"%"},{"description":"Mass ledger across free, gate-bound, and receptor-bound model states.","key":"total_construct_nmol","label":"Total modeled construct","unit":"nmol"},{"description":"Background open equilibrium ratio over the selected simulation window.","key":"background_open_equilibrium_ratio","label":"Background open equilibrium ratio","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true},{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":true},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":true}],"scenarios":[{"controls":[{"category":"gating","definition":"First-order opening rate when construct is not bound to tumor gate target.","description":"First-order opening rate when construct is not bound to tumor gate target.","key":"k_open_background_h","label":"Background opening rate","max":0.006,"min":0.002,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-06,"unit":"1/h","value":0.004},{"category":"gate target","definition":"Total accessible binding capacity of the generic tumor-enriched gate target.","description":"Total accessible binding capacity of the generic tumor-enriched gate target.","key":"gate_capacity_tumor_nmol","label":"Accessible tumor gate target capacity","max":0.22499999999999998,"min":0.075,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; target identity is intentionally unspecified","step":0.001,"unit":"nmol","value":0.15},{"category":"gate target","definition":"Dissociation rate of gate-bound open construct.","description":"Dissociation rate of gate-bound open construct.","key":"koff_gate_open_h","label":"Open construct gate dissociation","max":0.045,"min":0.015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-05,"unit":"1/h","value":0.03},{"category":"cargo receptor","definition":"Association rate shared by free-open and gate-retained open construct.","description":"Association rate shared by free-open and gate-retained open construct.","key":"kon_cargo_receptor_per_nM_h","label":"Cargo receptor association","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":0.001,"unit":"1/(nM*h)","value":0.4},{"category":"distribution","definition":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","description":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","key":"intercompartmental_clearance_tumor_L_h","label":"Central tumor exchange clearance","max":3.0000000000000004e-05,"min":1e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; intended for replacement by biodistribution data","step":1e-07,"unit":"L/h","value":2e-05}],"description":"Nominal synthetic probe intended to produce low-to-moderate systemic cargo-receptor occupancy and substantially higher tumor occupancy.","interpretation_guardrails":["The 30 nmol amount is a neutral exploratory perturbation, not a clinical dose.","All values are synthetic and uncalibrated.","Directional similarity to another model is not paper reproduction."],"name":"Balanced gate, 30 nmol IV","outputs":[{"classification":"qualified","description":"Central occupancy predicted from assumed receptor capacity and synthetic kinetic priors; not a safety threshold or clinical biomarker.","key":"central_receptor_occupancy_percent","label":"Systemic cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Tumor occupancy predicted from gate retention, opening, and cargo-receptor engagement; not a clinical efficacy claim.","key":"tumor_receptor_occupancy_percent","label":"Tumor cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Fraction of the assumed accessible gate capacity occupied by construct.","key":"tumor_gate_occupancy_percent","label":"Tumor gate target occupancy","unit":"%"},{"classification":"qualified","description":"Mass ledger across free, gate-bound, and receptor-bound model states.","key":"total_construct_nmol","label":"Total modeled construct","unit":"nmol"}],"scenario_id":"balanced_gate_30nmol_iv","scientific_questions":["Can the assumed gate create a tumor-versus-systemic receptor-occupancy window?","How much tumor gate capacity is occupied during the two-week probe?"],"time_span":{"end":336,"start":0,"step":6}},{"controls":[{"category":"gating","definition":"First-order opening rate when construct is not bound to tumor gate target.","description":"First-order opening rate when construct is not bound to tumor gate target.","key":"k_open_background_h","label":"Background opening rate","max":0.006,"min":0.002,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-06,"unit":"1/h","value":0.004},{"category":"gate target","definition":"Total accessible binding capacity of the generic tumor-enriched gate target.","description":"Total accessible binding capacity of the generic tumor-enriched gate target.","key":"gate_capacity_tumor_nmol","label":"Accessible tumor gate target capacity","max":1,"min":0,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; target identity is intentionally unspecified","step":0.01,"unit":"nmol","value":0},{"category":"gate target","definition":"Dissociation rate of gate-bound open construct.","description":"Dissociation rate of gate-bound open construct.","key":"koff_gate_open_h","label":"Open construct gate dissociation","max":0.045,"min":0.015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-05,"unit":"1/h","value":0.03},{"category":"cargo receptor","definition":"Association rate shared by free-open and gate-retained open construct.","description":"Association rate shared by free-open and gate-retained open construct.","key":"kon_cargo_receptor_per_nM_h","label":"Cargo receptor association","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":0.001,"unit":"1/(nM*h)","value":0.4},{"category":"distribution","definition":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","description":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","key":"intercompartmental_clearance_tumor_L_h","label":"Central tumor exchange clearance","max":3.0000000000000004e-05,"min":1e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; intended for replacement by biodistribution data","step":1e-07,"unit":"L/h","value":2e-05}],"description":"Matched negative control that removes tumor gate capacity while preserving PK, background opening, and cargo-receptor kinetics.","interpretation_guardrails":["The zero-gate control is a mechanism-isolation experiment, not a target-negative patient prediction."],"name":"No tumor gate, 30 nmol IV","outputs":[{"classification":"qualified","description":"Central occupancy predicted from assumed receptor capacity and synthetic kinetic priors; not a safety threshold or clinical biomarker.","key":"central_receptor_occupancy_percent","label":"Systemic cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Tumor occupancy predicted from gate retention, opening, and cargo-receptor engagement; not a clinical efficacy claim.","key":"tumor_receptor_occupancy_percent","label":"Tumor cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Fraction of the assumed accessible gate capacity occupied by construct.","key":"tumor_gate_occupancy_percent","label":"Tumor gate target occupancy","unit":"%"},{"classification":"qualified","description":"Mass ledger across free, gate-bound, and receptor-bound model states.","key":"total_construct_nmol","label":"Total modeled construct","unit":"nmol"}],"scenario_id":"no_tumor_gate_30nmol_iv","scientific_questions":["Does removing the tumor gate selectively reduce tumor receptor engagement?"],"time_span":{"end":336,"start":0,"step":6}},{"controls":[{"category":"gating","definition":"First-order opening rate when construct is not bound to tumor gate target.","description":"First-order opening rate when construct is not bound to tumor gate target.","key":"k_open_background_h","label":"Background opening rate","max":0.0006000000000000001,"min":0.0002,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":1e-06,"unit":"1/h","value":0.0004},{"category":"gate target","definition":"Total accessible binding capacity of the generic tumor-enriched gate target.","description":"Total accessible binding capacity of the generic tumor-enriched gate target.","key":"gate_capacity_tumor_nmol","label":"Accessible tumor gate target capacity","max":0.22499999999999998,"min":0.075,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; target identity is intentionally unspecified","step":0.001,"unit":"nmol","value":0.15},{"category":"gate target","definition":"Dissociation rate of gate-bound open construct.","description":"Dissociation rate of gate-bound open construct.","key":"koff_gate_open_h","label":"Open construct gate dissociation","max":0.045,"min":0.015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-05,"unit":"1/h","value":0.03},{"category":"cargo receptor","definition":"Association rate shared by free-open and gate-retained open construct.","description":"Association rate shared by free-open and gate-retained open construct.","key":"kon_cargo_receptor_per_nM_h","label":"Cargo receptor association","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":0.001,"unit":"1/(nM*h)","value":0.4},{"category":"distribution","definition":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","description":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","key":"intercompartmental_clearance_tumor_L_h","label":"Central tumor exchange clearance","max":3.0000000000000004e-05,"min":1e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; intended for replacement by biodistribution data","step":1e-07,"unit":"L/h","value":2e-05}],"description":"Reduces background opening tenfold while retaining gate-assisted tumor opening.","interpretation_guardrails":["This is an assumed engineering perturbation, not an experimentally achieved molecule."],"name":"Tighter systemic closure, 30 nmol IV","outputs":[{"classification":"qualified","description":"Central occupancy predicted from assumed receptor capacity and synthetic kinetic priors; not a safety threshold or clinical biomarker.","key":"central_receptor_occupancy_percent","label":"Systemic cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Tumor occupancy predicted from gate retention, opening, and cargo-receptor engagement; not a clinical efficacy claim.","key":"tumor_receptor_occupancy_percent","label":"Tumor cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Fraction of the assumed accessible gate capacity occupied by construct.","key":"tumor_gate_occupancy_percent","label":"Tumor gate target occupancy","unit":"%"},{"classification":"qualified","description":"Mass ledger across free, gate-bound, and receptor-bound model states.","key":"total_construct_nmol","label":"Total modeled construct","unit":"nmol"}],"scenario_id":"tight_systemic_gate_30nmol_iv","scientific_questions":["Can stronger systemic closure lower central occupancy while preserving gate-driven tumor engagement?"],"time_span":{"end":336,"start":0,"step":6}},{"controls":[{"category":"gating","definition":"First-order opening rate when construct is not bound to tumor gate target.","description":"First-order opening rate when construct is not bound to tumor gate target.","key":"k_open_background_h","label":"Background opening rate","max":0.06,"min":0.02,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-05,"unit":"1/h","value":0.04},{"category":"gate target","definition":"Total accessible binding capacity of the generic tumor-enriched gate target.","description":"Total accessible binding capacity of the generic tumor-enriched gate target.","key":"gate_capacity_tumor_nmol","label":"Accessible tumor gate target capacity","max":0.22499999999999998,"min":0.075,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; target identity is intentionally unspecified","step":0.001,"unit":"nmol","value":0.15},{"category":"gate target","definition":"Dissociation rate of gate-bound open construct.","description":"Dissociation rate of gate-bound open construct.","key":"koff_gate_open_h","label":"Open construct gate dissociation","max":0.045,"min":0.015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-05,"unit":"1/h","value":0.03},{"category":"cargo receptor","definition":"Association rate shared by free-open and gate-retained open construct.","description":"Association rate shared by free-open and gate-retained open construct.","key":"kon_cargo_receptor_per_nM_h","label":"Cargo receptor association","max":0.6000000000000001,"min":0.2,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":0.001,"unit":"1/(nM*h)","value":0.4},{"category":"distribution","definition":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","description":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","key":"intercompartmental_clearance_tumor_L_h","label":"Central tumor exchange clearance","max":3.0000000000000004e-05,"min":1e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; intended for replacement by biodistribution data","step":1e-07,"unit":"L/h","value":2e-05}],"description":"Raises background opening tenfold while leaving the tumor gate module unchanged.","interpretation_guardrails":["This is an assumed mechanism stress test, not a measured construct."],"name":"Leakier systemic gate, 30 nmol IV","outputs":[{"classification":"qualified","description":"Central occupancy predicted from assumed receptor capacity and synthetic kinetic priors; not a safety threshold or clinical biomarker.","key":"central_receptor_occupancy_percent","label":"Systemic cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Tumor occupancy predicted from gate retention, opening, and cargo-receptor engagement; not a clinical efficacy claim.","key":"tumor_receptor_occupancy_percent","label":"Tumor cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Fraction of the assumed accessible gate capacity occupied by construct.","key":"tumor_gate_occupancy_percent","label":"Tumor gate target occupancy","unit":"%"},{"classification":"qualified","description":"Mass ledger across free, gate-bound, and receptor-bound model states.","key":"total_construct_nmol","label":"Total modeled construct","unit":"nmol"}],"scenario_id":"leaky_systemic_gate_30nmol_iv","scientific_questions":["How strongly does systemic leakage erode the tumor-versus-systemic occupancy window?"],"time_span":{"end":336,"start":0,"step":6}},{"controls":[{"category":"gating","definition":"First-order opening rate when construct is not bound to tumor gate target.","description":"First-order opening rate when construct is not bound to tumor gate target.","key":"k_open_background_h","label":"Background opening rate","max":0.006,"min":0.002,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-06,"unit":"1/h","value":0.004},{"category":"gate target","definition":"Total accessible binding capacity of the generic tumor-enriched gate target.","description":"Total accessible binding capacity of the generic tumor-enriched gate target.","key":"gate_capacity_tumor_nmol","label":"Accessible tumor gate target capacity","max":0.22499999999999998,"min":0.075,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; target identity is intentionally unspecified","step":0.001,"unit":"nmol","value":0.15},{"category":"gate target","definition":"Dissociation rate of gate-bound open construct.","description":"Dissociation rate of gate-bound open construct.","key":"koff_gate_open_h","label":"Open construct gate dissociation","max":0.045,"min":0.015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-05,"unit":"1/h","value":0.03},{"category":"cargo receptor","definition":"Association rate shared by free-open and gate-retained open construct.","description":"Association rate shared by free-open and gate-retained open construct.","key":"kon_cargo_receptor_per_nM_h","label":"Cargo receptor association","max":0.06,"min":0.02,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption","step":9.999999999999999e-05,"unit":"1/(nM*h)","value":0.04},{"category":"distribution","definition":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","description":"Symmetric concentration-driven exchange clearance between central plasma and accessible tumor space.","key":"intercompartmental_clearance_tumor_L_h","label":"Central tumor exchange clearance","max":3.0000000000000004e-05,"min":1e-05,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"UBI synthetic exploratory assumption; intended for replacement by biodistribution data","step":1e-07,"unit":"L/h","value":2e-05}],"description":"Reduces cargo-receptor association tenfold to explore potency attenuation independently of gate-target binding.","interpretation_guardrails":["A receptor-association change may also alter pharmacology not represented by occupancy alone."],"name":"Attenuated cargo-receptor association, 30 nmol IV","outputs":[{"classification":"qualified","description":"Central occupancy predicted from assumed receptor capacity and synthetic kinetic priors; not a safety threshold or clinical biomarker.","key":"central_receptor_occupancy_percent","label":"Systemic cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Tumor occupancy predicted from gate retention, opening, and cargo-receptor engagement; not a clinical efficacy claim.","key":"tumor_receptor_occupancy_percent","label":"Tumor cargo receptor occupancy","unit":"%"},{"classification":"qualified","description":"Fraction of the assumed accessible gate capacity occupied by construct.","key":"tumor_gate_occupancy_percent","label":"Tumor gate target occupancy","unit":"%"},{"classification":"qualified","description":"Mass ledger across free, gate-bound, and receptor-bound model states.","key":"total_construct_nmol","label":"Total modeled construct","unit":"nmol"}],"scenario_id":"attenuated_cargo_receptor_30nmol_iv","scientific_questions":["Can cargo-receptor attenuation lower systemic engagement while tumor retention preserves a relative local advantage?"],"time_span":{"end":336,"start":0,"step":6}}],"targets":[{"key":"configurable_tumor_gate_target","label":"configurable tumor gate target"},{"key":"configurable_cargo_receptor","label":"configurable cargo receptor"}],"therapeutics":[{"key":"generic_target_gated_cargo","label":"generic target-gated cargo"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"2.0.0"},{"availability":{"catalog_qualified":true,"released":true},"description":"A subcutaneous quasi-steady-state TMDD model coupling erenumab disposition to CGRP-receptor abundance, unbound antibody, drug-target complex, and cumulative exposure.","diseases":[{"key":"migraine_prevention_and_cgrp_receptor_pharmacology","label":"Migraine prevention and CGRP-receptor pharmacology"}],"links":{"page":"/modeling/models/vu-2017-erenumab-cidbf-pkpd-tmdd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["TMDD"],"model_id":"vu_2017_erenumab_cidbf_pkpd_tmdd","name":"Erenumab PK, target binding, and receptor pharmacology","outputs":[{"description":"Total erenumab concentration over the selected simulation window.","key":"total_concentration_ng_mL","label":"Total erenumab concentration","unit":null},{"description":"Unbound erenumab concentration over the selected simulation window.","key":"unbound_concentration_ng_mL","label":"Unbound erenumab concentration","unit":null},{"description":"Erenumab receptor complex over the selected simulation window.","key":"bound_complex_ng_mL","label":"Erenumab receptor complex","unit":null},{"description":"Total cgrp receptor over the selected simulation window.","key":"R_total","label":"Total cgrp receptor","unit":"ng/mL"},{"description":"Cumulative total exposure over the selected simulation window.","key":"total_auc_ug_day_mL","label":"Cumulative total exposure","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.321,"min":0.107,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.214},{"category":"model parameter","definition":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_ref_L","label":"Central distribution volume reference","max":6.404999999999999,"min":2.135,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":4.27},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.648,"min":0.216,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.432},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"Kss_ng_mL","label":"Quasi-steady-state binding constant","max":28.200000000000003,"min":9.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ng/mL","value":18.8},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_1_day","label":"Target internalization rate","max":0.051750000000000004,"min":0.01725,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.0345}],"description":"How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time? Explore this intervention regimen through Total erenumab concentration, Unbound erenumab concentration, Erenumab–receptor complex, Total CGRP receptor, Cumulative total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"7 mg SC every 4 weeks 75 kg deterministic simulation","outputs":[{"classification":"provisional","description":"Total erenumab concentration over the selected simulation window.","key":"total_concentration_ng_mL","label":"Total erenumab concentration","unit":null},{"classification":"provisional","description":"Unbound erenumab concentration over the selected simulation window.","key":"unbound_concentration_ng_mL","label":"Unbound erenumab concentration","unit":null},{"classification":"provisional","description":"Erenumab receptor complex over the selected simulation window.","key":"bound_complex_ng_mL","label":"Erenumab receptor complex","unit":null},{"classification":"provisional","description":"Total cgrp receptor over the selected simulation window.","key":"R_total","label":"Total cgrp receptor","unit":"ng/mL"},{"classification":"provisional","description":"Cumulative total exposure over the selected simulation window.","key":"total_auc_ug_day_mL","label":"Cumulative total exposure","unit":null}],"scenario_id":"sc_7mg_q4w_75kg_dynamic","scientific_questions":["How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time?"],"time_span":{"end":84,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.321,"min":0.107,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.214},{"category":"model parameter","definition":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_ref_L","label":"Central distribution volume reference","max":6.404999999999999,"min":2.135,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":4.27},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.648,"min":0.216,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.432},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"Kss_ng_mL","label":"Quasi-steady-state binding constant","max":28.200000000000003,"min":9.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ng/mL","value":18.8},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_1_day","label":"Target internalization rate","max":0.051750000000000004,"min":0.01725,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.0345}],"description":"How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time? Explore this intervention regimen through Total erenumab concentration, Unbound erenumab concentration, Erenumab–receptor complex, Total CGRP receptor, Cumulative total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"70 mg SC every 4 weeks 75 kg deterministic simulation","outputs":[{"classification":"provisional","description":"Total erenumab concentration over the selected simulation window.","key":"total_concentration_ng_mL","label":"Total erenumab concentration","unit":null},{"classification":"provisional","description":"Unbound erenumab concentration over the selected simulation window.","key":"unbound_concentration_ng_mL","label":"Unbound erenumab concentration","unit":null},{"classification":"provisional","description":"Erenumab receptor complex over the selected simulation window.","key":"bound_complex_ng_mL","label":"Erenumab receptor complex","unit":null},{"classification":"provisional","description":"Total cgrp receptor over the selected simulation window.","key":"R_total","label":"Total cgrp receptor","unit":"ng/mL"},{"classification":"provisional","description":"Cumulative total exposure over the selected simulation window.","key":"total_auc_ug_day_mL","label":"Cumulative total exposure","unit":null}],"scenario_id":"sc_70mg_q4w_75kg_dynamic","scientific_questions":["How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time?"],"time_span":{"end":84,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.321,"min":0.107,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.214},{"category":"model parameter","definition":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_ref_L","label":"Central distribution volume reference","max":6.404999999999999,"min":2.135,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":4.27},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.648,"min":0.216,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.432},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"Kss_ng_mL","label":"Quasi-steady-state binding constant","max":28.200000000000003,"min":9.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ng/mL","value":18.8},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_1_day","label":"Target internalization rate","max":0.051750000000000004,"min":0.01725,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.0345}],"description":"How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time? Explore this intervention regimen through Total erenumab concentration, Unbound erenumab concentration, Erenumab–receptor complex, Total CGRP receptor, Cumulative total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"21 mg SC every 4 weeks 84 kg simulation","outputs":[{"classification":"provisional","description":"Total erenumab concentration over the selected simulation window.","key":"total_concentration_ng_mL","label":"Total erenumab concentration","unit":null},{"classification":"provisional","description":"Unbound erenumab concentration over the selected simulation window.","key":"unbound_concentration_ng_mL","label":"Unbound erenumab concentration","unit":null},{"classification":"provisional","description":"Erenumab receptor complex over the selected simulation window.","key":"bound_complex_ng_mL","label":"Erenumab receptor complex","unit":null},{"classification":"provisional","description":"Total cgrp receptor over the selected simulation window.","key":"R_total","label":"Total cgrp receptor","unit":"ng/mL"},{"classification":"provisional","description":"Cumulative total exposure over the selected simulation window.","key":"total_auc_ug_day_mL","label":"Cumulative total exposure","unit":null}],"scenario_id":"sc_21mg_q4w_84kg_s8_dynamic","scientific_questions":["How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time?"],"time_span":{"end":175,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.321,"min":0.107,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.214},{"category":"model parameter","definition":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_ref_L","label":"Central distribution volume reference","max":6.404999999999999,"min":2.135,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":4.27},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.648,"min":0.216,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.432},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"Kss_ng_mL","label":"Quasi-steady-state binding constant","max":28.200000000000003,"min":9.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ng/mL","value":18.8},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_1_day","label":"Target internalization rate","max":0.051750000000000004,"min":0.01725,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.0345}],"description":"How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time? Explore this intervention regimen through Total erenumab concentration, Unbound erenumab concentration, Erenumab–receptor complex, Total CGRP receptor, Cumulative total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"140 mg IV single-infusion deterministic simulation","outputs":[{"classification":"provisional","description":"Total erenumab concentration over the selected simulation window.","key":"total_concentration_ng_mL","label":"Total erenumab concentration","unit":null},{"classification":"provisional","description":"Unbound erenumab concentration over the selected simulation window.","key":"unbound_concentration_ng_mL","label":"Unbound erenumab concentration","unit":null},{"classification":"provisional","description":"Erenumab receptor complex over the selected simulation window.","key":"bound_complex_ng_mL","label":"Erenumab receptor complex","unit":null},{"classification":"provisional","description":"Total cgrp receptor over the selected simulation window.","key":"R_total","label":"Total cgrp receptor","unit":"ng/mL"},{"classification":"provisional","description":"Cumulative total exposure over the selected simulation window.","key":"total_auc_ug_day_mL","label":"Cumulative total exposure","unit":null}],"scenario_id":"iv_140mg_single_infusion_dynamic","scientific_questions":["How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time?"],"time_span":{"end":84,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","description":"Reference systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_ref_L_day","label":"Reference systemic clearance","max":0.321,"min":0.107,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.214},{"category":"model parameter","definition":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume reference used to convert modeled amount to concentration in the relevant compartment.","key":"Vc_ref_L","label":"Central distribution volume reference","max":6.404999999999999,"min":2.135,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":4.27},{"category":"model parameter","definition":"Absorption rate constant governing entry from the administration site.","description":"Absorption rate constant governing entry from the administration site.","key":"ka_1_day","label":"Absorption rate constant","max":0.648,"min":0.216,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"1/day","value":0.432},{"category":"model parameter","definition":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","description":"Quasi-steady-state binding constant describing equilibrium binding affinity in the modeled interaction.","key":"Kss_ng_mL","label":"Quasi-steady-state binding constant","max":28.200000000000003,"min":9.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"ng/mL","value":18.8},{"category":"model parameter","definition":"Target internalization rate coefficient used by the released system of model equations.","description":"Target internalization rate coefficient used by the released system of model equations.","key":"kint_1_day","label":"Target internalization rate","max":0.051750000000000004,"min":0.01725,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":9.999999999999999e-05,"unit":"1/day","value":0.0345}],"description":"How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time? Explore this intervention regimen through Total erenumab concentration, Unbound erenumab concentration, Erenumab–receptor complex, Total CGRP receptor, Cumulative total exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"70 mg SC every 4 weeks 75 kg simulation","outputs":[{"classification":"provisional","description":"Total erenumab concentration over the selected simulation window.","key":"total_concentration_ng_mL","label":"Total erenumab concentration","unit":null},{"classification":"provisional","description":"Unbound erenumab concentration over the selected simulation window.","key":"unbound_concentration_ng_mL","label":"Unbound erenumab concentration","unit":null},{"classification":"provisional","description":"Erenumab receptor complex over the selected simulation window.","key":"bound_complex_ng_mL","label":"Erenumab receptor complex","unit":null},{"classification":"provisional","description":"Total cgrp receptor over the selected simulation window.","key":"R_total","label":"Total cgrp receptor","unit":"ng/mL"},{"classification":"provisional","description":"Cumulative total exposure over the selected simulation window.","key":"total_auc_ug_day_mL","label":"Cumulative total exposure","unit":null}],"scenario_id":"sc_70mg_q4w_75kg_s8_dynamic","scientific_questions":["How do erenumab dose and target turnover shape total drug, unbound drug, and receptor-bound complex over time?"],"time_span":{"end":175,"start":0,"step":1}}],"targets":[{"key":"cgrp_receptor","label":"CGRP receptor"},{"key":"calcrl","label":"CALCRL"},{"key":"ramp1","label":"RAMP1"},{"key":"calcitonin_gene_related_peptide_receptor","label":"calcitonin gene-related peptide receptor"}],"therapeutics":[{"key":"erenumab","label":"Erenumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model representing atezolizumab concentration and exposure with body weight, albumin, sex, and anti-therapeutic-antibody covariates.","diseases":[{"key":"advanced_or_recurrent_non_small_cell_lung_cancer","label":"Advanced or recurrent non-small cell lung cancer"}],"links":{"page":"/modeling/models/yagishita-2024-atezolizumab-jtail-real-world-pk","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":null,"model_classes":["PopPK","Exposure-response"],"model_id":"yagishita_2024_atezolizumab_jtail_real_world_pk","name":"Atezolizumab real-world population PK","outputs":[{"description":"Central atezolizumab concentration over the selected simulation window.","key":"concentration_ug_per_mL","label":"Central atezolizumab concentration","unit":null},{"description":"Peripheral atezolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_per_mL","label":"Peripheral atezolizumab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_per_mL","label":"Exposure (AUC)","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC","label":"Exposure (AUC)","unit":"ug*day/mL"},{"description":"Central-compartment drug amount over the selected simulation window.","key":"A_central","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Population systemic clearance governing removal of modeled material from the relevant compartment.","description":"Population systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_pop_L_day","label":"Population systemic clearance","max":0.30000000000000004,"min":0.1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.2},{"category":"model parameter","definition":"Population central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Population central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_pop_L","label":"Population central distribution volume","max":4.92,"min":1.64,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.28},{"category":"model parameter","definition":"Population intercompartmental clearance governing exchange between model compartments.","description":"Population intercompartmental clearance governing exchange between model compartments.","key":"Q_pop_L_day","label":"Population intercompartmental clearance","max":0.8190000000000001,"min":0.273,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.546},{"category":"model parameter","definition":"Population peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Population peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_pop_L","label":"Population peripheral distribution volume","max":5.445,"min":1.815,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.63},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":87.9,"min":29.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":58.6}],"description":"How do real-world patient covariates change atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Peripheral atezolizumab concentration, Cumulative atezolizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Article median","outputs":[{"classification":"provisional","description":"Central atezolizumab concentration over the selected simulation window.","key":"concentration_ug_per_mL","label":"Central atezolizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral atezolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_per_mL","label":"Peripheral atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_per_mL","label":"Exposure (AUC)","unit":null}],"scenario_id":"jtail_article_figure1_public_fixed_effect","scientific_questions":["How do real-world patient covariates change atezolizumab concentration and exposure?"],"time_span":{"end":82,"start":0,"step":0.05}},{"controls":[{"category":"model parameter","definition":"Population systemic clearance governing removal of modeled material from the relevant compartment.","description":"Population systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_pop_L_day","label":"Population systemic clearance","max":0.30000000000000004,"min":0.1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.2},{"category":"model parameter","definition":"Population central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Population central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_pop_L","label":"Population central distribution volume","max":4.92,"min":1.64,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.28},{"category":"model parameter","definition":"Population intercompartmental clearance governing exchange between model compartments.","description":"Population intercompartmental clearance governing exchange between model compartments.","key":"Q_pop_L_day","label":"Population intercompartmental clearance","max":0.8190000000000001,"min":0.273,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.546},{"category":"model parameter","definition":"Population peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Population peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_pop_L","label":"Population peripheral distribution volume","max":5.445,"min":1.815,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.63},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":87.9,"min":29.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":58.6}],"description":"How do real-world patient covariates change atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Peripheral atezolizumab concentration, Cumulative atezolizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Article median EBE","outputs":[{"classification":"provisional","description":"Central atezolizumab concentration over the selected simulation window.","key":"concentration_ug_per_mL","label":"Central atezolizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral atezolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_per_mL","label":"Peripheral atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_per_mL","label":"Exposure (AUC)","unit":null}],"scenario_id":"jtail_article_figure1_exploratory_median_ebe","scientific_questions":["How do real-world patient covariates change atezolizumab concentration and exposure?"],"time_span":{"end":82,"start":0,"step":0.05}},{"controls":[{"category":"model parameter","definition":"Population systemic clearance governing removal of modeled material from the relevant compartment.","description":"Population systemic clearance governing removal of modeled material from the relevant compartment.","key":"CL_pop_L_day","label":"Population systemic clearance","max":0.30000000000000004,"min":0.1,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.2},{"category":"model parameter","definition":"Population central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Population central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V1_pop_L","label":"Population central distribution volume","max":4.92,"min":1.64,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.28},{"category":"model parameter","definition":"Population intercompartmental clearance governing exchange between model compartments.","description":"Population intercompartmental clearance governing exchange between model compartments.","key":"Q_pop_L_day","label":"Population intercompartmental clearance","max":0.8190000000000001,"min":0.273,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.546},{"category":"model parameter","definition":"Population peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Population peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"V2_pop_L","label":"Population peripheral distribution volume","max":5.445,"min":1.815,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.63},{"category":"model parameter","definition":"Body weight used for body-size scaling in the model.","description":"Body weight used for body-size scaling in the model.","key":"body_weight_kg","label":"Body weight","max":87.9,"min":29.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"kg","value":58.6}],"description":"How do real-world patient covariates change atezolizumab concentration and exposure? Explore this intervention regimen through Central atezolizumab concentration, Peripheral atezolizumab concentration, Cumulative atezolizumab exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"1200 mg every 3 weeks J-TAIL median-covariate exposure","outputs":[{"classification":"provisional","description":"Central atezolizumab concentration over the selected simulation window.","key":"concentration_ug_per_mL","label":"Central atezolizumab concentration","unit":null},{"classification":"provisional","description":"Peripheral atezolizumab concentration over the selected simulation window.","key":"peripheral_concentration_ug_per_mL","label":"Peripheral atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_ug_day_per_mL","label":"Exposure (AUC)","unit":null}],"scenario_id":"jtail_1200mg_q3w_median_covariate_exposure_overlay","scientific_questions":["How do real-world patient covariates change atezolizumab concentration and exposure?"],"time_span":{"end":42,"start":0,"step":0.0208333}}],"targets":[{"key":"pdl1","label":"PD-L1 / CD274"}],"therapeutics":[{"key":"atezolizumab","label":"Atezolizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model representing cemiplimab exposure, covariate-dependent disposition, and gradual time variation in clearance.","diseases":[{"key":"advanced_malignancies","label":"Advanced malignancies"}],"links":{"page":"/modeling/models/yang-2021-cemiplimab-advanced-malignancies-poppk","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PopPK"],"model_id":"yang_2021_cemiplimab_advanced_malignancies_poppk","name":"Cemiplimab time-varying population PK","outputs":[{"description":"Central cemiplimab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central cemiplimab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"AUC_day_mg_L","label":"Exposure (AUC)","unit":"day*mg/L"},{"description":"Individual clearance over the selected simulation window.","key":"CL_ind_L_day","label":"Individual clearance","unit":null},{"description":"Time varying clearance factor over the selected simulation window.","key":"clearance_time_factor","label":"Time varying clearance factor","unit":null},{"description":"Central-compartment drug amount over the selected simulation window.","key":"A_central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"TVCL_L_day","label":"Typical clearance","max":0.43499999999999994,"min":0.145,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.29},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV2_L","label":"Typical central distribution volume","max":4.9799999999999995,"min":1.66,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.32},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"TVQ_L_day","label":"Typical intercompartmental clearance","max":0.9570000000000001,"min":0.319,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.638},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV3_L","label":"Typical peripheral distribution volume","max":2.4749999999999996,"min":0.825,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.65},{"category":"model parameter","definition":"Time to half-maximal change coefficient used by the released system of model equations.","description":"Time to half-maximal change coefficient used by the released system of model equations.","key":"T50_day","label":"Time to half-maximal change","max":43.349999999999994,"min":14.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":28.9}],"description":"How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure? Explore this intervention regimen through Central cemiplimab concentration, Cumulative cemiplimab exposure, Individual clearance, Time-varying clearance factor.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Typical 3 mg/kg every 2 weeks IV regimen","outputs":[{"classification":"provisional","description":"Central cemiplimab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central cemiplimab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_day_mg_L","label":"Exposure (AUC)","unit":"day*mg/L"},{"classification":"provisional","description":"Individual clearance over the selected simulation window.","key":"CL_ind_L_day","label":"Individual clearance","unit":null},{"classification":"provisional","description":"Time varying clearance factor over the selected simulation window.","key":"clearance_time_factor","label":"Time varying clearance factor","unit":null}],"scenario_id":"dynamic_typical_3mgkg_q2w","scientific_questions":["How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure?"],"time_span":{"end":168,"start":0,"step":7}},{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"TVCL_L_day","label":"Typical clearance","max":0.43499999999999994,"min":0.145,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.29},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV2_L","label":"Typical central distribution volume","max":4.9799999999999995,"min":1.66,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.32},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"TVQ_L_day","label":"Typical intercompartmental clearance","max":0.9570000000000001,"min":0.319,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.638},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV3_L","label":"Typical peripheral distribution volume","max":2.4749999999999996,"min":0.825,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.65},{"category":"model parameter","definition":"Time to half-maximal change coefficient used by the released system of model equations.","description":"Time to half-maximal change coefficient used by the released system of model equations.","key":"T50_day","label":"Time to half-maximal change","max":43.349999999999994,"min":14.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":28.9}],"description":"How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure? Explore this intervention regimen through Central cemiplimab concentration, Cumulative cemiplimab exposure, Individual clearance, Time-varying clearance factor.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Low body-weight fixed-dose","outputs":[{"classification":"provisional","description":"Central cemiplimab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central cemiplimab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_day_mg_L","label":"Exposure (AUC)","unit":"day*mg/L"},{"classification":"provisional","description":"Individual clearance over the selected simulation window.","key":"CL_ind_L_day","label":"Individual clearance","unit":null},{"classification":"provisional","description":"Time varying clearance factor over the selected simulation window.","key":"clearance_time_factor","label":"Time varying clearance factor","unit":null}],"scenario_id":"dynamic_low_weight_350mg_q3w","scientific_questions":["How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure?"],"time_span":{"end":168,"start":0,"step":7}},{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"TVCL_L_day","label":"Typical clearance","max":0.43499999999999994,"min":0.145,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.29},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV2_L","label":"Typical central distribution volume","max":4.9799999999999995,"min":1.66,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.32},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"TVQ_L_day","label":"Typical intercompartmental clearance","max":0.9570000000000001,"min":0.319,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.638},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV3_L","label":"Typical peripheral distribution volume","max":2.4749999999999996,"min":0.825,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.65},{"category":"model parameter","definition":"Time to half-maximal change coefficient used by the released system of model equations.","description":"Time to half-maximal change coefficient used by the released system of model equations.","key":"T50_day","label":"Time to half-maximal change","max":43.349999999999994,"min":14.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":28.9}],"description":"How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure? Explore this intervention regimen through Central cemiplimab concentration, Cumulative cemiplimab exposure, Individual clearance, Time-varying clearance factor.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Typical 1 mg/kg every 2 weeks IV regimen","outputs":[{"classification":"provisional","description":"Central cemiplimab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central cemiplimab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_day_mg_L","label":"Exposure (AUC)","unit":"day*mg/L"},{"classification":"provisional","description":"Individual clearance over the selected simulation window.","key":"CL_ind_L_day","label":"Individual clearance","unit":null},{"classification":"provisional","description":"Time varying clearance factor over the selected simulation window.","key":"clearance_time_factor","label":"Time varying clearance factor","unit":null}],"scenario_id":"dynamic_typical_1mgkg_q2w","scientific_questions":["How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure?"],"time_span":{"end":168,"start":0,"step":7}},{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"TVCL_L_day","label":"Typical clearance","max":0.43499999999999994,"min":0.145,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.29},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV2_L","label":"Typical central distribution volume","max":4.9799999999999995,"min":1.66,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.32},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"TVQ_L_day","label":"Typical intercompartmental clearance","max":0.9570000000000001,"min":0.319,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.638},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV3_L","label":"Typical peripheral distribution volume","max":2.4749999999999996,"min":0.825,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.65},{"category":"model parameter","definition":"Time to half-maximal change coefficient used by the released system of model equations.","description":"Time to half-maximal change coefficient used by the released system of model equations.","key":"T50_day","label":"Time to half-maximal change","max":43.349999999999994,"min":14.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":28.9}],"description":"How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure? Explore this intervention regimen through Central cemiplimab concentration, Cumulative cemiplimab exposure, Individual clearance, Time-varying clearance factor.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Typical 200 mg every 2 weeks IV regimen","outputs":[{"classification":"provisional","description":"Central cemiplimab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central cemiplimab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_day_mg_L","label":"Exposure (AUC)","unit":"day*mg/L"},{"classification":"provisional","description":"Individual clearance over the selected simulation window.","key":"CL_ind_L_day","label":"Individual clearance","unit":null},{"classification":"provisional","description":"Time varying clearance factor over the selected simulation window.","key":"clearance_time_factor","label":"Time varying clearance factor","unit":null}],"scenario_id":"dynamic_typical_200mg_q2w","scientific_questions":["How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure?"],"time_span":{"end":168,"start":0,"step":7}},{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"TVCL_L_day","label":"Typical clearance","max":0.43499999999999994,"min":0.145,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.29},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV2_L","label":"Typical central distribution volume","max":4.9799999999999995,"min":1.66,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.32},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"TVQ_L_day","label":"Typical intercompartmental clearance","max":0.9570000000000001,"min":0.319,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.638},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"TVV3_L","label":"Typical peripheral distribution volume","max":2.4749999999999996,"min":0.825,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":1.65},{"category":"model parameter","definition":"Time to half-maximal change coefficient used by the released system of model equations.","description":"Time to half-maximal change coefficient used by the released system of model equations.","key":"T50_day","label":"Time to half-maximal change","max":43.349999999999994,"min":14.45,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":28.9}],"description":"How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure? Explore this biological starting configuration through Central cemiplimab concentration, Cumulative cemiplimab exposure, Individual clearance, Time-varying clearance factor.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"clearance-time fixed-effect","outputs":[{"classification":"provisional","description":"Central cemiplimab concentration over the selected simulation window.","key":"central_conc_mg_L","label":"Central cemiplimab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"AUC_day_mg_L","label":"Exposure (AUC)","unit":"day*mg/L"},{"classification":"provisional","description":"Individual clearance over the selected simulation window.","key":"CL_ind_L_day","label":"Individual clearance","unit":null},{"classification":"provisional","description":"Time varying clearance factor over the selected simulation window.","key":"clearance_time_factor","label":"Time varying clearance factor","unit":null}],"scenario_id":"suppfig1_clearance_timecourse_fixed_effect_probe","scientific_questions":["How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure?"],"time_span":{"end":504,"start":0,"step":28}}],"targets":[{"key":"pd1","label":"PD-1 / PDCD1"}],"therapeutics":[{"key":"cemiplimab","label":"Cemiplimab"},{"key":"libtayo","label":"Libtayo"},{"key":"regn2810","label":"REGN2810"},{"key":"cemiplimab_rwlc","label":"cemiplimab-rwlc"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"A TMDD PK/PD model coupling intravenous crenezumab disposition to free and antibody-bound amyloid-beta 1-40 and 1-42 turnover.","diseases":[{"key":"alzheimer_disease","label":"Alzheimer disease"}],"links":{"page":"/modeling/models/yoshida-2020-crenezumab-abeta-tmdd-pkpd","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"humanized IgG4 monoclonal antibody","model_classes":["PKPD","TMDD"],"model_id":"yoshida_2020_crenezumab_abeta_tmdd_pkpd","name":"Crenezumab PK and amyloid-beta binding","outputs":[{"description":"Crenezumab concentration over the selected simulation window.","key":"Ccren_nM","label":"Crenezumab concentration","unit":null},{"description":"Free amyloid beta 1 40 over the selected simulation window.","key":"free_abeta40_pM","label":"Free amyloid beta 1 40","unit":null},{"description":"Free amyloid beta 1 42 over the selected simulation window.","key":"free_abeta42_pM","label":"Free amyloid beta 1 42","unit":null},{"description":"Crenezumab amyloid beta 1 40 complex over the selected simulation window.","key":"complex40_pM","label":"Crenezumab amyloid beta 1 40 complex","unit":null},{"description":"Crenezumab amyloid beta 1 42 complex over the selected simulation window.","key":"complex42_pM","label":"Crenezumab amyloid beta 1 42 complex","unit":null}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Elimination clearance governing removal of modeled material from the relevant compartment.","description":"Elimination clearance governing removal of modeled material from the relevant compartment.","key":"CLel_L_day","label":"Elimination clearance","max":0.2385,"min":0.0795,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.159},{"category":"model parameter","definition":"Internalization clearance governing removal of modeled material from the relevant compartment.","description":"Internalization clearance governing removal of modeled material from the relevant compartment.","key":"CLint_L_day","label":"Internalization clearance","max":1.5150000000000001,"min":0.505,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/day","value":1.01},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vcent_L","label":"Central distribution volume","max":4.335,"min":1.445,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.89},{"category":"model parameter","definition":"Aβ40 dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"Aβ40 dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"Kd_abeta40_nM","label":"Aβ40 dissociation constant","max":18,"min":6,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"nM","value":12},{"category":"model parameter","definition":"Aβ42 dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"Aβ42 dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"Kd_abeta42_nM","label":"Aβ42 dissociation constant","max":14.055,"min":4.685,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM","value":9.37}],"description":"How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time? Explore this intervention regimen through Crenezumab concentration, Free amyloid-beta 1-40, Free amyloid-beta 1-42, Crenezumab–amyloid-beta 1-40 complex, Crenezumab–amyloid-beta 1-42 complex.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"style 15 mg/kg every 4 weeks IV","outputs":[{"classification":"provisional","description":"Crenezumab concentration over the selected simulation window.","key":"Ccren_nM","label":"Crenezumab concentration","unit":null},{"classification":"provisional","description":"Free amyloid beta 1 40 over the selected simulation window.","key":"free_abeta40_pM","label":"Free amyloid beta 1 40","unit":null},{"classification":"provisional","description":"Free amyloid beta 1 42 over the selected simulation window.","key":"free_abeta42_pM","label":"Free amyloid beta 1 42","unit":null},{"classification":"provisional","description":"Crenezumab amyloid beta 1 40 complex over the selected simulation window.","key":"complex40_pM","label":"Crenezumab amyloid beta 1 40 complex","unit":null},{"classification":"provisional","description":"Crenezumab amyloid beta 1 42 complex over the selected simulation window.","key":"complex42_pM","label":"Crenezumab amyloid beta 1 42 complex","unit":null}],"scenario_id":"fig8_15mgkg_q4w_iv_source_limited","scientific_questions":["How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time?"],"time_span":{"end":168,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Elimination clearance governing removal of modeled material from the relevant compartment.","description":"Elimination clearance governing removal of modeled material from the relevant compartment.","key":"CLel_L_day","label":"Elimination clearance","max":0.2385,"min":0.0795,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.159},{"category":"model parameter","definition":"Internalization clearance governing removal of modeled material from the relevant compartment.","description":"Internalization clearance governing removal of modeled material from the relevant compartment.","key":"CLint_L_day","label":"Internalization clearance","max":1.5150000000000001,"min":0.505,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/day","value":1.01},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vcent_L","label":"Central distribution volume","max":4.335,"min":1.445,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.89},{"category":"model parameter","definition":"Aβ40 dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"Aβ40 dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"Kd_abeta40_nM","label":"Aβ40 dissociation constant","max":18,"min":6,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"nM","value":12},{"category":"model parameter","definition":"Aβ42 dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"Aβ42 dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"Kd_abeta42_nM","label":"Aβ42 dissociation constant","max":14.055,"min":4.685,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM","value":9.37}],"description":"How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time? Explore this intervention regimen through Crenezumab concentration, Free amyloid-beta 1-40, Free amyloid-beta 1-42, Crenezumab–amyloid-beta 1-40 complex, Crenezumab–amyloid-beta 1-42 complex.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"style 60 mg/kg every 4 weeks IV","outputs":[{"classification":"provisional","description":"Crenezumab concentration over the selected simulation window.","key":"Ccren_nM","label":"Crenezumab concentration","unit":null},{"classification":"provisional","description":"Free amyloid beta 1 40 over the selected simulation window.","key":"free_abeta40_pM","label":"Free amyloid beta 1 40","unit":null},{"classification":"provisional","description":"Free amyloid beta 1 42 over the selected simulation window.","key":"free_abeta42_pM","label":"Free amyloid beta 1 42","unit":null},{"classification":"provisional","description":"Crenezumab amyloid beta 1 40 complex over the selected simulation window.","key":"complex40_pM","label":"Crenezumab amyloid beta 1 40 complex","unit":null},{"classification":"provisional","description":"Crenezumab amyloid beta 1 42 complex over the selected simulation window.","key":"complex42_pM","label":"Crenezumab amyloid beta 1 42 complex","unit":null}],"scenario_id":"fig8_60mgkg_q4w_iv_source_limited","scientific_questions":["How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time?"],"time_span":{"end":168,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Elimination clearance governing removal of modeled material from the relevant compartment.","description":"Elimination clearance governing removal of modeled material from the relevant compartment.","key":"CLel_L_day","label":"Elimination clearance","max":0.2385,"min":0.0795,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.159},{"category":"model parameter","definition":"Internalization clearance governing removal of modeled material from the relevant compartment.","description":"Internalization clearance governing removal of modeled material from the relevant compartment.","key":"CLint_L_day","label":"Internalization clearance","max":1.5150000000000001,"min":0.505,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L/day","value":1.01},{"category":"model parameter","definition":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"Vcent_L","label":"Central distribution volume","max":4.335,"min":1.445,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.89},{"category":"model parameter","definition":"Aβ40 dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"Aβ40 dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"Kd_abeta40_nM","label":"Aβ40 dissociation constant","max":18,"min":6,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"nM","value":12},{"category":"model parameter","definition":"Aβ42 dissociation constant describing equilibrium binding affinity in the modeled interaction.","description":"Aβ42 dissociation constant describing equilibrium binding affinity in the modeled interaction.","key":"Kd_abeta42_nM","label":"Aβ42 dissociation constant","max":14.055,"min":4.685,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"nM","value":9.37}],"description":"How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time? Explore this intervention regimen through Crenezumab concentration, Free amyloid-beta 1-40, Free amyloid-beta 1-42, Crenezumab–amyloid-beta 1-40 complex, Crenezumab–amyloid-beta 1-42 complex.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"style 120 mg/kg every 4 weeks IV","outputs":[{"classification":"provisional","description":"Crenezumab concentration over the selected simulation window.","key":"Ccren_nM","label":"Crenezumab concentration","unit":null},{"classification":"provisional","description":"Free amyloid beta 1 40 over the selected simulation window.","key":"free_abeta40_pM","label":"Free amyloid beta 1 40","unit":null},{"classification":"provisional","description":"Free amyloid beta 1 42 over the selected simulation window.","key":"free_abeta42_pM","label":"Free amyloid beta 1 42","unit":null},{"classification":"provisional","description":"Crenezumab amyloid beta 1 40 complex over the selected simulation window.","key":"complex40_pM","label":"Crenezumab amyloid beta 1 40 complex","unit":null},{"classification":"provisional","description":"Crenezumab amyloid beta 1 42 complex over the selected simulation window.","key":"complex42_pM","label":"Crenezumab amyloid beta 1 42 complex","unit":null}],"scenario_id":"fig8_120mgkg_q4w_iv_source_limited","scientific_questions":["How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time?"],"time_span":{"end":168,"start":0,"step":1}}],"targets":[{"key":"amyloid_beta","label":"Amyloid beta / APP"},{"key":"beta_amyloid","label":"beta-amyloid"},{"key":"abeta_1_40","label":"Abeta(1-40)"},{"key":"abeta_1_42","label":"Abeta(1-42)"}],"therapeutics":[{"key":"crenezumab","label":"Crenezumab"},{"key":"mabt5102a","label":"MABT5102A"},{"key":"rg7412","label":"RG7412"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"},{"availability":{"catalog_qualified":true,"released":true},"description":"Fixed-effect in vitro model linking CD3×5T4 immune-synapse formation to T-cell activation, differentiation, and delayed tumor-cell killing.","diseases":[{"key":"in_vitro_solid_tumor_cell_line_assay_not_disease_specific","label":"In vitro solid-tumor cell-line assay (not disease-specific)","review":{"date":null,"reviewer":null,"status":"source_supported_unreviewed"},"source":{"doi":"10.1208/s12248-026-01259-2","locator":"Primary publication abstract and methods: an in vitro QSP platform evaluated CD3-bispecific-antibody activity across 14 human solid-tumor cell lines co-cultured with human T cells.","relationship":"Assay context only; no patient population or disease indication is inferred."}}],"links":{"page":"/modeling/models/yuan-2026-cd3x5t4-in-vitro-qsp","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"CD3×5T4 bispecific antibody","model_classes":["QSP","TCE/BsAb"],"model_id":"yuan_2026_cd3x5t4_in_vitro_qsp","name":"CD3×5T4 In Vitro Activation and Cytotoxicity QSP","outputs":[{"description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"description":"An in vitro state fraction, not a clinical response rate or a cytokine-release measurement.","key":"tcell_activation_percent","label":"Activated or effector T cells","unit":"%"},{"description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"},{"description":"Dead tumor cells are excluded after leaving the final apoptosis stage.","key":"total_tumor_cells","label":"Viable and apoptotic tumor cells","unit":"cells/well"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true},{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":true}],"scenarios":[{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":3.195,"min":1.065,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":2.13},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":1.95e-05,"min":6.5e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-07,"unit":"1/(hour*cell)","value":1.3e-05}],"description":"Null-control culture with 16,000 tumor cells and 64,000 resting T cells, matching the referenced assay setup.","interpretation_guardrails":["This is an in vitro null control, not a clinical no-treatment prediction.","Natural T-cell loss and tumor proliferation remain active.","Zero drug-attributable killing is evaluated against the parallel untreated tumor state."],"name":"MDA-MB-468 untreated, E:T 4:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"An in vitro state fraction, not a clinical response rate or a cytokine-release measurement.","key":"tcell_activation_percent","label":"Activated or effector T cells","unit":"%"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"},{"classification":"provisional","description":"Dead tumor cells are excluded after leaving the final apoptosis stage.","key":"total_tumor_cells","label":"Viable and apoptotic tumor cells","unit":"cells/well"}],"scenario_id":"mda_mb_468_untreated_et4","scientific_questions":["Does the no-drug culture preserve zero trimer, activation, effector differentiation, and drug-attributable cytotoxicity?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":3.195,"min":1.065,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":2.13},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":1.95e-05,"min":6.5e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-07,"unit":"1/(hour*cell)","value":1.3e-05}],"description":"Population fixed-effect 72-hour in vitro culture at 6.86 nM DuoBody-CD3x5T4 and the default 4:1 effector-to-target ratio.","interpretation_guardrails":["The trajectory uses reported population fixed effects and is not an individual-culture prediction.","Raster-digitized Figure 2, 3, 6, and 7d comparators support private pointwise reproduction, but repeated figure renderings are non-independent and do not replace source arrays or culture-level donor records.","This assay concentration must not be converted into a clinical dose recommendation."],"name":"MDA-MB-468 synapse-to-killing cascade, E:T 4:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"An in vitro state fraction, not a clinical response rate or a cytokine-release measurement.","key":"tcell_activation_percent","label":"Activated or effector T cells","unit":"%"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"},{"classification":"provisional","description":"Dead tumor cells are excluded after leaving the final apoptosis stage.","key":"total_tumor_cells","label":"Viable and apoptotic tumor cells","unit":"cells/well"}],"scenario_id":"mda_mb_468_duobody_6_86nm_et4","scientific_questions":["How does the reported 6.86 nM condition propagate from synapse formation to T-cell activation, effector accumulation, and delayed cytotoxicity over 72 hours?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":3.195,"min":1.065,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":2.13},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":1.95e-05,"min":6.5e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-07,"unit":"1/(hour*cell)","value":1.3e-05}],"description":"Low-effector source-aligned condition with 16,000 resting T cells and 16,000 tumor cells.","interpretation_guardrails":["Compare this condition with the E:T 4:1 and 8:1 scenarios as an assay-design sensitivity.","The model's R_ET factor makes per-cell synapse kinetics depend dynamically on both T-cell and tumor-cell pools.","The result is not a clinical immune-cell infiltration prediction."],"name":"MDA-MB-468 DuoBody 6.86 nM, E:T 1:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"mda_mb_468_duobody_6_86nm_et1","scientific_questions":["How does lowering the initial effector-to-target ratio change per-cell trimer density, effector production, and cytotoxicity?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":3.195,"min":1.065,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":2.13},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":1.95e-05,"min":6.5e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-07,"unit":"1/(hour*cell)","value":1.3e-05}],"description":"High-effector source-aligned condition with 128,000 resting T cells and 16,000 tumor cells.","interpretation_guardrails":["Interpret per-cell trimer and aggregate trimer load together.","This is a source-aligned assay condition, not a patient-level tumor microenvironment.","Raster-digitized Figure 5, 6, and 7d endpoint comparators support private pointwise reproduction, but they are repeated renderings of one assay observation rather than independent validations."],"name":"MDA-MB-468 DuoBody 6.86 nM, E:T 8:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"mda_mb_468_duobody_6_86nm_et8","scientific_questions":["Does a larger initial effector pool increase aggregate effector function even when trimers per individual T cell change?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":3.195,"min":1.065,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":2.13},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":1.95e-05,"min":6.5e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-07,"unit":"1/(hour*cell)","value":1.3e-05}],"description":"Source-aligned intermediate-effector condition with 32,000 resting T cells and 16,000 tumor cells.","interpretation_guardrails":["Compare this condition with the E:T 1:1, 4:1, and 8:1 scenarios.","The result is an in vitro fixed-effect assay reconstruction, not a patient immune-infiltration prediction.","The published concentration grid was recovered by figure alignment and remains explicitly provenance-labeled."],"name":"MDA-MB-468 DuoBody 6.86 nM, E:T 2:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"mda_mb_468_duobody_6_86nm_et2","scientific_questions":["How does the source-reported E:T 2:1 condition bridge the low- and high-effector assay responses?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":6.8999999999999995,"min":2.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":4.6},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":6.36e-06,"min":2.12e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-08,"unit":"1/(hour*cell)","value":4.24e-06}],"description":"Cell-line covariate probe using the published MDA-MB-231 5T4 abundance, doubling time, activation threshold, and no-donor killing rate.","interpretation_guardrails":["The no-donor category maps to donor group 2 as disclosed in Supplement Table S4.","This comparison changes several measured or estimated cell-line attributes and is not a single-parameter causal attribution.","No tumor-type clinical efficacy inference is supported."],"name":"MDA-MB-231 DuoBody 6.86 nM, E:T 4:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"An in vitro state fraction, not a clinical response rate or a cytokine-release measurement.","key":"tcell_activation_percent","label":"Activated or effector T cells","unit":"%"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"mda_mb_231_duobody_6_86nm_et4","scientific_questions":["How do the disclosed MDA-MB-231 antigen, growth, activation-threshold, and killing covariates alter the mechanistic cascade relative to MDA-MB-468?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":24,"min":8,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":0.1,"unit":"nM","value":16},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":3.195,"min":1.065,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":2.13},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":1.95e-05,"min":6.5e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-07,"unit":"1/(hour*cell)","value":1.3e-05}],"description":"Measured high-affinity endpoint using the 16 nM CD3 3D KD and corresponding 174 molecules/cell 2D KD.","interpretation_guardrails":["The 16 nM 3D and 174 molecules/cell 2D KD values are paired measured endpoint values.","Affinity can alter both potency and hook-region behavior; do not assume monotonic benefit at every concentration.","This is candidate-design exploration in an in vitro model, not clinical optimization."],"name":"MDA-MB-468 high-affinity CD3 arm 6.86 nM, E:T 8:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"An in vitro state fraction, not a clinical response rate or a cytokine-release measurement.","key":"tcell_activation_percent","label":"Activated or effector T cells","unit":"%"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"mda_mb_468_high_affinity_6_86nm_et8","scientific_questions":["How does the measured 16 nM CD3-affinity variant alter synapse formation and downstream response at E:T 8:1?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":24,"min":8,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":0.1,"unit":"nM","value":16},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":6.8999999999999995,"min":2.3,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":4.6},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":6.36e-06,"min":2.12e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-08,"unit":"1/(hour*cell)","value":4.24e-06}],"description":"Source-reported MDA-MB-231 high-affinity assay condition using the complete published cell-line bundle and the measured 16 nM CD3-affinity endpoint.","interpretation_guardrails":["Supplement Table S2 confirms the condition family, but the requested figures do not expose its exact observed endpoint at 6.86 nM.","The no-donor category maps to donor group 2.","Treat the trajectory as source-aligned and source-limited, not pointwise paper-validated."],"name":"MDA-MB-231 high-affinity CD3 arm 6.86 nM, E:T 8:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"An in vitro state fraction, not a clinical response rate or a cytokine-release measurement.","key":"tcell_activation_percent","label":"Activated or effector T cells","unit":"%"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"mda_mb_231_high_affinity_6_86nm_et8","scientific_questions":["How does the measured high-affinity construct behave in the second breast-cancer cell-line profile?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":5.535,"min":1.845,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":3.69},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":3.6900000000000002e-06,"min":1.23e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-08,"unit":"1/(hour*cell)","value":2.46e-06}],"description":"Low-5T4 tumor-cell profile for exploring how weak target expression shapes the synapse-to-killing response.","interpretation_guardrails":["The cell-line bundle changes antigen, growth, activation threshold, and killing susceptibility together.","The no-donor fixed effect is donor group 2.","Do not infer clinical pancreatic-tumor efficacy."],"name":"BxPC-3 DuoBody 6.86 nM, E:T 4:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"bxpc_3_duobody_6_86nm_et4","scientific_questions":["How does a low-5T4, relatively resistant cell-line profile change 72-hour killing?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":5.535,"min":1.845,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":3.69},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":6.36e-06,"min":2.12e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-08,"unit":"1/(hour*cell)","value":4.24e-06}],"description":"Intermediate-5T4 tumor-cell profile for exploring how target abundance shapes the synapse-to-killing response.","interpretation_guardrails":["The paper uses both EPLC-272H and EPLC272H spellings; this scenario uses the Table S1 spelling.","The no-donor fixed effect is donor group 2.","Do not attribute the response to antigen abundance alone."],"name":"EPLC-272H DuoBody 6.86 nM, E:T 4:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"eplc_272h_duobody_6_86nm_et4","scientific_questions":["How does the medium-5T4 EPLC-272H profile compare with the low- and high-density Figure 4 profiles?"],"time_span":{"end":72,"start":0,"step":1}},{"controls":[{"category":"Binding","definition":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","description":"DuoBody-CD3x5T4 value; the high-affinity bsIgG1 variant is 16 nM. Values between the endpoints are exploratory and values outside them are outside this runtime contract.","key":"KD_CD3_3D_nM","label":"CD3-arm 3D dissociation constant","max":1024.5,"min":341.5,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table I measured construct endpoints","step":1,"unit":"nM","value":683},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 3 value.","description":"MDA-MB-468 cell-line group 3 value.","key":"EC50_activation_trimers_per_tcell","label":"Trimer threshold for half-maximal activation","max":5.535,"min":1.845,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Table S5","step":0.01,"unit":"molecule/cell","value":3.69},{"category":"Estimated population effect","definition":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","description":"Upper rate of trimer-dependent resting-to-activated T-cell conversion in the fixed-effect model.","key":"Max_activation_per_hr","label":"Maximum T-cell activation rate","max":0.0159,"min":0.0053,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":9.999999999999999e-05,"unit":"1/hr","value":0.0106},{"category":"Estimated population effect","definition":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","description":"Aggregate trimer load across effector T cells producing half-maximal per-effector killing drive.","key":"EC50_killing_total_trimers","label":"Aggregate trimer threshold for half-maximal killing","max":10647,"min":3549,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Table II population estimate","step":10,"unit":"molecule","value":7098},{"category":"Estimated population effect","definition":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","description":"MDA-MB-468 cell-line group 4 and no-donor/donor group 2 value.","key":"Max_kill_per_effector_hr","label":"Maximum per-effector tumor killing rate","max":1.95e-05,"min":6.5e-06,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Yuan 2026 Supplement Tables S4-S5","step":1e-07,"unit":"1/(hour*cell)","value":1.3e-05}],"description":"High-5T4 tumor-cell profile for exploring how strong target expression shapes the synapse-to-killing response.","interpretation_guardrails":["The cell-line killing group is a fitted categorical covariate and is not derived from 5T4 abundance.","The no-donor fixed effect is donor group 2.","Do not infer clinical esophageal-tumor efficacy."],"name":"SK-GT-4 DuoBody 6.86 nM, E:T 4:1","outputs":[{"classification":"qualified","description":"Read together with total effector-cell abundance: a high per-cell trimer signal does not by itself imply a large aggregate killing drive.","key":"trimer_per_tcell","label":"Immune-synapse trimers per T cell","unit":"trimers/T cell"},{"classification":"qualified","description":"This reflects the source differentiation mechanism and should not be interpreted as tumor infiltration in vivo.","key":"effector_tcells","label":"Effector T cells","unit":"cells/well"},{"classification":"qualified","description":"A model-derived in vitro cytotoxicity readout; it is not a clinical tumor-response endpoint.","key":"tumor_killing_percent","label":"Tumor-cell cytotoxicity","unit":"%"}],"scenario_id":"sk_gt_4_duobody_6_86nm_et4","scientific_questions":["How does the high-5T4, low-resistance SK-GT-4 profile alter 72-hour killing?"],"time_span":{"end":72,"start":0,"step":1}}],"targets":[{"key":"cd3","label":"CD3"},{"key":"5t4","label":"5T4"}],"therapeutics":[{"key":"duobody_cd3x5t4","label":"DuoBody-CD3x5T4"},{"key":"bsigg1_cd3x5t4","label":"bsIgG1-CD3x5T4"}],"unavailable_operations":[{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"2.0.1"},{"availability":{"catalog_qualified":true,"released":true},"description":"A two-compartment population PK model representing atezolizumab disposition, clinical covariate effects, time-varying clearance, concentration, and interval exposure.","diseases":[{"key":"oncology_dosing_regimen_simulation","label":"Oncology dosing-regimen simulation"}],"links":{"page":"/modeling/models/zeng-2026-atezolizumab-software-poppk-simulation","preview":"/api/v1/runs/preview","submit":"/api/v1/runs"},"minimum_plan":"free","modality":"Whole mAb","model_classes":["PopPK"],"model_id":"zeng_2026_atezolizumab_software_poppk_simulation","name":"Atezolizumab time-varying population PK","outputs":[{"description":"Atezolizumab concentration over the selected simulation window.","key":"out__concentration_ug_ml","label":"Atezolizumab concentration","unit":null},{"description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"description":"Time varying clearance over the selected simulation window.","key":"out__cl_time_l_day","label":"Time varying clearance","unit":null},{"description":"Current weekly exposure over the selected simulation window.","key":"out__weekly_auc_current_ug_day_ml","label":"Current weekly exposure","unit":null},{"description":"Central-compartment drug amount over the selected simulation window.","key":"central_mg","label":"Central-compartment drug amount","unit":"mg"}],"qualified_operations":[{"execution":"public_metadata","operation":"compare_public_metadata","qualified":true},{"execution":"public_metadata","operation":"inspect_public_evidence","qualified":true}],"scenarios":[{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"theta_cl_l_day","label":"Typical clearance","max":0.34500000000000003,"min":0.115,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.23},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vc_l","label":"Typical central distribution volume","max":4.875,"min":1.625,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.25},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"theta_q_l_day","label":"Typical intercompartmental clearance","max":0.9045,"min":0.3015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.603},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vp_l","label":"Typical peripheral distribution volume","max":4.32,"min":1.44,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.88},{"category":"model parameter","definition":"Typical time to half-maximal change coefficient used by the released system of model equations.","description":"Typical time to half-maximal change coefficient used by the released system of model equations.","key":"theta_t50_day","label":"Typical time to half-maximal change","max":94.19999999999999,"min":31.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":62.8}],"description":"How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure? Explore this intervention regimen through Atezolizumab concentration, Cumulative atezolizumab exposure, Time-varying clearance, Current weekly exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"1200 mg every 3 weeks standard dosing","outputs":[{"classification":"provisional","description":"Atezolizumab concentration over the selected simulation window.","key":"out__concentration_ug_ml","label":"Atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Time varying clearance over the selected simulation window.","key":"out__cl_time_l_day","label":"Time varying clearance","unit":null},{"classification":"provisional","description":"Current weekly exposure over the selected simulation window.","key":"out__weekly_auc_current_ug_day_ml","label":"Current weekly exposure","unit":null}],"scenario_id":"standard_1200_q3w","scientific_questions":["How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure?"],"time_span":{"end":273,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"theta_cl_l_day","label":"Typical clearance","max":0.34500000000000003,"min":0.115,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.23},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vc_l","label":"Typical central distribution volume","max":4.875,"min":1.625,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.25},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"theta_q_l_day","label":"Typical intercompartmental clearance","max":0.9045,"min":0.3015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.603},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vp_l","label":"Typical peripheral distribution volume","max":4.32,"min":1.44,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.88},{"category":"model parameter","definition":"Typical time to half-maximal change coefficient used by the released system of model equations.","description":"Typical time to half-maximal change coefficient used by the released system of model equations.","key":"theta_t50_day","label":"Typical time to half-maximal change","max":94.19999999999999,"min":31.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":62.8}],"description":"How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure? Explore this intervention regimen through Atezolizumab concentration, Cumulative atezolizumab exposure, Time-varying clearance, Current weekly exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"840 mg every 2 weeks x2 then 840 mg every 6 weeks","outputs":[{"classification":"provisional","description":"Atezolizumab concentration over the selected simulation window.","key":"out__concentration_ug_ml","label":"Atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Time varying clearance over the selected simulation window.","key":"out__cl_time_l_day","label":"Time varying clearance","unit":null},{"classification":"provisional","description":"Current weekly exposure over the selected simulation window.","key":"out__weekly_auc_current_ug_day_ml","label":"Current weekly exposure","unit":null}],"scenario_id":"loading_840_q2w_then_840_q6w","scientific_questions":["How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure?"],"time_span":{"end":266,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"theta_cl_l_day","label":"Typical clearance","max":0.34500000000000003,"min":0.115,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.23},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vc_l","label":"Typical central distribution volume","max":4.875,"min":1.625,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.25},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"theta_q_l_day","label":"Typical intercompartmental clearance","max":0.9045,"min":0.3015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.603},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vp_l","label":"Typical peripheral distribution volume","max":4.32,"min":1.44,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.88},{"category":"model parameter","definition":"Typical time to half-maximal change coefficient used by the released system of model equations.","description":"Typical time to half-maximal change coefficient used by the released system of model equations.","key":"theta_t50_day","label":"Typical time to half-maximal change","max":94.19999999999999,"min":31.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":62.8}],"description":"How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure? Explore this intervention regimen through Atezolizumab concentration, Cumulative atezolizumab exposure, Time-varying clearance, Current weekly exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"1680 mg every 4 weeks x2 then 840 mg every 6 weeks","outputs":[{"classification":"provisional","description":"Atezolizumab concentration over the selected simulation window.","key":"out__concentration_ug_ml","label":"Atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Time varying clearance over the selected simulation window.","key":"out__cl_time_l_day","label":"Time varying clearance","unit":null},{"classification":"provisional","description":"Current weekly exposure over the selected simulation window.","key":"out__weekly_auc_current_ug_day_ml","label":"Current weekly exposure","unit":null}],"scenario_id":"loading_1680_q4w_then_840_q6w","scientific_questions":["How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure?"],"time_span":{"end":280,"start":0,"step":1}},{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"theta_cl_l_day","label":"Typical clearance","max":0.34500000000000003,"min":0.115,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.23},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vc_l","label":"Typical central distribution volume","max":4.875,"min":1.625,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.25},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"theta_q_l_day","label":"Typical intercompartmental clearance","max":0.9045,"min":0.3015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.603},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vp_l","label":"Typical peripheral distribution volume","max":4.32,"min":1.44,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.88},{"category":"model parameter","definition":"Typical time to half-maximal change coefficient used by the released system of model equations.","description":"Typical time to half-maximal change coefficient used by the released system of model equations.","key":"theta_t50_day","label":"Typical time to half-maximal change","max":94.19999999999999,"min":31.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":62.8}],"description":"How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure? Explore this intervention regimen through Atezolizumab concentration, Cumulative atezolizumab exposure, Time-varying clearance, Current weekly exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Cycle 1 840 mg every 2 weeks x2 then 840 mg every 6 weeks","outputs":[{"classification":"provisional","description":"Atezolizumab concentration over the selected simulation window.","key":"out__concentration_ug_ml","label":"Atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Time varying clearance over the selected simulation window.","key":"out__cl_time_l_day","label":"Time varying clearance","unit":null},{"classification":"provisional","description":"Current weekly exposure over the selected simulation window.","key":"out__weekly_auc_current_ug_day_ml","label":"Current weekly exposure","unit":null}],"scenario_id":"cycle1_loading_840_q2w_then_840_q6w","scientific_questions":["How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure?"],"time_span":{"end":14,"start":0,"step":0.25}},{"controls":[{"category":"model parameter","definition":"Typical clearance governing removal of modeled material from the relevant compartment.","description":"Typical clearance governing removal of modeled material from the relevant compartment.","key":"theta_cl_l_day","label":"Typical clearance","max":0.34500000000000003,"min":0.115,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.23},{"category":"model parameter","definition":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical central distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vc_l","label":"Typical central distribution volume","max":4.875,"min":1.625,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":3.25},{"category":"model parameter","definition":"Typical intercompartmental clearance governing exchange between model compartments.","description":"Typical intercompartmental clearance governing exchange between model compartments.","key":"theta_q_l_day","label":"Typical intercompartmental clearance","max":0.9045,"min":0.3015,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.001,"unit":"L/day","value":0.603},{"category":"model parameter","definition":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","description":"Typical peripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.","key":"theta_vp_l","label":"Typical peripheral distribution volume","max":4.32,"min":1.44,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.01,"unit":"L","value":2.88},{"category":"model parameter","definition":"Typical time to half-maximal change coefficient used by the released system of model equations.","description":"Typical time to half-maximal change coefficient used by the released system of model equations.","key":"theta_t50_day","label":"Typical time to half-maximal change","max":94.19999999999999,"min":31.4,"range_authority":"exploratory_from_released_default","review_status":"not asserted","source":"Released executable model definition; exact publication locator not reported","step":0.1,"unit":"day","value":62.8}],"description":"How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure? Explore this intervention regimen through Atezolizumab concentration, Cumulative atezolizumab exposure, Time-varying clearance, Current weekly exposure.","interpretation_guardrails":["Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.","Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario."],"name":"Cycle 1 1680 mg every 4 weeks x2 then 840 mg every 6 weeks","outputs":[{"classification":"provisional","description":"Atezolizumab concentration over the selected simulation window.","key":"out__concentration_ug_ml","label":"Atezolizumab concentration","unit":null},{"classification":"provisional","description":"Exposure (AUC) over the selected simulation window.","key":"auc_ug_day_ml","label":"Exposure (AUC)","unit":"ug*day/mL"},{"classification":"provisional","description":"Time varying clearance over the selected simulation window.","key":"out__cl_time_l_day","label":"Time varying clearance","unit":null},{"classification":"provisional","description":"Current weekly exposure over the selected simulation window.","key":"out__weekly_auc_current_ug_day_ml","label":"Current weekly exposure","unit":null}],"scenario_id":"cycle1_loading_1680_q4w_then_840_q6w","scientific_questions":["How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure?"],"time_span":{"end":28,"start":0,"step":0.25}}],"targets":[{"key":"pdl1","label":"PD-L1 / CD274"}],"therapeutics":[{"key":"atezolizumab","label":"Atezolizumab"}],"unavailable_operations":[{"execution":"governed_run","operation":"pkpd.simulate_scenario","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_simulation_not_released"},{"execution":"governed_run","max_runs":25,"operation":"pkpd.parameter_scan","qualified":false,"unavailability_category":"model_release_scope","unavailable_reason":"model_parameter_scan_not_released"},{"execution":"governed_run","operation":"pkpd.fit_data","qualified":false,"unavailability_category":"fit_contract","unavailable_reason":"model_fit_contract_not_qualified"}],"version":"0.2.2"}],"schema":"ubi.models-catalog/v1","source_digest":"7decde63cacb82f0d0e634b063ca22794e5f9e0907607f77c8ef25ecbea6f640"}